A publication of the
American Pharmaceutical Association—
the National Professional Society
of Pharmacists

JOURNAL OF PHARMACEUTICAL SCIENCES

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 68
JANUARY TO DECEMBER, 1979

Published monthly under the supervision of the Board of Trustees

MARY H. FERGUSON
Editor

SHELLY ELLIOTT
Production Editor

MARCIA GARTRELL
Copy Editor

NICOLETTE TRIANTAFELLU
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

BELLE R. BECK
Editorial Secretary

DAVID BOHARDT
Director of Publications

L. LUAN CORRIGAN
Assistant Director of Publications

EDITORIAL ADVISORY BOARD

John Autian
Norman R. Farnsworth
William O. Foye
William J. Jusko
Herbert A. Lieberman
David E. Mann, Jr.
Gerald J. Papariello
Edward G. Rippie

© Copyright 1979 by the American Pharmaceutical Association; all rights reserved.

AUTHOR INDEX

A

Abbey, V., *see* O'Brien, J. E., 75
Abd El Rahman, A. E. R. H., *see* Moniot, J. L., 705
Abdine, H., *see* Belal, S., 750
——*see* Elsayed, M. A.-H., 9, 739
Abdou, H. M., *see* Ast, T. M., 421
——*see* Medwick, T., 301
Abouleish, E., *see* Wingard, L. B., Jr., 914
Achari, R. G., *see* Koziol, T. R., 1135
Adams, W. J., and Krueger, D. S., specific and sensitive high-performance liquid chromatographic determination of glyburide, 1138
Adams, W. P., Hasegawa, J., Johnson, R. N., and Haring, R. C., conjugated estrogens bioinequivalence: comparison of four products in postmenopausal women, 986
Agnellini, D., *see* Pietta, P. G., 1565
Al-Ani, M. R., *see* Wood, S. G., 374
Al-Badr, A. A., *see* Hassan, M. M. A., 800
Albert, K. S., Brown, S. W., Jr., DeSante, K. A., DiSanto, A. R., Stewart, R. D., and Chen, T. T., double Latin square study to determine variability and relative bioavailability of methylprednisolone, 1312
——Welch, R. D., DeSante, K. A., and DiSanto, A. R., decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture, 586
Albright, J. D., Schaffer, S. A., and Shepherd, R. G., cetaben sodium, an antiatherosclerotic agent, 936
Alkalay, D., Volk, J., Roth, W., Khemani, L., and Bartlett, M. F., metabolism, plasma or serum levels, and elimination of phenformin in guinea pigs, rats, and dogs, 156
Allen, M. D., *see* Greenblatt, D. J., 57
Al-Obeidi, F. A., *see* Taha, H. M., 631
Alton, K. B., and Patrick, J. E., high-performance liquid chromatographic assay for the antiprotozoal agent, tinidazole, in human plasma, 599
——Patrick, J. E., and McGuire, J. L., high-performance liquid chromatographic assay for the anthelmintic agent mebendazole in human plasma, 880
Amann, A. H., *see* Baaske, D. M., 481
Ambrosio, T. J., *see* Jagnandan, I., 916
Amin, K., *see* Howard, S. A., 1475
Amin, Y. M., Thompson, E. B., and Chiou, W. L., fluorocarbon aerosol propellants XII: correlation of blood levels of trichloromonofluoromethane to cardiovascular and respiratory responses in anesthetized dogs, 160
Amsel, L. P., Cravitz, L., VanderWyk, R., and Zahry, S., comparison of *in vitro* activity of undecylenic acid and tolnaftate against athlete's foot fungi, 384
Anderson, J. M., *see* Olanoff, L., 1147, 1151
Ando, H. Y., *see* Leung, L. C., 571
——*see* Vadino, W. A., 1316
Andresen, B. D., Davis, F. T., and Long, M. D., identification and synthesis of a methylated catechol metabolite of glutethimide isolated from biological fluids of overdose victims, 283
Anmo, T., *see* Yoshida, H., 670
Antonini, I., Claudi, F., Gulini, U., Micossi, L., and Venturi, F., indolizine derivatives with biological activity IV: 3-(2-aminoethyl)-2-methylindolizine, 3-(2-aminoethyl)-2-methyl-5,6,7,8-tetrahydroindolizine, and their *N*-alkyl derivatives, 321
Aratani, T., *see* Ishida, T., 928
Arison, B. H., *see* VandenHeuvel, W. J. A., 1156
Arnold, A., McAuliff, J. P., and Beyler, A. L., metabolic effects of a new hypolipidemic agent, ciprofibrate, 1557
Asakawa, Y., *see* Ishida, T., 928
Ashcraft, S. B., *see* Reuning, R. H., 411
Askar, A. F. A. A., *see* Shafik, R. M., 776
Assanelli, D., *see* Astorri, E., 104
Ast, T. M., and Abdou, H. M., analysis of fludrocortisone acetate and its solid dosage forms by high-performance liquid chromatography, 421
Astorri, E., Bianchi, G., La Canna, G., Assanelli, D., Visioli, O., and Marzo, A., bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients, 104
Aullo, J. M., *see* Tomas, F., 772
Austin, A. M., *see* Waddell, T. G., 715
Axelson, J. E., *see* Tam, Y. K., 1254
Ayres, J. W., *see* Baker, R. W., 20
——*see* Block, J. H., 605
——*see* Lock, A., 1105

B

Baaske, D. M., Carter, J. E., and Amann, A. H., rapid and accurate stability-indicating assay for nitroglycerin, 481
——Lai, C.-M., Klein, L., Look, Z. M., and Yacobi, A., comparison of GLC and high-pressure liquid chromatographic methods for analysis of urinary pseudoephedrine, 1472
Bailey, C. A., *see* Bailey, L. C., 508
Bailey, L. C., and Bailey, C. A., analysis of dienestrol and its dosage forms by high-performance liquid chromatography, 508
Baker, R. W., Tuttle, M. E., Lonsdale, H. K., and Ayres, J. W., development of an estriol-releasing intrauterine device, 20
Ballerini, R., Cambi, A., Del Soldato, P., Melani, F., and Meli, A., determination of ketoprofen by direct injection of deproteinized body fluids into a high-pressure liquid chromatographic system, 366
Baltzer, B., Lund, F., and Rastrup-Andersen, N., degradation of *mecillinam in aqueous solution*, 1207
Banker, G. S., *see* Gore, A. Y., 197
Banks, W. F., *see* Peterson, J. E., 626
Bargo, E., GLC determination of trihexyphenidyl hydrochloride dosage forms, 503
Barnick, C. T., *see* Peterson, J. E., 1447
Barry, H., III, *see* Mathur, L. K., 699
Bartlett, M. F., *see* Alkalay, D., 156
Basu, M. K., *see* Colacicco, G., 1246
Bates, T. R., *see* Pieniaszek, H. J., Jr., 1323
——*see* Resetarits, D. E., 126
Bathala, M. S., *see* Reuning, R. H., 411
Batra, V. K., *see* Reuning, R. H., 411
Bawarshi, R., *see* Hussain, A., 513, 1196
Bayne, W. F., Chu, L.-C., and Theeuwes, F., acetazolamide binding to two carbonic anhydrase isoenzymes in human erythrocytes, 912
——*see* Chu, L.-C., 72
Beard, C. C., *see* Gardner, J. O., 182
Bechtol, L. D., *see* Nash, J. F., 1087
——*see* Ridolfo, A. S., 850
Behme, R. J., *see* Kensler, T. T., 172
Belal, S., Elsayed, M. A.-H., El-Waliely, A., and Abdine, H., colorimetric acetaminophen determination in pharmaceutical formulations, 750
——*see* Elsayed, M. A.-H., 739
Bendrot, H., *see* Cioffi, F. J., 1280
Benet, L. Z., mathematical treatment of linear mammillary using models inverse Laplace transforms: a reply, 933
——and Galeazzi, R. L., noncompartmental determination of the steady-state volume of distribution, 1071
Benmaman, J. D., *see* Haborak, G. E., 932
Benson, G. A., *see* Spillane, W. J., 372
Benziger, D., *see* Peterson, J. E., 626, 1447
Bernard, N., *see* Sassard, J., 1190
Beyler, A. L., *see* Arnold, A., 1557
Bhansali, K. G., *see* Jadhav, A. L., 1202
Bhatia, R. P., and Lordi, N. G., conductivity and hardness changes in aged compacts, 896
——and Lordi, N. G., electrical conductance of directly compressible materials under pressure, 222
Bianchi, G., *see* Astorri, E., 104
Biehl, E. R., *see* Graham, R. E., 871
Bigot, M. C., *see* DeBruyne, D., 511
Blackwood, R. K., Jr., *see* Bogardus, J. B., 188, 1183
Blake, D. A., *see* Perdue, G. P., 124
Block, J. H., Levine, H. L., and Ayres, J. W., paired-ion reversed-phase high-pressure liquid chromatographic assay of pentobarbital–pyrilamine suppositories, 605
Blomster, R. N., *see* Perdue, G. P., 124
Boakye-Yiadom, K., and Heman-Ackah, S. M., cryptolepine hydrochloride effect on *Staphylococcus aureus*, 1510
Bochner, R., *see* Fung, H.-L., 1198
Bogaert, M. G., *see* Rosseel, M. T., 659
Bogardus, J. B., and Blackwood, R. K., Jr., dissolution rates of doxycycline free base and hydrochloride salts, 1183
——and Blackwood, R. K., Jr., solubility of doxycycline in aqueous solution, 188
Boisseau, J., *see* Mourot, D., 796
Bolhuis, G. K., *see* Lerk, C. F., 205
Bolhuis-de Vries, A. S., *see* Jonkman, J. H. G., 69
Bolles, T. F., *see* Kubiatowicz, D. O., 621
Bonora, A., and Borea, P. A., high-pressure liquid chromatographic feprazone determination in pharmaceutical formulations, 798
Bonuccelli, C., stable solutions for marijuana analysis, 262
Bootman, J. L., Wertheimer, A. I., Zaske, D., and Rowland, C., individualizing gentamicin dosage regimens in burn patients with Gram-negative *septicemia: a cost–benefit analysis*, 267
Boots, M. R., *see* Rogers, M. E., 903
Boots, S. G., *see* Rogers, M. E., 903
Bopp, R. J., *see* Nash, J. F., 1087
Borazan, H. N., *see* Taha, H. M., 631
Borea, P. A., *see* Bonora, A., 798
Borgman, R. J., *see* O'Donnell, J. P., 1236
Borman, C. H., *see* Thompson, T. A., 996
Born, G. S., *see* Porubcan, L. S., 358
Bortesi, F., *see* Mangia, A., 652
Bourland, W. A., *see* Williamson, H. E., 1178
Bourne, D. W. A., Triplett, J. W., Hayden, T. L., DeSimone, P. A., and Hoeschele, J. D., pharmacokinetics of *cis*-dichlorodiammine platinum(II) in rats using an external loop–eigenfunction expansion technique, 1571
——*see* Chungi, V. S., 1552
——*see* McAllister, R. G., Jr., 574
Bouwsma, O. J., Stewart, J. T., and Vallner, J. J., interaction of the antimalarial α-dibutylaminomethyl-2,6-bis(trifluoromethylphenyl)-4-pyridinemethanol with human serum albumin, 45
Boykin, D. W., *see* Sawhney, S. N., 524
Brake, N. W., *see* Tan, H. S. I., 1413
Brenner, G. S., *see* Oberholtzer, E. R., 863
Breuer, A., *see* Yashphe, J., 924
Briggs, C. J., Mulhall, D. W., Simons, K. J., and Simons, F. E. R., novel method for determining protein binding of theophylline, 129
——*see* Simons, K. J., 252
Briley, M. R., *see* Otani, T. T., 261, 496, 1366
Brittain, R. J., *see* Wojnar, R. J., 12
Broersma, P., *see* Lerk, C. F., 634
Brooke, D., *see* Kensler, T. T., 172
Brooks, J. C., *see* Burke, D. H., 693
Brooks, M. A., *see* Lee, T. L., 454
Brousseau, D. R., *see* Lesko, L. J., 1392
Brower, J. F., *see* Juenge, E. C., 551
Brown, M. R. W., and Tomlinson, E., sensitivity of *Pseudomonas aeruginosa* envelope mutants to alkylbenzyldimethylammonium chlorides, 146

Brown, R., *see* Peterson, J. E., 1447
Brown, S. W., Jr., *see* Albert, K. S., 1312
Brown, W., *see* Needham, T. E., 952
Brown, W. J., *see* Kotzan, J. A., 1002
Bunde, C. A., *see* Nash, J. F., 1087
Burke, D. H., and Brooks, J. C., cobaltous chloride-induced hypothermia II: pretreatment with sympathoplegics, antihistamines, and narcotic antagonists, 693
Burkman, A. M., *see* Yuen, P.-H., 1163
Burnell, J. M., see Colacicco, G., 1246
Burton, F. W., Gadde, R. R., and McKenzie, W. L., high-pressure liquid chromatographic assay of benzoyl peroxide in dermatological gels and lotions, 280
Butterfield, A. G., *see* Robertson, D. L., 577

C

Caine, D. S., *see* Landen, W. O., Jr., 1039
Cambi, A., *see* Ballerini, R., 366
Cammarata, A., molecular topology and aqueous solubility of aliphatic alcohols, 839
Canada, A. T., *see* Lesko, L. J., 1392
Capitano, G., and Tscherne, R., separation and quantitation of esterified estrogens in bulk mixtures and combination drug preparations using high-performance liquid chromatography, 311
Cardinal, J. R., *see* Zentner, G. M., 794, 970
Carlotti, M. E., *see* Gasco, M. R., 612
Carmichael, R. H., *see* Ridolfo, A. S., 850
Carstensen, J. T., *see* Cavé, G., 424
——*see* Kaminski, E. E., 368
Carter, J. E., *see* Baaske, D. M., 481
Cascella, P. J., and Feldman, S., effect of lidocaine and derivatives on time of death and overturn in goldfish, 401
Cavallito, C. J., *see* Chen, W.-S., 1025
Cavé, G., Puisieux, F., and Carstensen, J. T., dielectric constants of solid–liquid and liquid–liquid systems as a function of composition, 424
Chan, C. W., *see* Stewart, J. T., 910
Chan, K. K., Giannini, D. D., Staroscik, J. A., and Sadee, W., 5-azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and ^{13}C-NMR spectroscopy, 807
Chandler, R. F., Hooper, S. N., and Ismail, H. A., antihypercholesterolemic studies with sterols: β-sitosterol and stigmasterol, 245
Chang, C.-J., and Hem, S. L., carbon-13 magnetic resonance spectroscopy of drugs III: penicillins, 64
Chao, M. K., Holcomb, I. J., and Fusari, S. A., ion-pair reversed-phase high-pressure liquid chromatographic analysis of cough–cold syrups I: pseudoephedrine hydrochloride, brompheniramine maleate, and dextromethorphan hydrobromide, 1463
Chatterji, D. C., and Gallelli, J. F., stabilization of 5-azacytidine by nucleophilic addition of bisulfite ion, 822
——*see* Grimes, G., 52
Chen, C.-P., and Vu, V. T., myoinositol uptake by rat hepatocytes *in vitro*, 1022
Chen, H.-S. G., and Gross, J. F., clearance constants in physiologically based pharmacokinetic models, 1066
——and Gross, J. F., pharmacokinetics of drugs subject to enterohepatic circulation, 792
Chen, T. T., *see* Albert, K. S., 1312
Chen, W.-S., Cocolas, G. H., and Cavallito, C. J., binding of mono- and bis-*N*-substituted benzoquinolinium halides to butyrylcholinesterase: fluorescence measurements, 1025
Cheng, C. C., Zbinden, G., and Zee-Cheng, R. K. Y., comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics, 393
Cheung, W.-M., *see* Shargel, L., 1052
Chheda, G. B., Hong, C. I., Gurwara, S. K., and Mittelman, A., metabolic fate of N^6-benzyladenosine and N^6-benzyladenosine-5′-phosphate in rats, 1054
Chi, C. H., and Dixit, B. N., sensitive fluorescence assay for *d,l*-methadone, 1097
Chien, M. M., Svoboda, G. H., Schiff, P. L., Jr., Slatkin, D. J., and Knapp, J. E., chemical constituents of *Echites hirsuta* (Apocynaceae), 247
Chien, Y. W., Jefferson, D. M., Cooney, J. G., and Lambert, H. J., controlled drug release from polymeric delivery devices V: hydroxy group effects on drug release kinetics and thermodynamics, 689
Childers, R. G., *see* Quay, J. F., 227
Chiou, W. L., creatinine IX: specificity and sensitivity of high-performance liquid chromatographic and ion-exchange membrane methods for determination of endogenous creatinine, 802
——equations for estimation of first-pass effect and apparent distribution volume of drug with incomplete oral absorption and partial renal excretion, 260
——new calculation method for mean apparent drug volume of distribution and application to rational dosage regimens, 1067
——rapid compartment- and model-independent estimation of times required to attain various fractions of steady-state plasma level during multiple dosing of drugs obeying superposition principle and having various absorption or infusion kinetics, 1546
——and Kyle, L. E., differential thermal, solubility, and aging studies on various sources of digoxin and digitoxin powder: biopharmaceutical implications, 1224
——*see* Amin, Y. M., 160
——*see* Nation, R. L., 532
——*see* Pu, F. S., 534
Cho, M. J., and Morozowich, W., prostaglandin prodrugs IV: empirical relationship between functional group contributions and melting points of C_1-esters, 1069
Christy, D. P., Kim, S. W., and Petersen, R. V., effect of temperature and an ion-exchange resin on cation diffusion through silicone polymer tubing, 1102
Christy, M. E., *see* Roman, R., 1329
Chu, L.-C., Bayne, W. F., Tao, F. T., Schmitt, L. G., and Shaw, J. E., determination of submicrogram quantities of clonidine in biological fluids, 72
——*see* Bayne, W. F., 912
Chungi, V. S., Bourne, D. W. A., and Dittert, L. W., competitive inhibition between folic acid and methotrexate for transport carrier in the rat small intestine, 1552
Cioffi, F. J., Martynovych, S., and Bendrot, H., ADS-12: an automated programmable 12-tablet dissolution testing system, 1280
Clark, A. M., *see* Hufford, C. D., 1239
Claudi, F., *see* Antonini, I., 321
Clemans, S., *see* Peterson, J. E., 626, 1447
Cochran, J. W., *see* Hall, I. H., 537
——*see* Waddell, T. G., 715
Cocolas, G. H., *see* Chen, W.-S., 1025
Cohen, E. M., *see* Roman, R., 1329
Cohn, R. M., *see* Kaminski, E. E., 368
Colacicco, G., Burnell, J. M., and Basu, M. K., surface properties of membrane systems: interaction of ketamine with monomolecular films of gangliosides and mitochondrial lipids, 1246
Colaizzi, J. L., *see* Mathur, L. K., 699
Coldren, J. W., *see* Honigberg, I. L., 253
——*see* Stewart, J. T., 32
Cole, J. R., *see* Torrance, S. J., 664
Collins, C. C., *see* Hufford, C. D., 1239
Collins, J. M., *see* Johnson, D. M., 112
Combs, A. B., *see* McGinity, J. W., 662
——*see* Newburger, J., 651
Congleton, G., *see* Driscoll, J. S., 185
Connors, K. A., and Wong, M. P., micellar catalysis of an analytical reaction: spectrophotometric determination of amino acids and peptides after cetrimonium bromide-catalyzed reaction with 1-fluoro-2,4-dinitrobenzene, 1470
Cooney, J. G., *see* Chien, Y. W., 689
Cooper, E. R., effect of diffusional lag time on multicompartmental pharmacokinetics for transepidermal infusion, 1469
Cooper, J. K., *see* Midha, K. K., 557
Cooper, T. B., and Kelly, R. G., GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine, 216
Corbin, N. C., Fraher, P., and McChesney, J. D., simple epoxide analogs of trichothecans, 1501
Cornette, J. C., *see* Morozowich, W., 949
Corrick-West, H. P., *see* Welling, P. G., 150
Cosyns-Duyck, M. Cl., *see* De Leenheer, A. P., 1174
Coutts, S. M., Reid, D. M., and Weinryb, I., facile *in vitro* method for screening inhibitors of IgE binding to mast cells, 353
Couvreur, P., Kante, B., Roland, M., and Speiser, P., adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum, 1521
Cox, H. L. M., *see* Jonkman, J. H. G., 69
Cradock, J. C., *see* Poochikian, G. K., 728
Craven, B. M., see Wang, A., 361
Cravitz, L., *see* Amsel, L. P., 384
Crawford, H. T., *see* Skinner, W. A., 390, 391
Crouthamel, W. G., and Dorsch, B., specific high-performance liquid chromatographic assay for nitroglycerin in dosage forms, 237
——*see* Narang, P. K., 917
Crow, J. W., Gibaldi, M., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XLI: effect of phenobarbital on systemic availability of orally administered dicumarol in rats, 958
——Gibaldi, M., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XLII: effect of phenobarbital on systemic availability of orally administered dicumarol in rats with ligated bile ducts, 1309
Cuisinaud, G., *see* Sassard, J., 1190
Curran, N. M., *see* Poirier, M. A., 1124
Cutie, A., *see* Jochsberger, T., 1061

D

Dalal, K. J., see Tan, H. S. I., 1413
Daniels, R., *see* Kornet, M. J., 1331
Danielson, D., *see* Turi, J. S., 275
D'Arconte, L., *see* Lee, T. L., 454
Darling, C. M., and Pryor, P., anticonvulsant activity of alkyl-substituted *N*-benzylcyanoacetamides, 108
Das, M. K., *see* Hall, I. H., 685
Daun, H., *see* Jagnandan, I., 916
Davies, R. H., Sheard, B., and Taylor, P. J., conformation, partition, and drug design, 396
Davis, F. T., see Andresen, B. D., 283
Davis, J. R., *see* Jadhav, A. L., 1202
Davis, R., Wells, C. H. J., and Taylor, A. R., photolytic decomposition of indapamide, 1063
Deamer, R. L., *see* Sturgeon, R. J., 1064
DeAngelis, A., *see* Gershon, H., 82
DeAngelis, N. J., *see* Shearer, C. M., 1010
de Boer, A. H., *see* Lerk, C. F., 205
DeBruyne, D., Kinsun, H., Moulin, M. A., and Bigot, M. C., improved electron-capture GLC determination of alprenolol and oxprenolol in serum using a wall-coated open tubular column, 511
Dedrick, R. L., *see* Yang, K. H., 941
De Fabrizio, F., GLC analysis of theophylline, hydroxyethyltheophylline, and diphenylpyraline hydrochloride syrup, 521
De Hertogh, L., *see* Vandeputte, M., 1416
Delaney, M., *see* Dixon, R., 1471
De Leenheer, A. P., and Cosyns-Duyck, M. Cl., flame-ionization GLC assay for fluorouracil in plasma of cancer patients, 1174
——and Nelis, H. J. C. F., doxycycline determination in human serum and urine by high-performance liquid chromatography, 999
——and Nelis, H. J. C. F., liquid chromatographic determination of minocycline in human serum, 1527
Delepine, B., see Mourot, D., 796
Del Soldato, P., *see* Ballerini, R., 366
DeLuca, P. P., *see* Munson, J. W., 1333
De Nève, R. E., *see* Van Damme, J. G., 16
Denman, S. L., *see* Yuen, P.-H., 1163
DeSante, K. A., *see* Albert, K. S., 586, 1312
DeSimone, P. A., *see* Bourne, D. W. A., 1571
Desmond, P. V., *see* Johnson, R. F., 1320
de Vries-Nijboer, G. W., *see* Schoonen, A. J. M., 163
Deyman, M. E., *see* Peat, M. A., 1467
de Zeeuw, R. A., see Jonkman, J. H. G., 69
Di Biletto, M., *see* Mangia, A., 652
Dietz, J. V., *see* Foglesong, M. A., 797

DiGregorio, G. J., Pirainõ, A. J., and Ruch, E., correlations of parotid saliva and plasma lidocaine concentrations in rats, 1192
DiMenna, W. S., and Piantadosi, C., synthesis of 9-allyladenine N^1-oxide, 667
Dimmock, J. R., Hamon, N. W., Noble, L. M., and Wright, D. E., nuclear-substituted styryl ketone analogs: effects on neoplasms, microorganisms, and mitochondrial respiration of tumorous and normal cells, 1033
——Nyathi, C. B., and Smith, P. J., syntheses and bioactivities of 1-(hydroxyphenyl)-1-nonen-3-ones and related ethers and esters, 1216
——Repta, A. J., and Kaminski, J. J., formation of a thio analog of noracronine, 36
——Smith, P. J., and Tsui, S. K., synthesis and evaluation of benzylfluorenyl and 1-arylethyl quaternary ammonium salts for antimicrobial and antineoplastic activities, 866
——*see* Nyathi, C. B., 1383
Di Paolo, T., Kier, L. B., and Hall, L. H., molecular connectivity study of halocarbon anesthetics, 39
DiSanto, A. R., *see* Albert, K. S., 586, 1312
Dittert, L. W., *see* Chungi, V. S., 1552
Dixit, B. N., *see* Chi, C. H., 1097
Dixon, R., Glover, W., Earley J., and Delaney, M., desmethyldiazepam: a specific radioimmunoassay, 1471
——Lucek, R., Earley, J., and Perry, C., chlordiazepoxide: a new, more sensitive and specific radioimmunoassay, 261
Dokladalova, J., *see* Whall, T. J., 1454
Donahe, S., *see* Zucconi, T. D., 426
Donbrow, M., *see* Samuelov, Y., 325
Donigan, B. E., *see* Popp, F. D., 519
Dorsch, B., *see* Crouthamel, W. G., 237
Douglas, S. L., *see* Morozowich, W., 833, 836, 949
Drew, J. H., *see* Hall, I. H., 696
Driscoll, J. S., catecholamine analogs as potential antitumor agents, 1519
——Dudeck, L., Congleton, G., and Gera, R. I., potential CNS antitumor agents VI: aziridinylbenzoquinones III, 185
——*see* Hwang, D. R., 816
Dryon, L., *see* Vandeputte, M., 1416
Dubroff, L. S., Ward, C. O., and Jarowski, C. I., effect of dietary lysine and tryptophan supplementation on growth rate and toxicity of barbiturates and ethanol in rats, 1554
Dudeck, L., *see* Driscoll, J. S., 185
Dumain, M. S., *see* Levy, R. H., 399, 934
Duncan, C. A. H., *see* Vickers, S., 1559
Duvall, R. N., *see* Slater, J. G., 49
Dzelzkalns, E., *see* Wojnar, R. J., 12

E

Earley, J. V., Fryer, R. I., and Ning, R. Y., quinazolines and 1,4-benzodiazepines LXXXIX: haptens useful in benzodiazepine immunoassay development, 845
——*see* Dixon, R., 261, 1471
Eastwood, G., *see* Lesko, L. J., 1392
Edelson, J., *see* Peterson, J. E., 626, 1447
Eickman, M., *see* Lock, A., 1105
Ejima, A., *see* Ogata, H., 708, 712
El Dine, S. A. S., *see* Ibrahim, E. S. A., 243
ElGebaly, S. A., Hall, I. H., Lee, K. H., Sumida, Y., Imakura, Y., and Wu, R. Y., antitumor agents XXXV: effects of brusatol, bruceoside A, and bruceantin on P-388 lymphocytic leukemia cell respiration, 887
——*see* Hall, I. H., 883
Elliott, R. L., *see* Welling, P. G., 150
El-Rashidy, R., and Niazi, S., GLC determination of butylated hydroxyanisole in human plasma and urine, 103
Elsabbagh, H. M., Whitworth, C. W., and Schramm, L. C., separation, identification, and quantitation of anthralin and its decomposition products, 388
Elsayed, M. A.-H., Abdine, H., and Elsayed, Y. M., spectrophotometric determination of theophylline formulations, 9
——Belal, S. F., Elwalily, A. F. M., and Abdine, H., spectrophotometric determination of tolbutamide, thiamine hydrochloride, and pyridoxine hydrochloride in combination products, 739
——*see* Belal, S. F., 750
Elsayed, Y. M., *see* Elsayed, M. A.-H., 9
El-Sebakhy, N. A., *see* Habib, A. A. M., 1221
El-Wallely, A., *see* Belal, S., 750
Elwalily, A. F. M., *see* Elsayed, M. A.-H., 739
Embil, K., and Torosian, G., dissolution behavior of commercial enteric-coated aspirin tablets, 1290
——and Torosian, G., effect of instrumental vibration levels on dissolution, 1336
Emery, M., and Kowtko, J., high-performance liquid chromatography of benzodiazepines I: stability-indicating assay of diazepam tablets, 1185
Enever, R. P., Li Wan Po, A., and Shotton, E., flupenthixol dihydrochloride decomposition in aqueous solution, 169
——*see* Sherriff, M., 842
Eng-Wilmot, D. L., and Martin, D. F., short-term effects on *Artemia salina* of aponin and *Gomphosphaeria aponina* in unialgal cultures and in mixed cultures with *Gymnodinium breve*, 963
Epstein, J., *see* Hull, L. A., 856
Erdreich-Naftali, G., *see* Yashphe, J., 924
Erhardt, P. W., and Soine, T. O., stereochemical preferences for curarimimetic neuromuscular junction blockade IV: monoquaternary ammonium probes, possessing carbon and nitrogen asymmetry, 522
Eskola, P., *see* VandenHeuvel, W. J. A., 1156
Evans, B. K., James, K. C., and Luscombe, D. K., quantitative structure–activity relationships and carminative activity II: steric considerations, 370

F

Fadil, F. A., and McSharry, W. O., extraction and TLC separation of food, drug, and cosmetic dyes from tablet-coating formulations, 97
Farid, K. Z., *see* Nash, J. F., 1087
Farid, N. A., fluorescamine use in high-performance liquid chromatographic determination of aminocaproic acid in serum, 249
Farinotti, R., and Mahuzier, G., high-performance liquid chromatographic determination of ketoprofen in blood and urine, 484
Farnsworth, N. R., *see* Perdue, G. P., 124
Farnum, S. A., *see* Singh, S. P., 89, 470, 890
Feeney, W. P., *see* Li, H. H. C., 569
Feijen, J., *see* Zentner, G. M., 970
Feldman, S., *see* Cascella, P. J., 401
——*see* Ravis, W. R., 945
Ferrari, A., *see* Smith, R. H., 1016
Field, F. P., *see* Threatte, R. M., 1530
Finkle, B. S., *see* Peat, M. A., 1467
Finster, M., *see* O'Brien, J. E., 75
Fleuren, H. L. J., van Ginneken, C. A. M., and van Rossum, J. M., differential potentiometric method for determining dissociation constants of very slightly water-soluble drugs applied to the sulfonamide diuretic chlorthalidone, 1056
Flouret, G., *see* Widder, K., 79
Flynn, G. L., Shah, Y., Prakongpan, S., Kwan, K. H., Higuchi, W. I., and Hofmann, A. F., cholesterol solubility in organic solvents, 1090
Foglesong, M. A., Kavanagh, F., and Dietz, J. V., possibility for error in FDA diffusion assays, 797
Förch, A. D., *see* Roseboom, H., 515
Fouda, H. G., Hobbs, D. C., and Stambaugh, J. E., sensitive assay for determination of hydroxyzine in plasma and its human pharmacokinetics, 1456
Fox, J. L., *see* Yu, C. D., 1341, 1347
Foye, W. O., and Hu, J. M., metal-binding abilities of radioprotective aminoalkyl disulfides and thiosulfates, 202
——and Kaewchansilp, V., mercaptoalkylamine coordination compounds of platinum(II) and palladium(II) and their anticancer activity, 1131
——and Kauffman, J. M., 6-substituted 1-methylquinolinium-2-dithioacetic acid zwitterions: antileukemia activity, 336
——and Tovivich, S., heterocyclic analogs of amphetamine: thioureas, dithiocarbamates, and negatively substituted amides, 591
Fraher, P., *see* Corbin, N. C., 1501
——*see* McChesney, J. D., 1116
Franke, K., *see* Greenblatt, D. J., 57
Fregly, M. J., *see* Threatte, R. M., 1530
Friedman, M., *see* Samuelov, Y., 325
Fryer, R. I., *see* Earley, J. V., 845
Fung, H.-L., Lettieri, J. T., and Bochner, R., percutaneous butyrolactone absorption in rats, 1198
——*see* Horhota, S. T., 608
——*see* Morrison, R. A., 1198
Fung, W. P., *see* Yang, K. H., 941
Fusari, S. A., see Chao, M. K., 1463

G

Gabr, M., *see* Ibrahim, E. S. A., 332
Gadde, R. R., *see* Burton, F. W., 280
Gaffney, G. R., *see* Williamson, H. E., 1178
Gal, J., convenient synthesis of *N*-alkoxymethylbarbituric acids and *N*-alkoxymethylhydantoins, 1562
Galante, R. N., Visalli, A. J., and Patel, D. M., solid-state acetylation of codeine phosphate by aspirin, 1494
Galeazzi, R. L., *see* Benet, L. Z., 1071
Galinsky, R. E., Slattery, J. T., and Levy, G., effect of sodium sulfate on acetaminophen elimination by rats, 803
Gallelli, J. F., *see* Chatterji, D. C., 822
——*see* Grimes, G., 52
Gardner, J. O., and Beard, C. C., synthesis and antimicrobial activity of 3*H*-1,2,4-thiadiazolo fused heterocycles, 182
Gardner, M. J., *see* Jusko, W. J., 1358
Garrett, E. R., and Gurkan, T., pharmacokinetics of morphine and its surrogates II: methods of separation of stabilized heroin and its metabolites from hydrolyzing biological fluids and applications to protein binding and red blood cell partition studies, 26
——and Jackson, A. J., pharmacokinetics of morphine and its surrogates III: morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose, 753
Garrett, R. J., *see* Kornet, M. J., 377
Garzia, A., Villanti, A., and Tuccini, G., quantitative structure–selectivity relationships: selective drug design, 1081
Gasco, M. R., and Carlotti, M. E., kinetics of dopamine oxidation by dialkylaminoalkylphenothiazine cation radicals, 612
Gaylord, J. C., *see* Weinstein, S. H., 527
Gayot, G., *see* Mourot, D., 796
Gentner, W. A., *see* Vincent, P. G., 87
Geran, R. I., *see* Driscoll, J. S., 185
Gerhart, K. G., *see* Hall, I. H., 537
——*see* Waddell, T. G., 715
Gershbein, L. L., percutaneous toxicity of thioglycolate mixtures in rabbits, 1230
Gershon, H., Shanks, L., and DeAngelis, A., antifungal properties of *n*-alkoxyacetic acids and their methyl esters, 82
Giannini, D. D., *see* Chan, K. K., 807
Gibaldi, M., *see* Crow, J. W., 958, 1309
Gieschen, D. P., *see* Pettit, G. R., 1539
Gilbert, S. G., *see* Jagnandan, I., 916
Giles, H. G., Miller, R., and Sellers, E. M., high-performance liquid chromatographic determination of plasma propylthiouracil, 1459
Girton, M., *see* Grimes, G., 52
Gish, R., *see* Stella, V. J., 1042, 1047
Glemza, R., *see* Yang, K. Y., 560
Glennon, R. A., Kier, L. B., and Shulgin, A. T., molecular connectivity analysis of hallucinogenic mescaline analogs, 906
Glover, W., *see* Dixon, R., 1471
Godbey, R. E. W., Green, K., and Hull, D. S., influence of cetylpyridinium chloride on corneal permeability to penicillin, 1176
Goehl, T. J., Sundaresan, G. M., and Prasad, V. K., fluorometric high-pressure liquid chromatographic determination of hydrocortisone in human plasma, 1374
——*see* Mathur, L. K., 699
——*see* Shiu, G. K., 232
——*see* Wingard, L. B., Jr., 914
Goetz, J. F., *see* Tsuki, K., 1075
Goggin, L. K., *see* Ludden, T. M., 1423
Golander, Y., and Sternson, L. A., metabolic conver-

sion of fluorenone oxime to phenanthridinone by hepatic enzymes, 820
Goldenberg, M. M., *see* Schwan, T. J., 1325
Goodblatt, R. S., see Thompson, T. A., 996
Gopal, G. S., *see Pandey, V. N., 256*
Gorczynski, R. J., *see* O'Donnell, J. P., 1236
Gore, A. Y., and Banker, G. S., surface chemistry of *colloidal silica and a possible application to stabilize* aspirin in solid matrixes, 197
Gorodetzky, C. W., *see* Yeh, S. Y., 133
Graham, K., *see* LeBelle, M., 555
Graham, M., see Peterson, J. E., 626
Graham, R. E., Biehl, E. R., and Kenner, C. T., separation and determination of testosterone and testosterone esters in selected pharmaceutical formulations, 871
Gratzll, M. M., *see* Pitt, C. G., 1534
Gray, J. E., *see* Schwan, T. J., 529
Green, K., *see* Godbey, R. E. W., 1176
Green, L., *see* Mergens, W. J., 827
Greenblatt, D. J., Shader, R. I., Franke, K., MacLaughlin, D. S., Harmatz, J. S., Allen, M. D., Werner, A., and Woo, E., pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans, 57
——*see* Woo, E., 466
Gregonis, D. E., *see* Zentner, G. M., 794
Grier, N., synthesis and antimicrobial evaluation of quaternary salts of 4-phenyl-1,2,3,6-tetrahydropyridine and 3,6-dimethyl-6-phenyltetrahydro-2*H*-1,3-oxazine, 407
Grimes, G., Vermess, M., Gallelli, J. F., Girton, M., and Chatterji, D. C., formulation and evaluation of ethiodized oil emulsion for intravenous hepatography, 52
Grisanti, G., *see* Mangia, A., 652
Groningsson, K., and Jansson, L., TLC determination of biotin in a lyophilized multivitamin preparation, 364
Gross, J. F., *see* Chen, H.-S. G., 792, 1066
Guerret, M., Lavene, D., Longchampt, J., and Kiger, J. L., determination of guanfacine in biological fluids by electron-capture GLC, 219
Guillory, J. K., *see* Stagner, W. C., 1005
Guilmette, R. A., Parks, J. E., and Lindenbaum, A., synthesis and therapeutic testing of mono- and dialkyl esters of pentetic (diethylenetriaminepentaacetic) acid for decorporation of polymeric plutonium, 194
Gulini, U., *see* Antonini, I., 321
Gupta, V. D., applications of paired ion high-pressure liquid chromatography: quantitative determination of potassium guaiacolsulfonate and other ingredients in cough syrups, 118
——high-pressure liquid chromatographic evaluation of aqueous vehicles for preparation of prednisolone and prednisone liquid dosage forms, 908
——quantitative dexamethasone and dexamethasone sodium phosphate determinations in pharmaceutical dosage forms by high-pressure liquid chromatography, 926
Gupta, V. S., *see* Nyathi, C. B., 1383
Gurkan, T., *see* Garrett, E. R., 26
Gurwara, S. K., *see* Chheda, G. B., 1054

H

Habib, A. A. M., El-Sebakhy, N. A., and Kadry, H. A., new and simple methylene blue colorimetric assay for glycyrrhizin in pharmaceuticals, 1221
Haborak, G. E., Benmaman, J. D., and Warren, J. W., Jr., mathematical treatment of linear mammillary models using inverse Laplace transforms, 932
Haedicke, E., *see* Schenck, H.-U., 1505
Haegele, K. D., see Ludden, T. M., 1423
Hagerman, W. B., *see* Roman, R., 1329
Haggerty, W. J., *see* Lakings, D. B., 1113
Hajdu, P., *see* Stewart, J. T., 494
Hall, I. H., Drew, J. H., Sajadi, Z., and Loeffler, L. J., antifertility and antiproteolytic activity of activated *N*-carbobenzoxy amino acid esters, 696
——Lee, K. H., Eigebaly, S. A., Imakura, Y., Sumida, Y., and Wu, R. Y., antitumor agents XXXIV: mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells, 883
——Lee, K. H., Starnes, C. O., Sumida, Y., Wu, R. Y., Waddell, T. G., Cochran, J. W., and Gerhart, K. G., anti-inflammatory activity of sesquiterpene lactones and related compounds, 537
——*Starnes, C. O., Spielvogel, B. F., Wisian-Neilson,* P., Das, M. K., and Wojnowich, L., boron betaine analogs: antitumor activity and effects on Ehrlich ascites tumor cell metabolism, 685
——*see* ElGebaly, S. A., 887
——*see Waddell, T. G., 715*
Hall, L. H., *see* Di Paolo, T., 39
——*see* Kier, L. B., 120
Hammesfahr, P., *see* Ravikumar, P. R., 900
Hammouda, N. A., *see* Soliman, R., 1377
Hamon, N. W., *see* Dimmock, J. R., 1033
Hanifin, J. W., Johnson, B. D., Menschik, J., Ridge, D. N., and Sloboda, A. E., potential antiarthritic agents I: benzoylacetonitriles, 535
Hanigan, J. J., *see* Pierson, S. L., 1550
Harbison, H. A., see Sturgeon, R. J., 1064
Haring, R. C., *see* Adams, W. P., 986
Harmatz, J. S., *see* Greenblatt, D. J., 57
Harrigan, S. E., *see* Reuning, R. H., 411
Hasegawa, J., *see* Adams, W. P., 986
Haslam, J. L., *see* Nakagawa, T., 718
Hassan, M. M. A., Muhtadi, F. J., and Al-Badr, A. A., GLC–mass spectrometry of *Teucrium polium* oil, 800
Hayden, T. L., *see* Bourne, D. W. A., 1571
Heidemann, D. R., rapid, stability-indicating, high-pressure liquid chromatographic determination of theophylline, guaifenesin, and benzoic acid in liquid and solid pharmaceutical dosage forms, 530
Heikius, B., *see* Lundberg, B., 542
Heller, J., and Trescony, P. V., controlled drug release by polymer dissolution II: enzyme-mediated delivery device, 919
Hem, S. L., *see* Chang, C.-J., 64
——*see* Porubcan, L. S., 358
——*see* Vanderlaan, R. K., 1498
Heman-Ackah, S. M., *see* Boakye-Yiadom, K., 1510
Hersey, J. A., *see* Yeung, C. C., 721
Hersh, S. D., *see* Wantland, L. R., 1144
Higson, H. G., *see* Tan, H. S. I., 1413
Higuchi, T., Shih, F.-M. L., Kimura, T., and Rytting, J. H., solubility determination of barely aqueous-soluble organic solids, 1267
——*see* Kreuter, J., 451
——*see* Lee, H. K., 288
——*see* Mendenhall, D. W., 746
——*see* Nakagawa, T., 718
——*see* Thakker, K. D., 93
Higuchi, W. I., *see* Flynn, G. L., 1090
——*see* Yu, C. D., 1341, 1347
Hincal, A. A., and Sheth, B. B., evaluation of adsorption from dispersion charge profile, 472
Hinsvark, O., *see* O'Brien, J. E., 75
Hirai, S., *see* Hussain, A. A., 1196
Hirayama, F., *see* Uekama, K., 1059
Hite, G., *see* Makriyannis, A., 788
Ho, N. F. H., and Roseman, T. J., lyophilization of pharmaceutical injections: theoretical physical model, 1170
——*see* Yu, C. D., 1341, 1347
Hobbs, D. C., *see* Fouda, H. G., 1456
Hodes, B., *see* Miksic, J. R., 1200
Hoeschele, J. D., *see* Bourne, D. W. A., 1571
Hoffman, D. J., sensitive GLC assay for pemoline in biological fluids using nitrogen-specific detection, 445
——*see* Sun, S. R., 386
Hoffmann, J. J., *see* Torrance, S. J., 664
Hofmann, A. F., *see* Flynn, G. L., 1090
Holak, W., and Shostak, D., differential pulse polarographic analysis of thyroid hormone: determination of iodine, thyroxine, and liothyronine, 338
Holcomb, I. J., *see* Chao, M. K., 1463
Holtzman, J. L., *see* Yost, Y., 1181
Hong, C. I., *see* Chheda, G. B., 1054
Hong, W. H., and Szulczewski, D. H., stability-indicating assay for vidarabine, 499
Honigberg, I. L., Stewart, J. T., and Coldren, J. W., liquid chromatography in pharmaceutical analysis X: determination of chlorzoxazone and hydroxy metabolite in plasma, 253
——see Kotzan, J. A., 1002
——*see Stewart, J. T., 32, 494*
Hooper, S. N., *see* Chandler, R. F., 245
Hoover, J. L., *see* Nelson, W. L., 115
Horhota, S. T., and Fung, H. L., percutaneous nitroglycerin absorption in rats, 608
Hori, R., *see Yoshida, H., 670*
Howard, S. A., Mauger, J., Hsieh, J. W., and Amin, K., suspending agent effects on steroid suspension *dissolution profiles, 1475*
——Mauger, J. W., Khwangsopha, A., and Pasquerelli, D. A., tablet position and basket type effects in spin-filter dissolution device, 1542
——*see* Mauger, J. W., 1084
Hsieh, J. W., *see* Howard, S. A., *1475*
Hsu, T. F., *see* Newburger, J., 651
Hu, J. M., see Foye, W. O., 202
Huang, C. L., *see* Pong, S. F., 666
Huang, S. M., *see* Nation, R. L., 532
Hubbard, W. D., *see* Sheppard, A. J., 98
Huber, H. E., Streng, W. H., and Tan, H. G. H., osmolality of parenteral solutions, 1028
Hufford, C. D., Collins, C. C., and Clark, A. M., microbial transformations and ^{13}C-NMR analysis of colchicine, 1239
Huizinga, T., *see* Schoonen, A. J. M., 163
Hull, D. S., *see* Godbey, R. E. W., 1176
Hull, L. A., Rosenblatt, D. H., and Epstein, J., 3-quinuclidinyl benzilate hydrolysis in dilute aqueous solution, 856
Hunke, L. A., *see* McGinity, J. W., 662
Hunt, D. H., *see* Smith, R. H., 1016
Hunter, H. H., and Kotzan, J. A., effect of obtrusive measures on antibiotic compliance, 272
Huq, A. S. M. S., *see* Rippie, E. G., 938
Hussain, A., and Bawarshi, R., new spectrophotometric determination of inorganic bromide and chloride salts in aqueous solutions, 513
——and Truelove, J., effect of hydroxyl group substituents on pyran ring on hydrolysis rate of benzoates: 2-tetrahydropyranyl benzoate, 235
——Hirai, S., and Bawarshi, R., nasal absorption of propranolol in rats, 1196
——Truelove, J., and Kostenbauder, H., kinetics and mechanism of hydrolysis of 1-(2′-acetoxybenzoyl)-2-deoxy-α-D-glucopyranose, a novel aspirin prodrug, 299
Hwang, D. R., and Driscoll, J. S., pyridones as potential antitumor agents, 816

I

Ibrahim, E. S. A., El Dine, S. A. S., Soliman, F. S. G., and Labouta, I. M., potential antineoplastics I: substituted 3,5-dioxo- and 3-thioxo-5-oxo-2,3,4,5-tetrahydro-1,2,4-triazines, 243
——Soliman, R., and Gabr, M., synthesis of 4-substituted aminobenzoate quaternary salts as potent antispasmodic agents, 33
Ikeda, K., *see* Uekama, K., 1059
Ikeda, S., *see* Sugiura, M., 1381
Imakura, Y., *see* ElGebaly, S. A., 887
——*see* Hall, I. H., 883
Inaba, K., *see* Uekama, K., 1059
Inoue, T., *see* Ogata, H., 708, 712
Intoccia, A. P., *see* Randolph, W. C., 1451
Ishida, T., Asakawa, Y., Takemoto, T., and Aratani, T., terpenoid biotransformation in mammals II: biotransformation of *dl*-camphene in rabbits, 928
Ismail, H. A., *see* Chandler, R. F., 245
Itami, T., *see* Tsukatani, H., 1426
Ithakissios, D. S., *see* Kubiatowicz, D. O., 621
Iwahashi, M., *see* Muramatsu, M., 175
Iyer, B. V., and Vasavada, R. C., evaluation of lanolin alcohol films and kinetics of triamcinolone acetonide release, 782

J

Jacknowitz, A. I., *see* Lim, J. K., 295
Jackson, A. J., *see* Garrett, E. R., 753
Jacob, J. T., *see* Koziol, T. R., 1135
Jadhav, A. L., Bhansali, K. G., and Davis, J. R., 6,6′-azopurine, a potent *in vitro* inhibitor of rabbit liver aldehyde oxidase, 1202
Jaffe, J. M., *see* Mathur, L. K., 699

Jagnandan, I., *Daun, H., Ambrosio, T. J., and Gilbert, S. G.*, isolation and identification of 3,3′,5,5′-tetrabis(*tert*-butyl)stilbenequinone from polyethylene closures containing titanium dioxide and butylated hydroxytoluene, 916
James, K. C., *see* Evans, B. K., 370
Janauer, G. E., *see* Zucconi, T. D., 426
Jansson, L., *see* Groningsson, K., 364
Jao, M. Y., *see Reuning, R. H., 411*
Jarowski, C. I., *see* Dubroff, L. S., 1554
——*see* Yang, K. Y., 560
Javid, P., *see* Needham, T. E., 952
Jeffcoat, A. R., *see* Pitt, C. G., 1534
Jefferson, D. M., *see Chien, Y. W., 689*
Jochsberger, T., Cutie, A., and Mills, J., differential pulse polarography of tetracycline: determination of complexing tendencies of tetracycline analogs in the presence of cations, 1061
John, P. M., Minatoya, H., and Rosenberg, F. J., microencapsulation of bitolterol for controlled release and its effect on bronchodilator and heart rate activities in dogs, 475
Johnson, B. D., *see* Hanifin, J. W., 535
Johnson, D. M., Reuter, A., Collins, J. M., and Thompson, G. F., enantiomeric purity of naproxen by liquid chromatographic analysis of its diastereomeric octyl esters, 112
Johnson, D. W., *see* Quay, J. F., 227
Johnson, R. F., Schenker, S., Roberts, R. K., Desmond, P. V., and Wilkinson, G. R., plasma binding of benzodiazepines in humans, 1320
Johnson, R. N., *see* Adams, W. P., 986
Johnson, R. W., Keenan, T. H., Kosh, J. W., and Sowell, J. W., Sr., synthesis of substituted 2-aminopyrrole analogs of lidocaine I, 317
——Keenan, T. H., Kosh, J. W., and Sowell, J. W., Sr., synthesis of substituted 2-aminopyrrole analogs of lidocaine II, 955
Johnston, M. M., Rosenberg, M., and Kamath, B., automated analysis of chlorthalidone, 967
——*see* Li, H. H. C., 569
Jones, P. K., *see* Threatte, R. M., 1530
Jonkman, J. H. G., van Bork, L. E., Wijsbeek, J., Bolhuis-de Vries, A. S., de Zeeuw, R. A., Orie, N. G. M., and Cox, H. L. M., first-pass effect after rectal administration of thiazinamium methylsulfate, 69
Juenge, E. C., and Brower, J. F., high-performance liquid chromatographic separation and identification of epimeric 17-ketone impurities in commercial sample of dexamethasone sodium phosphate, 551
Jun, H. W., *see* Kotzan, J. A., 1002
Juneau, R., Mitchell, S., and Wolgamott, G., new compounds: arylsulfonylhydrazones derived from various heterocycles, 930
Jung, D., *see* Die, S., 128
Jusko, W. J., Gardner, M. J., Mangione, A., Schentag, J. J., Koup, J. R., and Vance, J. W., factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol, 1358
——*see* MacKichan, J. J., 623
——*see* Sutfin, T. A., 703

K

Kabra, P. M., *see* McChesney, J. D., 1116
Kadry, H. A., *see* Habib, A. A. M., 1221
Kaetsu, I., *see* Yoshida, M., 628, 860
Kaewchansilp, V., *see* Foye, W. O., 1131
Kamath, B., *see* Johnston, M. M., 967
Kaminski, E. E., Cohn, R. M., McGuire, J. L., and Carstensen, J. T., light stability of norethindrone and ethinyl estradiol formulated with FD&C colorants, 368
Kaminski, J. J., *see* Dimmock, J. R., 36
Kante, B., *see* Couvreur, P., 1521
Kapoor, A., *see* Veronich, K., 1515
Kauffman, J. M., *see* Foye, W. O., 336
Kavanagh, F., *see* Foglesong, M. A., 797
Keenan, T. H., *see* Johnson, R. W., 317, 955
Keily, H. J., *see* Tan, H. S. I., 1413
Keller, W. J., macromerine and normacromerine biosynthesis in *Coryphantha macromeris* var. *runyonii*, 85
Kelly, R. G., *see* Cooper, T. B., 216
Kemmerer, J. M., Rubio, F. A., McClain, R. M., and Koechlin, B. A., stereospecific assay and stereospecific disposition of racemic carprofen in rats, 1274
Kendall, F. M., *see Landin, W. E., 978*
——*see* Tansy, M. F., 127, 1107
Kenner, C. T., *see* Graham, R. E., 871
Kensler, T. T., Behme, R. J., and Brooke, D., high-performance liquid chromatographic analysis of cyclophosphamide, 172
Khalil, S. K. W., *see* Nygard, G., 379, 1318
Khemani, L., *see* Alkalay, D., 156
Khwangsopha, A., *see* Howard, S. A., 1542
——*see* Mauger, J. W., 1084
Kier, L. B., and Hall, L. H., molecular connectivity analyses of structure influencing chromatographic retention indexes, 120
——*see* Di Paolo, T., 39
——*see* Glennon, R. A., 906
Kiger, J. L., *see* Guerret, M., 219
Kim, S. W., *see* Christy, D. P., 1102
Kimura, T., *see* Higuchi, T., 1267
Kingston, D. G. I., and Sami, S. M., cytotoxicity of modified indole alkaloids, 1403
Kinsun, H., *see* DeBruyne, D., 511
Kirchhoefer, R. D., *see* Reepmeyer, J. C., 1167
Kissinger, P. T., *see* Miner, D. J., 96
Klein, L., *see* Baaske, D. M., 1472
Klein, L. C., *see* Staubus, A. E., 1438
Knapp, J. E., *see* Chien, M. M., 247
Koechlin, B. A., *see* Kemmerer, J. M., 1274
Koinis, T., *see* Olanoff, L., 1147
Kolasinski, H., *see* Robertson, D. L., 577
Kolb, V. M., long-range substituent effects in morphine-type agonists and antagonists: a possible explanation for some opiate anomalies, 1250
Komatsu, H., and Suzuki, M., percutaneous absorption of butylparaben through guinea pig skin *in vitro*, 596
Kornet, M. J., synthesis of α-methylenebutyrolactams as potential antitumor agents, 350
——and Daniels, R., 1,2-dialkyl-4-pyrazolidinethiols as potential antiradiation agents, 1331
——and Garrett, R. J., synthesis of 1-phenyl-2-(phenylcarbamoyl)pyrazolidines as potential anticonvulsant agents, 377
Korol, B., and Miller, L. D., oxybutynin influence on autonomic measures in dogs, 643
Kosh, J. W., *see* Johnson, R. W., 317, 955
Kostenbauder, H., *see* Hussain, A., 299
Kotzan, J. A., Needham, T. E., Honigberg, I. L., Vallner, J. J., Stewart, J. T., Brown, W. J., and Jun, H. W., examination of blood clobazam levels and several pupillary measures in humans, 1002
——*see* Hunter, R. H., 272
Koup, J. R., *see* Jusko, W. J., 1358
Koupparis, M. A., Walczak, K. M., and Malmstadt, H. V., corticosteroid determination in skin preparations by a reaction rate method, 1479
Kowtko, J., *see* Emery, M., 1185
Koziol, T. R., Jacob, J. T., and Achari, R. G., ion-pair liquid chromatographic assay of decongestants and antihistamines, 1135
Kravetz, T. M., *see* Moniot, J. L., 705
Krebs, H. A., *see* Yeh, S. Y., 133
Kreuter, J., and Higuchi, T., improved delivery of methoxsalen, 451
——Täuber, U., and Illi, V., distribution and elimination of poly(methyl-2-^{14}C-methacrylate) nanoparticle radioactivity after injection in rats and mice, 1443
Krogerus, V. E., *see* Sirenius, I., 791
Krueger, D. S., *see* Adams, W. J., 1138
Kubiatowicz, D. O., Bollas, T. F., Nora, J. C., and Ithakissios, D. S., localization of low molecular weight ^{99m}Tc-labeled dimercaptodicarboxylic acids in kidney tissue, 621
Kubo, O., *see* Tsuji, A., 812
Kullberg, M. P., *see* Peterson, J. E., 1447
Kulsa, P., *see* VandenHeuvel, W. J. A., 1156
Kumakura, M., *see* Yoshida, M., 628, 860
Kunka, R. L., and Mattocks, A. M., nonlinear model for acetazolamide, 342
——and Mattocks, A. M., relationship of pharmacokinetics to pharmacological response for acetazolamide, 347
Kunz, A. L., see Staubus, A. E., 1438
Kupinić, M., *Medić-Sarić, M., Movrin, M., and Maysinger, D.*, antibacterial and antifungal activities of isatin *N*-Mannich bases, 459
Küppers, F. J. E. M., *see* Vincent, P. G., 87
Kurata, K., Takeuchi, M., and Yoshida, K., quantitative flash-methylation analysis of phenobarbital, 1187
Kurobe, M., *see* Sugiura, M., 1381
Kwan, K. C., *see* Yeh, K. C., 1120
Kwan, K. H., *see* Flynn, G. L., 1090
Kwon, Y. G., *see* Nelson, W. L., 115
Kyle, L. E., *see* Chiou, W. L., 1224

L

Labouta, I. M., *see* Ibrahim, E. S. A., 243
La Canna, G., *see* Astorri, E., 104
Lagas, M., *see* Lerk, C. F., 634
Lai, A. A., and Levy, R. H., pharmacokinetic description of drug interactions by enzyme induction: carbamazepine–clonazepam in monkeys, 416
——*see* Levy, R. H., 399
Lai, C. M., Stoll, R. G., Look, Z. M., and Yacobi, A., urinary excretion of chlorpheniramine and pseudoephedrine in humans, 1243
——*see* Baaske, D. M., 1472
Lakings, D. B., Lizarraga, C., Haggerty, W. J., and Williamson, M. J., high-performance liquid chromatographic microdetermination of indoprofen in human milk, 1113
Lambert, H. J., *see* Chien, Y. W., 689
——*see* Lee, H. K., 288
Landen, W. O., Jr., and Caine, D. S., preparation of diastereomeric urethane derivatives of atropine and *l*-hyoscyamine using (–)-1-phenylethylisocyanate, 1039
Landin, W. E., Kendall, F. M., and Tansy, M. F., metabolic performance and GI function in magnesium-deficient rats, 978
——*see* Tansy, M. F., 127, 1107
Lau-Cam, C. A., and Pizzitola, V., simple field test for marijuana, 976
——*see* Rosenberg, J. M., 1179
Lavene, D., *see* Guerret, M., 219
Lawson, A., *see* Wood, S. G., 374
Lawson, C. F., see Morozowich, W., 833, 949
LeBelle, M. J., Graham, K., and Wilson, W. L., high-performance liquid chromatographic analysis of penicillin V benzathine oral suspensions, 555
——*see* Wilson, W. L., 1322
Lee, H. K., Lambert, H., Stella, V. J., Wang, D., and Higuchi, T., hydrolysis and dissolution behavior of a prolonged-release prodrug of theophylline: 7,7′-succinylditheophylline, 288
Lee, K. H., *see* ElGebaly, S. A., 887
——*see* Hall, I. H., 537, 883
——*see* Waddell, T. G., 715
Lee, M. G., *see* Nation, R. L., 532
Lee, T. L., D'Arconte, L., and Brooks, M. A., high-pressure liquid chromatographic determination of amoxicillin in urine, 454
——*see* Weinfeld, R. E., 1387
Lee, V. H.-L., and Robinson, J. R., mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits, 673
Legheand, J., *see* Sassard, J., 1190
Lemanowicz, E. F., Sugita, E. T., Niebergall, P. J., and Schnaare, R. L., kinetics of absorption and elimination of pralidoxime chloride in dogs, 141
Leppanen, T., *see* Sirenius, I., 791
Lerk, C. F., Bolhuis, G. K., and de Boer, A. H., effect of microcrystalline cellulose on liquid penetration in and disintegration of directly compressed tablets, 205
——Lagas, M., Lie-a-Huen, L., Broersma, P., and Zuurman, K., *in vitro* and *in vivo* availability of hydrophilized phenytoin from capsules, 634
Lesko, L. J., Canada, A. T., Eastwood, G., Walker, D., and Brousseau, D. R., pharmacokinetics and relative bioavailability of oral theophylline capsules, 1392
Leslie, J., alkaline hydrolysis of 1,3-dimethylphenobarbital, 639
Lettieri, J. T., *see* Fung, H.-L., 1198

Leung, L. C., and Ando, H. Y., rotating-disk method for *determining cutaneous metabolism,* 571
Leveque, M. J., *see* Sun, S.-R., 1567
Levine, H. L., *see* Block, J. H., 605
Levy, G., *see* Crow, J. W., 958, 1309
——*see* Galinsky, R. E., 805
——*see* Oie, S., 1, 6
——*see* Slattery, J. T., 393
——see Takada, K., 1569
——*see* Wiegand, U. W., 1483
——*see* Yacobi, A., 742
Levy, R. H., and Dumain, M. S., time-dependent kinetics VI: direct relationship between equations for drug levels during induction and those involving constant clearance, 934
——Lai, A. A., and Dumain, M. S., time-dependent kinetics IV: pharmacokinetic theory of enzyme induction, 398
——*see* Lai, A. A., 416
Lewkowicz, C., *see* Zucconi, T. D., 426
Li, H. H. C., Feeney, W. P., and Johnston, M. M., use of a nitrogen-specific detector for GLC determination of plasma bucainide, 569
Li, K. L., *see* Sena, F. J., 1465
Liao, R. C. H., *see* Lien, E. J., 463
Liao, W. C., and Zatz, J. L., critical surface tensions of pharmaceutical solids, 488
——and Zatz, J. L., surfactant solutions as test liquids for measurement of critical surface tension, 486
Lie-a-Huen, L., *see* Lerk, C. F., 634
Lien, E. J., Liao, R. C. H., and Shinouda, H. G., quantitative structure–activity relationships and dipole moments of anticonvulsants and CNS depressants, 463
Lim, J. K., specificity of nitroglycerin assays: a response, 1198
——Narang, P. K., Overman, D. O., and Jacknowitz, A. I., beneficial effects of methionine and histidine in aspirin solutions on gastric mucosal damage in rats, 295
——*see* Narang, P. K., 645
Lin, S. K., Moss, A. A., and Riegelman, S., kinetics of drug–drug interactions: biliary excretion of iodoxamic acid and iopanoic acid in rhesus monkeys, 1430
Lindemann, C. J., *see* Ryan, J. A., 1194
Lindenbaum, A., *see* Guilmette, R. A., 194
Lindenbaum, S., *see* Zimmerer, R. O., Jr., 581
Lindstrom, R. E., solubility in amide–water cosolvent systems II: cosolvent excess at solute surface, 1141
Li Wan Po, A., *see* Enever, R. P., 169
Lizarraga, C., *see* Lakings, D. B., 1113
Lo, L., *see* Simons, K. J., 252
Lock, A., Eckman, B. M., and Ayres, J., antipyretic effect of acetaminophen suppositories in rats, 1105
Loeffler, L. J., and Pittman, A. W., development of radioimmunoassay for guanethidine, 1419
——and Schran, H. F., antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay, 1433
——*see* Hall, I. H., 696
Long, M. D., *see* Andresen, B. D., 283
Longschampt, J., *see* Guerret, M., 219
Lonsdale, H. K., *see* Baker, R. W., 20
Look, Z. M., *see* Baaske, D. M., 1472
——*see* Lai, C. M., 1243
Lordi, N. G., *see* Bhatia, R. P., 222, 896
——*see* Timko, R. J., 601
Lovering, E. G., *see* Poirier, M. A., 1124
——*see* Robertson, D. L., 577
Lövgren, T., *see* Lundberg, B., 542
Lowry, J. B., direct spectrophotometric assay of quaternary ammonium compounds using bromthymol blue, 110
Luber, E., Jr., *see* Warner, P. L., Jr., 1453
Luber, J. R., Visalli, A. J., and Patel, D. M., modified USP assay for simultaneous determination of aspirin and nonaspirin salicylates in aspirin and buffered aspirin tablets, 780
Lucek, R., *see* Dixon, R., 261
Ludden, T. M., Goggin, L. K., McNay, J. L., Jr., Haegele, K. D., and Shepherd, A. M. M., high-pressure liquid chromatographic assay for hydralazine in human plasma, 1423
——*see* Reuning, R. H., 411
Lund, F., *see* Baltzer, B., 1207
Lundberg, B., Lövgren, T., and Heikius, B., simultaneous solubilization of steroid hormones II: androgens and estrogens, 542
Lundblad, J. L., *see* Ng, P. K., 239
Luscombe, D. K., *see* Evans, B. K., 370
Lutz, R. J., *see* Yang, K. H., 941
Lyons, L. L., see Welling, P. G., 150

M

Ma, J. K. H., *see* O'Donnell, J. P., 1256, 1524
——*see* Zia, H., 1335
MacKichan, J. J., and Jusko, W. J., *hydrocortisone* stability in human feces, 623
MacLaughlin, D. S., *see* Greenblatt, D. J., 57
Maeda, T., Takenaka, H., Yamahira, Y., and Noguchi, T., use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets, 1286
Mahn, F. P., *see* McSharry, W. O., 241
Mahuzier, G., *see* Farinotti, R., 484
Makoid, M. C., and Robinson, J. R., pharmacokinetics of topically applied pilocarpine in the albino rabbit eye, 435
——*see* Ueda, C. T., 448
Makriyannis, A., and Hite, G., nortropacocaine hydrochloride conformation in aqueous and hydrophobic media, 788
Malmstadt, H. V., *see* Koupparis, M. A., 1479
Malspeis, L., *see* Reuning, R. H., 411
Mangia, A., Silingardi, S., Bortesi, F., Grisanti, G., and Di Bitetto, M., high-performance liquid chromatographic determination of cephacetrile, 652
Mangione, A., *see* Jusko, W. J., 1358
Manius, G. J., determination of ethylene oxide, ethylene chlorohydrin, and ethylene glycol residues in ophthalmic solutions at proposed concentration limits, 1547
Marshall, G. L., *see* Nelson, W. L., 115
Martin, D. F., *see* Eng-Wilmot, D. L., 963
Martin, E., Yalkowsky, S. H., and Wells, J. E., fusion of disubstituted benzenes, 565
Martin, J. S., *see* Tansy, M. F., 127, 1107
Martynovych, S., *see* Cioffi, F. J., 1280
Marzo, A., *see* Astorri, E., 104
Massart, D. L., *see* Vandeputte, M., 1416
Matheson, L. E., Jr., Wurster, D. E., and Ostrenga, J. A., sarin transport across excised human skin II: effect of solvent pretreatment on permeability, 1410
——*see* Wurster, D. E., 1406
Mathur, L. K., Jaffe, J. M., Poust, R. I., Barry, H., Goehl, T. J., Shah, V. P., and Colaizzi, J. L., bioavailability and dissolution behavior of trisulfapyrimidine suspensions, 699
Matsui, F. F., *see* Robertson, D. L., 577
Mattocks, A. M., *see* Kunka, R. L., 342, 347
Mauger, J. W., Howard, S. A., and Khwangsopha, A., hydrodynamic characterization of a spin-filter dissolution device, 1084
——*see* Howard, S. A., 1475, 1542
Maysinger, D., *see* Kupinic, M., 459
McAllister, R. G., Jr., Tan, T. G., and Bourne, D. W. A., GLC assay of verapamil in plasma: identification of fluorescent metabolites after oral drug administration, 574
McAuliff, J. P., *see* Arnold, A., 1557
McCarthy, D. A., *see* Reuning, R. H., 411
McChesney, J. D., Kabra, P. M., and Fraher, P., simple analogs of the toxin callicarpone, 1116
——*see* Corbin, N. C., 1501
McClain, R. M., *see* Kemmerer, J. M., 1274
McClurg, J. E., *see* Pierson, S. L., 1550
McErlane, K. M., *see* Poirier, M. A., 1124
McGarry, P. F., *see* Umagat, H., 922
McGaughran, W. R., *see* Ryan, J. A., 1194
McGilveray, I. J., *see* Midha, K. K., 557
McGinity, J. W., Hunke, L. A., and Combs, A. B., effect of water-soluble carriers on morphine sulfate release from a silicone polymer, 662
McGlinchey, G., *see* Spillane, W. J., 372
McGuire, H., *see* Rosenberg, J. M., 1179
McGuire, J. L., *see* Alton, K. B., 880
——*see* Kaminski, E. E., 368
McKenzie, W. L., *see* Burton, F. W., 280
McNay, J. L., Jr., *see* Ludden, T. M., 1423
McSharry, W. O., and Mahn, F. P., high-pressure liquid chromatographic assay of folic acid: a collaborative study, 241
——*see* Fadil, F. A., 97
Medić-Šarić, M., *see* Kupinić, M., 459
Medwick, T., and Abdou, H. M., kinetics and mechanism of reaction of *m*-nitrobenzhydrazide and other hydrazines with acetic acid, 301
Melani, F., see Ballerini, R., 366
Meli, A., *see* Ballerini, R., 366
Melikian, A. P., *see* Straughn, A. B., 1099
Mendenhall, D. W., Higuchi, T., and Sternson, L. A., analysis of hydrophobic amine antimalarials in biological fluids with the plastic ion-selective electrode, 746
——*see* Nakagawa, T., 718
Menschik, J., *see* Hanifin, J. W., 535
Mergens, W. J., Vane, F. M., Tannenbaum, S. R., Green, L., and Skipper, P. L., *in vitro* nitrosation of methapyrilene, 827
Merkle, J., and Zeller, H., absence of povidone-iodine-induced mutagenicity in mice and hamsters, 100
Meyer, M. C., and Raghow, G., high-pressure liquid chromatographic assay for griseofulvin in plasma, 1127
——*see* Straughn, A. B., 1099
Micossi, L., *see* Antonini, I., 321
Midha, K. K., Cooper, J. K., and McGilveray, I. J., simple and specific electron-capture GLC assay for plasma and urine ephedrine concentrations following single doses, 557
Miksic, J. R., and Hodes, B., theophylline analysis by reversed-phase high-pressure liquid chromatography: elimination of interferences, 1200
Miles, N. J., *see* Schwan, T. J., 1325
Millar, J. F., *see* Roman, R., 733, 736
Miller, A. K., *see* VandenHeuvel, W. J. A., 1156
Miller, B. M., *see* VandenHeuvel, W. J. A., 1156
Miller, L. D., *see* Korol, B., 643
Miller, R., *see* Giles, H. G., 1459
Miller, T. W., *see* VandenHeuvel, W. J. A., 1156
Miller, W. L., *see* Morozowich, W., 833, 836, 949
Mills, J., *see* Jochsberger, T., 1061
Minatoya, H., *see* John, P. M., 475
Miner, D. J., and Kissinger, P. T., trace determination of acetaminophen in serum, 96
Mitchell, S., *see* Juneau, R., 930
Mittelman, A., *see* Chheda, C. B., 1054
Miyamoto, E., *see* Tsuji, A., 616, 812, 1259
Moniot, J. L., Kravetz, T. M., Abd El Rahman, A. E. R. H., and Shamma, M., chemistry of 8-chloroberberine, 705
Moody, J. E., *see* O'Hare, M. J., 106
——*see* Sapio, J. P., 506
Moore, H. A., *see* Ross, A. J., 657
Moros, S. A., *see* Ross, A. J., 657
Morozowich, W., Oesterling, T. O., Miller, W. L., and Douglas, S. L., prostaglandin prodrugs II: new method for synthesizing prostaglandin C_1-aliphatic esters, 836
——Oesterling, T. O., Miller, W. L., Lawson, C. F., Cornette, J. C., Weeks, J. R., and Douglas, S. L., prostaglandin prodrugs III: synthesis and biological properties of C_9- and C_{15}-monoesters of dinoprost (prostaglandin $F_{2\alpha}$), 949
——Oesterling, T. O., Miller, W. L., Lawson, C. F., Weeks, J. R., Stehle, R. G., and Douglas, S. L., prostaglandin prodrugs I: stabilization of dinoprostone (prostaglandin E_2) in solid state through formation of crystalline C_1-phenyl esters, 833
——*see* Cho, M. J., 1069
Morrison, B. E., *see* Reuning, R. H., 411
Morrison, R., and Fung, H.-L., specificity of nitroglycerin assays, 1197
Moss, A. A., *see* Lin, S. K., 1430
Motycka, S., and Nairn, J. G., preparation and evaluation of microencapsulated ion-exchange resin beads, 211
Moulin, M. A., *see* DeBruyne, D., 511
Mourot, D., Delépine, B., Boisseau, J., and Gayot, G., high-pressure liquid chromatographic analysis of veterinary anthelmintics I: quantitative determination of tetramisole, 796

Moussa, M. A., *see* Skinner, W. A., 390, 391
Movrin, M., *see* Kupinic, M., 459
Mrozik, H., see VandenHeuvel, W. J. A., 1156
Muhtadi, F. J., *see* Hassan, M. M. A., 800
Mulhall, D. W., *see* Briggs, C. J., 129
Munson, J. W., Papadimitriou, D., and DeLuca, P. P., colorimetric determination of penicillins and related compounds in intravenous solutions by nickel(II)-catalyzed hydroxamic acid formation, 1333
Muramatsu, M., Iwahashi, M., and Takeuchi, U., thermodynamic relationship between α- and β-forms of crystalline progesterone, 175
Musson, D. G., and Sternson, L. A., analysis of nitrosamines in aqueous and biological fluids based on measurement of photochemically liberated nitrite, 1159
Musto, J. D., Sane, J. N., and Warner, V. D., quantitative determination of hexylresorcinol in commercial antiseptic solution by high-pressure liquid chromatography, 240

N

Naghaway, J., and Soine, T. O., preparation of semisynthetic (+)-tubocurarine chloride, 655
Nairn, J. G., *see* Motycka, S., 211
Nakagawa, T., Higuchi, T., Haslam, J. L., Shaffer, R. D., and Mendenhall, D. W., GLC determination of whole blood antimalarial concentrations, 718
Nakano, N. I., temperature-dependent aqueous solubilities of lidocaine, mepivacaine, and bupivacaine, 667
Nakashima, E., *see* Tsuji, A., 308
Narang, P. K., and Crouthamel, W. G., dihydroquinidine contamination of quinidine raw materials and dosage forms: rapid estimation by high-performance liquid chromatography, 917
——and Lim, J. K., amino acid effect on aspirin stability in propylene glycol, 645
——*see* Lim, J. K., 295
Nash, J. F., Bechtol, L. D., Bunde, C. A., Bopp, R. J., Farid, K. Z., and Spradlin, C. T., linear pharmacokinetics of orally administered fenoprofen calcium, 1087
——*see* Quay, J. F., 227
Nasir, S. M., *see* Nasir, S. S., 177
Nasir, S. S., Wilken, L. O., Jr., and Nasir, S. M., new *in vitro* dissolution test apparatus, 177
Nation, R. L., Lee, M. G., Huang, S. M., and Chiou, W. L., precaution in use of high-pressure liquid chromatographic simultaneous plasma procainamide and *N*-acetylprocainamide determination, 532
Needham, T. E., Javid, P., and Brown, W., bioavailability and dissolution parameters of seven lithium carbonate prodrugs, 952
——*see* Kotzan, J. A., 1002
——*see* Shah, K. A., 1486
Nelis, H. J. C. F., *see* De Leenheer, A. P., 999
——*see* De Leenheer, A. P., 1527
Nelson, W. L., Kwon, Y. G., Marshall, G. L., Hoover, J. L., and Pfeffer, G. T., fluorinated phenytoin anticonvulsant analogs, 115
Newburger, J., Hsu, T. F., and Combs, A. B., high steady-state levels of uric acid produced in rats by dietary training and potassium oxonate, 651
Newton, B. N., *see* Staubus, A. E., 1438
Newton, D. W., pKa of 2-methylamino-5-chlorobenzophenone, a diazepam hydrolysis product, 937
Ng, P. K., and Lundblad, J. L., quantitation of sodium in human albumin solutions, 239
Niazi, S., *see* El-Rashidy, R., 103
Niebergall, P. J., *see* Lemanowicz, E. F., 141
——*see* Vadino, W. A., 1316
Ning, R. Y., *see* Earley, J. V., 845
Noble, L. M., *see* Dimmock, J. R., 1033
Noguchi, T., *see* Maeda, T., 1286
Nora, J. C., *see* Kubiatowicz, D. O., 621
Nyathi, C. B., Gupta, V. S., and Dimmock, J. R., evaluation of 1-(3,4-dichlorophenyl)-4-dimethylaminomethyl-1-nonen-3-one hydrochloride effect on nucleic acid and protein syntheses using murine leukemia L-1210 cells, 1383
——*see* Dimmock, J. R., 1216
Nygard, G., Shelver, W. H., and Khalil, S. K. W., sensitive high-pressure liquid chromatographic determination of disopyramide and mono-*N*-dealkyldisopyramide, 1318
——Shelver, W. H., and Khalil, S. K. W., sensitive high-pressure liquid chromatographic determination of propranolol in plasma, 379

O

Oberholtzer, E. R., and Brenner, G. S., cefoxitin sodium: solution and solid-state chemical stability studies, 863
O'Brien, J. E., Abbey, V., Hinsvark, O., Perel, J., and Finster, M., metabolism and measurement of chloroprocaine, an ester-type local anesthetic, 75
O'Dell, C. A., *see* Shealy, Y. F., 670
O'Donnell, J. P., *Parekh, S., Borgman, R. J., and* Gorczynski, R. J., synthesis and pharmacology of potential β-blockers, 1236
——Proveaux, W. J., and Ma, J. K. H., high-performance liquid chromatographic studies of reaction of hydralazine with biogenic aldehydes and ketones, 1524
——Proveaux, W. J., and Ma, J. K. H., kinetic studies of hydralazine reaction with acetaldehyde, 1256
——*see* Zia, H., 1335
Oesterling, T. O., *see* Morozowich, W., 833, 836, 949
Ogata, H., Shibazaki, T., Inoue, T., and Ejima, A., comparative studies on eight dissolution methods using 21 commercial chloramphenicol tablets and a nondisintegrating benzoic acid tablet, 708
——Shibazaki, T., Inoue, T., and Ejima, A., dissolution systems for chloramphenicol tablet bioavailability, 712
O'Hare, M. J., Tan, E., and Moody, J. E., quantitative determination of chlorthalidone in pharmaceutical dosage forms by high-pressure liquid chromatography, 106
Øie, S., and Jung, D., bioavailability under variable renal clearance conditions, 128
——and Levy, G., effect of salicylic acid on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia, 1
——and Levy, G., effect of sulfisoxazole on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia, 6
——and Tozer, T. N., effect of altered plasma protein binding on apparent volume of distribution, 1203
Okumura, K., *see* Yoshida, H., 670
Olanoff, L., and Anderson, J. M., controlled release of tetracycline II: development of an *in vivo* flow-limited pharmacokinetic model, 1151
——Koinis, T., and Anderson, J. M., controlled release of tetracycline I: *in vitro* studies with a trilaminate 2-hydroxyethyl methacrylate–methyl methacrylate system, 1147
O'Melia, P., *see* Peterson, J. E., 1447
O'Neill, J., *see* Roman, R., 733
Ongley, R., *see* Tam, Y. K., 1254
Orie, N. G. M., *see* Jonkman, J. H. G., 69
Osborne, V. L., *see* Randolph, W. C., 1451
Ostrenga, J. A., *see* Matheson, L. E., Jr., 1410
——*see* Wurster, D. E., 1406
Otani, T. T., and Briley, M. R., *N*-benzoyl derivatives of amino acids and amino acid analogs as growth inhibitors in microbial antitumor screen, 1366
——and Briley, M. R., *N*-benzoyl derivatives of amino acids and amino acid analogs as inhibitors in microbial antitumor screen, 260
——and Briley, M. R., effect of *N*-trifluoroacetyl derivatives of amino acids and amino acid analogs on microbial antitumor screen, 496
Overman, D. O., *see* Lim, J. K., 295
Owen, W. R., and Stewart, P. J., kinetics and mechanism of chlorambucil hydrolysis, 992

P

Pace, M., *see* Pietta, P. G., 1565
Pai, J. K., *see* Ravikumar, P. R., 1302
Palermo, B. T., *see* Slater, J. G., 49
Palermo, P. J., and Tsai, P. S.-F., high-pressure liquid chromatographic determination of saccharin in artificial sweeteners and pharmaceuticals, 878
Palmieri, A., III, microencapsulation and dissolution parameters of undecenovanillylamide: a potential coyote deterrent, 1561
Pandey, V. N., Rao, K. P. S., Patel, K. M., and Gopal, N. G. S., antimicrobial activity of chlormerodrin, 256
Papadimitriou, D., *see* Munson, J. W., 1333
Parekh, S., *see* O'Donnell, J. P., 1236
Parks, J. E., see Guilmette, R. A., 194
Parmar, S. S., *see Singh, S. P., 89, 470, 890*
Parsons, D. L., and Vallner, J. J., dynamic dialysis in drug–erythrocyte interactions, 546
Pasquerelli, D. A., *see* Howard, S. A., 1542
Patel, D. M., *see* Galante, R. N., 1494
——*see* Luber, J. R., 780
Patel, K. M., *see* Pandey, V. N., 256
Patrick, J. E., *see* Alton, K. B., 599, 880
Peat, M. A., Finkle, B. S., and Deyman, M. E., high-pressure liquid chromatographic determination of chlordiazepoxide and its major metabolites in biological fluids, 1467
Perdue, G. P., Blomster, R. N., Blake, D. A., and Farnsworth, N. R., South American plants II: taspine isolation and anti-inflammatory activity, 124
Perel, J., *see* O'Brien, J. E., 75
Perry, C., *see* Dixon, R., 261
Petersen, R. V., *see* Christy, D. P., 1102
Peterson, J. E., Barnick, C. T., Benziger, D., Kullberg, M. P., Brown, R., O'Melia, P., Clemans, S., and Edelson, J., analysis of cyclazocine in plasma, 1447
——Graham, M., Banks, W. F., Benziger, D., Rowe, E. A., Clemans, S., and Edelson, J., plasma pentazocine radioimmunoassay, 626
Pettit, G. R., and Smith, T. H., structural biochemistry XIII: synthesis of luteinizing hormone-releasing hormone modification [Trp^6]-LH-RH, 1013
——Gieschen, D. P., and Pettit, W. E., antineoplastic agents LXIV: 1,4-bis(2′-chloroethyl)-1,4-diazabicyclo[2.2.1]heptane dihydrogen dimaleate, 1539
Pettit, W. E., *see* Pettit, G. R., 1539
Pfeffer, G. T., *see* Nelson, W. L., 115
Phillips, E. W., *see* Vilallonga, F. A., 314
Piantadosi, C., see DiMenna, W. S., 667
Piechocki, J. T., *see* Sena, F. J., 1465
Pieniaszek, H. J., Jr., and Bates, T. R., capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats, 1323
Pierson, S. L., Hanigan, J. J., Taylor, R. E., and McClurg, J. E., simple and rapid high-pressure liquid chromatographic determination of papaverine in plasma, 1550
Pietta, P. G., Agnellini, D., and Pace, M., colorimetric determination of 1-(4′-nitrophenyl)-2-aminopropane-1,3-diol with 2,4,6-trinitrobenzenesulfonic acid in the presence of chloramphenicol, 1565
Piraino, A. J., *see* DiGregorio, G. J., 1192
Pitlick, W. H., *see* Shiu, G. K., 232
Pitt, C. G., Gratzl, M. M., Jeffcoat, A. R., Zweidinger, R., and Schindler, A., sustained drug delivery systems II: factors affecting release rates from poly(ϵ-caprolactone) and related biodegradable polyesters, 1534
Pitterle, M. E., *see* Welling, P. G., 150
Pittman, A. W., *see* Loeffler, L. J., 1419
Pizzitola, V., *see* Lau-Cam, C. A., 976
Place, J. F., comparison of high-pressure liquid chromatographic and ion-exchange membrane methods for creatinine, 802
Piazonnet, B., *see* Schmitt, C., 381
Pluym, A., TLC differentiation of butyrophenone and diphenylbutylpiperidine compounds from phenothiazine derivatives, 1050
Poirier, M. A., Curran, N. M., McErlane, K. M., and Lovering, E. G., impurities in drugs III: trihexyphenidyl, 1124
Pong, S. F., and Huang, C. L., effect of UV irradiation and tritiation on hydroxyzine, 666
Poochikian, G. K., and Cradock, J. C., enhanced chartreusin solubility by hydroxybenzoate hydrotropy, 728
Popp, F. D., and Donigan, B. E., synthesis of 3-hydroxy-3-phenacyloxindole analogs, 519
Porubcan, L. S., Born, G. S., White, J. L., and Hem, S.

L., interaction of digoxin and montmorillonite: mechanism of adsorption and degradation, 358
Poust, R. I., *see* Mathur, L. K., 699
Prakongpan, S., *see* Flynn, G. L., 1090
Prasad, V. K., *see* Goehl, T. J., 1374
Proveaux, W. J., *see* O'Donnell, J. P., 1256, 1524
Pryor, P., *see* Darling, C. M., 108
Pu, F. S., and Chiou, W. L., creatinine VII: determination of saliva creatinine by high-performance liquid chromatography, 534
Pulsieux, F., *see* Cave, G., 424

Q

Quay, J. F., Childers, R. F., Johnson, D. W., Nash, J. F., and Stucky, J. F., II, cinoxacin in female mongrel dogs: effect of urine pH on urinary drug excretion and correlation of *in vitro* characteristics of oral dosage forms with bioavailability, 227

R

Rackur, G., *see* Skinner, W. A., 330
Raghow, G., *see* Meyer, M. C., 1127
Randolph, W. C., Osborne, V. L., and Intoccia, A. P., high-pressure liquid chromatographic analysis of ticrynafen and one of its metabolites in urine and serum, 1451
Rao, K. P. S., *see* Pandey, V. N., 256
Rao, K. V., interaction of streptonigrin with metals and with DNA, 853
Rastrup-Andersen, N., *see* Baltzer, B., 1207
Rattie, E. S., Zimmerman, J. J., and Ravin, L. J., degradation kinetics of a new cephalosporin derivative in aqueous solution, 1369
Ravikumar, P. R., Hammesfahr, P., and Sih, C. J., Cytotoxic saponins from the Chinese herbal drug Yunnan Bai Yao, 900
——Pai, J. K., Zmijewski, M. J., and Sih, C. J., biosynthesis of prostaglandin D_2, 15-ketoprostaglandin E_2, and hydroxy fatty acids by ram seminal vesicle microsomes, 1302
Ravin, L. J., *see* Rattie, E. S., 1369
Ravis, W. R., and Feldman, S., effect of enzyme-inducing and enzyme-inhibiting agents on drug absorption II: influence of proadifen on 3-*O*-methylglucose transport in rats, 945
Razzak, K. S. A., synthesis of phenyl-3- and phenyl-5-acetamidosalicylates as potential analgesics, 893
Reepmeyer, J. C., and Kirchhoefer, R. D., isolation of salicylsalicylic acid, acetylsalicylsalicylic acid, and acetylsalicylic anhydride from aspirin tablets by extraction and high-pressure liquid chromatography, 1167
Reid, D. M., *see* Coutts, S. M., 353
Renzi, N. L., Jr., and Tam, J. N., quantitative GLC determination of oxycodone in human plasma, 43
Repta, A. J., *see* Dimmock, J. R., 36
Resetarits, D. E., and Bates, T. R., errors in chlorothiazide bioavailability estimates based on a Bratton–Marshall colorimetric method for chlorothiazide in urine, 126
Reuning, R. H., Batra, V. K., Ludden, T. M., Jao, M. Y., Morrison, B. E., McCarthy, D. A., Harrigan, S. E., Ashcraft, S. B., Sams, R. A., Bathala, M. S., Staubus, A. E., and Malspeis, L., plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys, 411
Reuter, A., *see* Johnson, D. M., 112
Richards, J. M., *see* Richards, R. M. E., 1436
Richards, R. M. E., and Richards, J. M., *Pseudomonas cepacia* resistance to antibacterials, 1436
Ridge, D. N., *see* Hanifin, J. W., 535
Ridolfo, A. S., Thompkins, L., Bechtol, L. D., and Carmichael, R. H., benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans, 850
Riedy, M., *see* Stella, V. J., 648
Riegelman, S., *see* Lin, S. K., 1430
Ringhand, H. P., and Ritschel, W. A., high-pressure liquid chromatographic determination of propylthiouracil in human plasma, 1461
Ripple, E. G., and Huq, A. S. M. S., drug dissolution within a cascade barrier bed, 938
Ritschel, W. A., *see* Ringhand, H. P., 1461
Ritter, C. O., *see* Ross, A. J., 657
Roberts, R. K., *see* Johnson, R. F., 1320
Robertson, D. L., Butterfield, A. G., Kolasinski, H., Lovering, E. G., and Matsui, F. F., stability-indicating high-performance liquid chromatographic determination of chlorpropamide, tolbutamide, and their respective sulfonamide degradates, 577
Robinson, J. R., *see* Lee, V. H. L., 873
——*see* Makoid, M. C., 435
——*see* Sieg, J. W., 724
Rodriguez, H. J., and Vanderwielen, A. J., molecular weight determination of commercial heparin sodium USP and its sterile solutions, 588
Rogers, M. E., Boots, S. G., and Boots, M. R., phosphodiesterase inhibition by succinic and related acid biphenylalkyl monoesters, 903
Roland, M., *see* Couvreur, P., 1521
Roman, R., Cohen, E. M., Christy, M. E., and Hagerman, W. B., stability of amitriptyline hydrochloride in a commercial aqueous solution, 1329
——Yates, C. H., and Millar J. F., *syn–anti* isomerization in testosterone 17-enanthate 3-benzilic acid hydrazone, 736
——Yates, C. H., Millar, J. F., O'Neill, J., and Zweig, J. S., stability-indicating analysis of injectable estrogen–androgen combinations in formulations containing corn oil, 733
Roseboom, H., and Förch, A. D., stability of 10-acetylphenothiazine, 515
Roseman, T. J., selectivity of silicone rubber toward prostaglandin permeability, 263
——*see* Ho, N. F. H., 1170
——*see* Yalkowsky, S. H., 114
Rosenberg, F. J., *see* John, P. M., 475
Rosenberg, J. M., Lau-Cam, C. A., and McGuire, H., effects of pyridoxine hydrochloride (vitamin B_6) on chlorpromazine-induced serum prolactin rise in male rats, 1179
Rosenberg, M., *see* Johnston, M. M., 967
Rosenblatt, D. H., *see* Hull, L. A., 856
Ross, A. J., Moore, H. A., Ritter, C. O., and Moros, S. A., differential pulse polarographic determination of 2,3-dimercaptosuccinic acid and tin(II) in radiopharmaceuticals, 657
Rosseel, M. T., and Bogaert, M. G., simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC, 659
Roth, W., *see* Alkalay, D., 156
Roth, W. J., III, *see* Thompson, T. A., 996
Rowe, E. A., *see* Peterson, J. E., 626
Rowe, E. L., anomalous solution behavior of 2-palmitate esters of lincomycin and clindamycin, 1292
Rowland, C., *see* Bootman, J. L., 267
Rubio, F. A., *see* Kemmerer, J. M., 1274
Ruch, E., *see* DiGregorio, G. J., 1192
Rutledge, L. C., *see* Skinner, W. A., 390, 391
Ryan, J. A., McGaughran, W. R., Lindemann, C. J., and Zacchei, A. G., separation and spectral properties of diisopropylphosphate, the major decomposition product of isoflurophate, 1194
Rytting, J. H., *see* Higuchi, T., 1267

S

Sadee, W., *see* Chan, K. K., 807
Sajadi, Z., *see* Hall, I. H., 696
Sakai, T., application of thermochromism in spectrophotometric analysis: selective determination of berberine in pharmaceuticals by solvent extraction, 875
Salemink, C. A., *see* Vincent, P. G., 87
Sami, S. M., *see* Kingston, D. G. I., 1403
Sams, R. A., *see* Reuning, R. H., 411
Samuelov, Y., Donbrow, M., and Friedman, M., sustained release of drugs from ethylcellulose–polyethylene glycol films and kinetics of drug release, 325
Sane, J. N., *see* Muston, J. D., 240
Sapio, J. P., Sethachutkul, K., and Moody, J. E., simultaneous GLC determination of methyl salicylate and menthol in a topical analgesic formulation, 506
Sarpotdar, P., *see* Zatz, J. L., 1491
Sassard, J., Bernard, N., Legheand, J., Cuisinaud, G., and Traeger, J., pharmacokinetics and bioavailability of pyridinol carbamate in humans, 1190
Sawhney, S. N., and Boykin, D. W., phenazines with two cationic chains as potential antimalarials, 524
Sawyer, W. T., predictability of warfarin dose requirements: theoretical considerations, 432
Schaffer, S. A., *see* Albright, J. D., 936
Schenck, H.-U., Simak, P., and Haedicke, E., structure of polyvinylpyrrolidone-iodine (povidone-iodine), 1505
Schenk, G. H., *see* Street, K. W., Jr., 1306
Schenker, S., *see* Johnson, R. F., 1320
Schentag, J. J., *see* Jusko, W. J., 1358
Schieffer, G. W., reversed-phase high-performance liquid chromatographic investigation of levodopa preparations I: amino acid impurities, 1296
——reversed-phase high-performance liquid chromatographic investigation of levodopa preparations II: levodopa determination, 1299
Schiff, P. L., Jr., *see* Chien, M. M., 247
Schindler, A., *see* Pitt, C. G., 1534
Schmitt, C., VandenHeuvel, W. J. A., Walker, R. W., and Plazonnet, B., electron-capture GLC assay of dichlorphenamide, 381
Schmitt, L. G., *see* Chu, L.-C., 72
Schnaare, R. L., *see* Lemanowicz, E. F., 141
——*see* Vadino, W. A., 1316
Schnitzer, L., *see* Zatz, J. L., 1491
Schoonen, A. J. M., de Vries-Nijboer, G. W., and Huizinga, T., solution rate of crystals at fluid–fluid interface, 163
Schramm, L. C., *see* Elsabbagh, H. M., 388
Schran, H. F., *see* Loeffler, L. J., 1433
Schwan, T. J., Goldenberg, M. M., and Miles, N. J., 4-acetoxy-1,2,3,4-tetrahydro-2,2-dimethyl-6,7-methylenedioxyisoquinolinium iodide, an acetylcholine analog, 1325
——Gray, J. E., and Wright, G. C., synthesis of methyl 1-(3,4-dichlorobenzyl)-hexahydro-2,3-dioxo-4-pyridinecarboxylate, 529
Segal, R., *see* Yashphe, J., 924
Seifen, A. B., *see* Smith, R. H., 1016
Sellers, E. M., *see* Giles, H. G., 1459
Sena, F. J., Piechocki, J. T., and Li, K. L., stability-indicating assay of acetaminophen in an effervescent tablet by ion-pair high-performance liquid chromatography, 1465
Senyei, A., *see* Widder, K., 79
Sethachutkul, K., *see* Sapio, J. P., 506
Shader, R. I., *see* Greenblatt, D. J., 57
Shaffer, R. D., *see* Nakagawa, T., 718
Shafik, R. M., and Askar, A. F. A. A., new biphenyl derivatives II: 1-(4-biphenylyl)-1-hydroxy-2-aminoethanes and 1-(4-biphenylyl)-1-chloro-2-aminoethanes as potential β-adrenoceptor blocking agents, 776
Shah, K. A., and Needham, T. E., correlation of urinary excretion with *in vitro* dissolution using several dissolution methods for hydrochlorothiazide formulations, 1486
Shah, V. P., *see* Mathur, L. K., 699
Shah, Y., *see* Flynn, G. L., 1090
Shamma, M., *see* Moniot, J. L., 705
Shanks, L., *see* Gershon, H., 82
Shargel, L., Cheung, W.-M., and Yu, A. B. C., high-pressure liquid chromatographic analysis of antipyrine in small plasma samples, 1052
Shaw, J. E., *see* Chu, L.-C., 72
Shealy, Y. F., and O'Dell, C. A., carbocyclic analog of cytarabine, 668
Sheard, B., *see* Davies, R. H., 397
Shearer, C. M., and DeAngelis, N. J., guanabenz degradation products and stability assay, 1010
Shelver, W. H., *see* Nygard, G., 379, 1318
Shepherd, A. M. M., *see* Ludden, T. M., 1423
Shepherd, R. G., *see* Albright, J. D., 936
Sheppard, A. J., and Hubbard, W. D., collaborative study of a GLC method for vitamin E, 98
Sherriff, M., and Enever, R. P., rheological and drug release properties of oil gels containing colloidal silicon dioxide, 842
Sheth, B. B., *see* Hincal, A. A., 472
Shibazaki, T., *see* Ogata, H., 708, 712
Shih, F.-M. L., *see* Higuchi, T., 1267

Shinouda, H. G., *see* Lien, E. J., 463
Shiu, G. K., Goehl, T. J., and Pitlick, W. H., rapid high-performance liquid chromatographic determination of bleomycin A_2 in plasma, 232
Shostak, D., *see* Holak, W., 338
Shotton, E., *see* Enever, R. P., 169
Shulgin, A. T., *see* Glennon, R. A., 906
Shum, Y. Y., and Sinsheimer, J. E., determination of iodide in metabolic studies of ^{125}I-labeled compounds, 258
Sieg, J. W., and Robinson, J. R., vehicle effects on ocular drug bioavailability III: shear-facilitated pilocarpine release from ointments, 724
Sih, C. J., *see* Ravikumar, P. R., 900, 1302
Silingardi, S., *see* Mangia, A., 652
Simak, P., *see* Schenck, H.-U., 1505
Simons, F. E. R., *see* Briggs, C. J., 129
——*see* Simons, K. J., 252, 1327
Simons, K. J., and Simons, F. E. R., urinary excretion of dyphylline in humans, 1327
——Simons, F. E. R., Briggs, C. J., and Lo, L., theophylline protein binding in humans, 252
——*see* Briggs, C. J., 129
Singh, S. P., Farnum, S. A., Stenberg, V. I., and Parmar, S. S., Fourier transform carbon-13 NMR spectra of ampyrone and aminopyrine, 470
——Parmar, S. S., Farnum, S. A., and Stenberg, V. I., ^{13}C-NMR spectra of α-adrenergic blocking agents, 890
——Stenberg, V. I., Parmar, S. S., and Farnum, S. A., ^{13}C-NMR spectra of strychnos alkaloids: brucine and strychnine, 89
Sinsheimer, J. E., *see* Shum, Y. Y., 258
Sirenius, I., Krogerus, V. E., and Leppänen, T., dissolution rate of *p*-aminobenzoates from solid xylitol dispersions, 791
Skeggs, H., *see* VandenHeuvel, W. J. A., 1156
Skinner, W. A., Crawford, H. T., Rutledge, L. C., and Moussa, M. A., topical mosquito repellents XI: carbamates derived from *N,N'*-disubstituted diamines, 390
——Crawford, H. T., Rutledge, L. C., and Moussa, M. A., topical mosquito repellents XII: *N*-substituted ureas and cyclic ureas, 391
——Rackur, G., and Uyeno, E., structure–activity studies on tetrahydro- and hexahydrocannabinol derivatives, 330
Skipper, P. L., *see* Mergens, W. J., 827
Slater, J. G., Stone, H. A., Palermo, B. T., and Duvall, R. N., reliability of Arrhenius equation in predicting vitamin A stability in multivitamin tablets, 49
Slatkin, D. J., *see* Chien, M. M., 247
Slattery, J. T., and Levy, G., ticrynafen effect on warfarin protein binding in human serum, 393
——*see* Galinsky, R. E., 805
Sloboda, A. E., *see* Hanifin, J. W., 535
Smith, P. J., *see* Dimmock, J. R., 866, 1216
Smith, R. H., Hunt, D. H., Seifert, A. B., Ferrari, A., and Thompson, D. S., pharmacokinetic model for procaine in humans during and following intravenous infusion, 1016
Smith, T. H., *see* Pettit, G. R., 1013
Soine, T. O., *see* Erhardt, P. W., 522
——*see* Naghaway, J., 655
Sokoloski, T. D., *see* Yuen, P.-H., 1163
Soliman, F. S. G., *see* Ibrahmi, E. S. A., 243
Soliman, R., and Hammouda, N. A., synthesis of new mercaptotriazoles with potential antibilharzial activity, 1377
——*see* Ibrahim, E. S. A., 332
Song, S.-Z., *see* Zentner, G. M., 970
Sowell, J. W., Sr., *see* Johnson, R. W., 317, 955
Speiser, P., *see* Couvreur, P., 1521
Spiegel, D., *see* Volpe, F., 1264
Spielvogel, B. F., *see* Hall, I. H., 685
Spillane, W. J., Benson, G. A., and McGlinchey, G., metabolic studies with nonnutritive sweeteners cyclooctylsulfamate and 4-methylcyclohexylsulfamate, 372
Spitz, H. D., determination of water in aluminum chlorohydrate and effervescent tablets by Karl Fischer analysis, 122
Spradlin, C. T., *see* Nash, J. F., 1087
Sprague, G. L., and Takemori, A. E., improved method for morphine extraction from biological samples, 660
Stagner, W. C., and Guillory, J. K., physical characterization of solid iopanoic acid forms, 1005
Stambaugh, J. E., *see* Fouda, H. G., 1456
Starnes, C. O., *see* Hall, I. H., 537, 685
Staroscik, J. A., *see* Chan, K. K., 807
Staubus, A. E., Newton, B. N., Klein, L. C., Weinrib, A. B., and Kunz, A. L., urinary iodine excretion rates following intrathecal injections of iodinated organic carbonates, 1438
——*see* Reuning, R. H., 411
Stehle, R. G., *see* Morozowich, W., 833
Stella, V. J., and Gish, R., ionization kinetics of the carbon acid phenindione, 1042
——and Gish, R., kinetics and mechanism of ionization of the carbon acids 4′-substituted 2-phenyl-1,3-indandiones, 1047
——Varia, S. A., and Riedy, M., radiochemical plasma salicylamide assay using ring-labeled tritiated salicylamide, 648
——*see* Lee, H. K., 288
Stenberg, V. I., *see* Singh, S. P., 89, 470, 890
Sternson, L. A., *see* Golander, Y., 820
——*see* Mendenhall, D. W., 746
——*see* Musson, D. G., 1159
——*see* Thakker, K. D., 93
Stewart, J. T., and Chan, C. W., fluorometric determination of chlorzoxazone in tablets and biological fluids, 910
——Honigberg, I. L., and Coldren, J. W., liquid chromatography in pharmaceutical analysis XI: determination of muscle relaxant–analgesic mixtures using reversed-phase and ion-pair techniques, 32
——Honigberg, I. L., Tsai, A. Y., and Hajdu, P., fluorometric determination of clobazam, a 1,5-benzodiazepine, in human plasma, 494
——*see* Bouwsma, O. J., 45
——*see* Honigberg, I. L., 253
——*see* Kotzan, J. A., 1002
Stewart, P. J., *see* Owen, W. R., 992
Stewart, R. D., *see* Albert, K. S., 1312
Stoll, R. G., *see* Lai, C. M., 1243
Stone, H. A., *see* Slater, J. G., 49
Straughn, A. B., Melikian, A. P., and Meyer, M. C., bioavailability of chlorothiazide tablets in humans, 1099
Street, K. W., Jr., and Schenk, G. H., *p*-aminophenol fluorescence and determination in the presence of acetaminophen, 1306
Streng, W. H., *see* Huber, H. E., 1028
Stucky, J. F., II, *see* Quay, J. F., 227
Sturgeon, R. J., Deamer, R. L., and Harbison, H. A., improved spectrophotometric determination of glycerol and its comparison with an enzymatic method, 1064
Sugita, E. T., *see* Lemanowicz, E. F., 141
——*see* Vadino, W. A., 1316
Sugiura, M., Kurobe, M., Tamura, S., and Ikeda, S., kinetics of digestive enzyme stability in solid state I: application of Weibull distribution function to solid-state enzyme inactivation, 1381
Sumida, Y., *see* ElGebaly, S. A., 887
——*see* Hall, I. H., 537, 883
Sun, F. F., *see* Taylor, B. M., 983
Sun, S.-R., rapid determination of theophylline in serum by electron-capture GLC, 443
——and Hoffman, D. J., rapid, sensitive GLC determination of pentobarbital and other barbiturates in serum using nitrogen-specific detector, 386
——and Leveque, M. J., electron-capture GLC determination of pseudoephedrine in serum, 1567
Sundaresan, G. M., *see* Goehl, T. J., 1374
Superstine, E., *see* Yanuka, Y., 1400
Superstine, S. Y., *see* Yanuka, Y., 1400
Sutfin, T. A., and Jusko, W. J., high-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites, 703
Süverkrüp, R., discontinuous absorption processes in pharmacokinetic models, 1395
Suzuki, M., *see* Komatsu, H., 596
Svoboda, G. H., *see* Chien, M. M., 247
Szulczewski, D. H., *see* Hong, W. H., 499

T

Taha, H. M., Al-Obeidi, F. A., and Borazan, H. N., UV studies of nucleic acid base complexation with isoproterenol in different solvents, 631
Takada, K., and Levy G., comparative pharmacokinetics of coumarin anticoagulants XLIII: concentration-dependent hepatic uptake of warfarin in rats, 1569
Takauchi, K., *see* Tsukatani, H., 1426
Takemori, A. E., *see* Sprague, G. L., 660
Takemoto, T., *see* Ishida, T., 928
Takenaka, H., *see* Maeda, T., 1286
Takeuchi, M., *see* Kurata, K., 1187
Takeuchi, U., *see* Muramatsu, M., 175
Tam, J. N., *see* Renzi, N. L., Jr., 43
Tam, Y. K., Axelson, J. E., and Ongley, R., modification of metoclopramide GLC assay: application to human biological specimens, 1254
Tamura, S., *see* Sugiura, M., 1381
Tan, E., *see* O'Hare, M. J., 106
Tan, H. G. H., *see* Huber, H. E., 1028
Tan, H. S. I., Brake, N. W., Keily, H. J., Dalal, K. J., and Higson, H. G., high-performance liquid chromatographic determination of azosemide in commercial animal feed, 1413
Tan, T. G., *see* McAllister, R. G., Jr., 574
Tannenbaum, S. R., *see* Mergens, W. J., 827
Tansy, M. F., Martin, J. S., Landin, W. E., and Kentall, F. M., localization of isoproterenol-induced contractions of canine small intestine, 127
——Martin, J. S., Landin, W. E., and Kendall, F. M., species difference in GI motor response to somatostatin, 1107
——*see* Landin, W. E., 978
Tao, F. T., *see* Chu, L.-C., 72
Täuber, U., *see* Kreuter, J., 1443
Taylor, A. R., *see* Davis, R., 1063
Taylor, B. M., and Sun, F. F., absorption and penetration of dinoprost (prostaglandin $F_{2\alpha}$) and dinoprost methyl ester into perfused mesenteric circulation in rats, 983
Taylor, P. J., *see* Davies, R. H., 397
Taylor, R. E., *see* Pierson, S. L., 1550
Terasaki, T., *see* Tsuji, A., 1259
Thakker, K. D., Higuchi, T., and Sternson, L. A., loss of a hydrophobic amine from solution by adsorption onto container surfaces, 93
Theeuwes, F., *see* Bayne, W. F., 912
Thompkins, L., *see* Ridolfo, A. S., 850
Thompson, D. S., *see* Smith, R. H., 1016
Thompson, E. B., *see* Amin, Y. M., 160
Thompson, G. F., *see* Johnson, D. M., 112
Thompson, T. A., Borman, C. H., Goodblatt, R. S., and Roth, W. J., III, effects of aspirin on ^{14}C-pirprofen disposition in rats, 996
Threatte, R. M., Fregly, M. J., Field, F. P., and Jones, P. K., use of an iodide-specific electrode to study lactoperoxidase-catalyzed iodination of *L*-tyrosine, 1530
Timko, R. J., and Lordi, N. G., thermal characterization of citric acid solid dispersions with benzoic acid and phenobarbital, 601
Tokumura, A., *see* Tsukatani, H., 1426
Tomas, F., and Aullo, J. M., monoamine oxidase inhibition by β-carbolines: a quantum chemical approach, 772
Tomlinson, E., *see* Brown, M. R. W., 146
Torosian, G., *see* Embil, K., 1290, 1336
Torrance, S. J., Hoffmann, J. J., and Cole, J. R., wikstromol, antitumor lignan from *Wikstroemia foetida* var. *oahuensis* Gray and *Wikstroemia uva-ursi* Gray (Thymelaeaceae), 664
Tovivich, S., *see* Foye, W. O., 591
Tozer, T. N., *see* Die, S., 1203
Traeger, J., *see* Sassard, J., 1190
Trescony, P. V., *see* Heller, J., 919
Tripiett, J. W., *see* Bourne, D. W. A., 1571
Truelove, J., *see* Hussain, A., 235, 299
Tsai, A. Y., *see* Stewart, J. T., 494
Tsai, P. S. F., *see* Palermo, P. J., 878
Tscherne, R. J., *see* Capitano, G., 311
——*see* Umagat, H., 922
Tsui, S. K., *see* Dimmock, J. R., 866
Tsuji, A., Miyamoto, E., and Yamana, T., chemical reactions in cephalosporin allergy: high-pressure liquid chromatographic analysis of cephalosporin aminolysis kinetics, 616
——Miyamoto, E., Kubo, O., and Yamana, T., GI absorption of β-lactam antibiotics III: kinetic evidence

for *in situ* absorption of ionized species of monobasic penicillins and cefazolin from the rat small intestine and structure–absorption rate relationships, 812
——Miyamoto, E., Terasaki, T., and Yamana, T., carbenicillin prodrugs: stability kinetics of α-phenyl and α-indanyl esters in aqueous solution, 1259
——Nakashima, E., and Yamana, T., physicochemical properties of amphoteric β-lactam antibiotics II: solubility and dissolution behavior of aminocephalosporins as a function of pH, 308
Tsuji, K., Goetz, J. F., and Vanmeter, W., effect of ^{60}Co-irradiation on penicillin G procaine in veterinary mastitis products, 1075
Tsukatani, H., Yamada, S., Tokumura, A., Itami, T., and Takauchi, K., occurrence of short-duration hypotensive phospholipid from dog peritoneal dialysate, 1426
Tuccini, G., *see* Garzia, A., 1081
Turi, J. S., Danielson, D., and Woltersom, J. W., effects of polyoxypropylene 15 stearyl ether and propylene glycol on percutaneous penetration rate of diflorasone diacetate, 275
Tuttle, M. E., *see* Baker, R. W., 20

U

Ueda, C. T., and Makoid, M. C., quinidine and dihydroquinidine interactions in human plasma, 448
Uekama, K., Hirayama, F., Yamada, Y., Inaba, K., and Ikeda, K., improvements of dissolution characteristics and chemical stability of 16,16-dimethyl-*trans*-Δ2-prostaglandin E_1 methyl ester by cyclodextrin complexation, 1059
Umagat, H., McGarry, P. F., and Tscherne, R. J., stability-indicating sulfa drug analysis using high-performance liquid chromatography, 922
Uyeno, E., *see* Skinner, W. A., 330

V

Vadino, W. A., Sugita, E. T., Schnaare, R. L., Ando, H. Y., and Niebergall, P. J., separation of penicillin G potassium and its degradation products using high-pressure liquid chromatography, 1316
Valiner, J. J., *see* Bouwsma, O. J., 45
——*see* Kotzan, J. A., 1002
——*see* Parsons, D. L., 546
van Bork, L. E., *see* Jonkman, J. H. G., 69
Vance, J. W., *see* Jusko, W. J., 1358
Van Damme, J. G., and De Nève, R. E., fluorescence assay of hydroxynaphthoquinones, 16
VandenHeuvel, W. J. A., Arison, B. H., Miller, T. W., Kulsa, P., Eskola, P., Mrozik, H., Miller, A. K., Skeggs, H., Zimmerman, S. B., and Miller, B. M., urinary metabolites of 3*a*,4,5,6,7,7*a*-hexahydro-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-1,2-benzisoxazole in the dog, 1156
——*see* Schmitt, C., 381
Vandeputte, M., Dryon, L., De Hertogh, L., and Massart, D. L., potentiometric determination of iodine in pharmaceutical preparations, 1416
Vanderlaan, R. K., White, J. L., and Hem, S. L., effect of interaction of aluminum hydroxycarbonate gel and magnesium hydroxide gel on acid neutralization, 1498
Vanderwielen, A. J., *see* Rodriguez, H. J., 588
VanderWyk, R., *see* Amsel, L. P., 384
Vane, F. M., *see* Mergens, W. J., 827
van Ginneken, C. A. M., *see* Fleuren, H. L. J., 1056
Vanmeter, W., *see* Tsuji, K., 1075
van Rossum, J. M., *see* Fleuren, H. L. J., 1056
Varia, S. A., *see* Stella, V. J., 648
Vasavada, R. C., *see* Iyer, B. V., 782
Venho, V. M. K., drug absorption from *in situ* rat small intestine during metoclopramide administration, 517
Venturi, F., *see* Antonini, I., 321
Vermess, M., *see* Grimes, G., 52
Veronich, K., White, G., and Kapoor, A., effects of phenylbutazone, tolbutamide, and clofibric acid on binding of racemic warfarin and its enantiomers to human serum albumin, 1515
Vickers, S., and Duncan, C. A. H., GLC determination of *S*-2-(3-*tert*-butylamino-2-hydroxypropoxy)-3-cyanopyridine in human plasma, 1559
Vilallonga, F. A., and Phillips, E. W., surface activities of procaine, lidocaine, and tetracaine and their interaction energies with phospholipid monolayers, 314
Villanti, A., *see* Garzia, A., 1081
Vincent, P. G., Gentner, W. A., Kuppers, F. J. E. M., and Salemink, C. A., *Papaver bracteatum* Lindl.: quantitative extraction and determination of thebaine, 87
Visalli, A. J., *see* Galante, R. N., 1494
——*see* Luber, J. R., 780
Visioli, O., *see* Astorri, E., 104
Volk, J., *see* Alkalay, D., 156
Volpe, F., Zintel, J., and Spiegel, D., high-performance liquid chromatography of two peripheral vasodilators, nylidrin hydrochloride and isoxsuprine hydrochloride, in pharmaceutical dosage forms, 1264
Vu, V. T., *see* Chen, C.-P., 1022

W

Waddell, T. G., Austin, A. M., Cochran, J. W., Gerhart, K. G., Hall, I. H., and Lee, K. H., antitumor agents: structure–activity relationships in tenulin series, 715
——*see* Hall, I. H., 537
Walczak, K. M., *see* Koupparis, M. A., 1479
Walker, D., *see* Lesko, L. J., 1392
Walker, R. W., *see* Schmitt, C., 381
Wang, A., and Craven, B. M., crystal structure of 1:1 complex of barbital with 1-methylimidazole, 361
Wang, D., *see* Lee, H. K., 288
Wantland, L. R., and Hersh, S. D., high-performance liquid chromatographic assay of cyclophosphamide in raw material and parenteral dosage forms, 1144
Ward, C. O., *see* Dubroff, L. S., 1554
Warner, P. L. Jr., Luber, E., Jr., and Zusi, F. C., frozen conformers of clotrimazole: reaction of imidazole with 1-chloro-9-hydroxy-9-phenylxanthene, 1453
Warner, V. D., *see* Musto, J. D., 240
Warren, J. W., Jr., *see* Haborak, G. E., 933
Weeks, J. R., *see* Morozowich, W., 833, 949
Weinfeld, R. E., and Lee, T. L., simultaneous automated determination of free and total sulfisoxazole and sulfamethoxazole in plasma and urine, 1387
Weinrib, A. B., *see* Staubus, A. E., 1438
Weinryb, I., *see* Coutts, S. M., 353
Weinstein, S. H., and Gaylord, J. C., determination of oxycodone in plasma and identification of a major metabolite, 527
Welch, R. D., *see* Albert, K. S., 586
Welles, H. L., *see* Wood, R. W., 1272
Welling, P. G., Elliott, R. L., Pitterle, M. E., Corrick-West, H. P., and Lyons, L. L., plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate, 150
Wells, C. H. J., *see* Davis, R., 1063
Wells, J. E., *see* Martin, E., 565
Werner, A., *see* Greenblatt, D. J., 57
Wertheimer, A. I., *see* Bootman, J. L., 267
West, D. C., *see* Wingard, L. B., Jr., 914
Whall, T. J., and Dokladalova, J., high-performance liquid chromatographic determination of (*Z*)- and (*E*)-doxepin hydrochloride isomers, 1454
White, G., *see* Veronich, K., 1515
White, J. L., *see* Porubcan, L. S., 358
——*see* Vanderlaan, R. K., 1498
Whitworth, C. W., *see* Elsabbagh, H. M., 388
Widder, K., Flouret, G., and Senyei, A., magnetic microspheres: synthesis of a novel parenteral drug carrier, 79
Wiegand, U. W., and Levy, G., effect of heparin injection on plasma protein binding of bilirubin and salicylate in rats, 1483
Wijsbeek, J., *see* Jonkman, J. H. G., 69
Wilken, L. O., Jr., *see* Nasir, S. S., 177
Wilkinson, G. R., *see* Johnson, R. F., 1320
Williamson, H. E., Gaffney, G. R., and Bourland, W. A., renal actions of oxyphenbutazone, 1178
Williamson, M. J., *see* Lakings, D. B., 1113
Wilson, W. L., and LeBelle, M. J., indentification of an imidazolinium salt, the major product from reaction of benzathine with iodine, 1322
——*see* LeBelle, M., 555
Wingard, L. B., Jr., Abouleish, E., West, D. C., and Goehl, T. J., modified fluorometric quantitation of pancuronium bromide and metabolites in human maternal and umbilical serums, 914
Wisian-Neilson, P., *see* Hall, I. H., 685
Wojnar, R. J., Brittain, R. J., and Dzelzkalns, E., effect of nonsteroidal anti-inflammatory and other pharmacological agents on tuberculin reaction, 12
Wojnowich, L., *see* Hall, I. H., 685
Wolgamott, G., *see* Juneau, R., 930
Woltersom, J. W., *see* Turi, J. S., 275
Wong, M. P., *see* Connors, K. A., 1470
Woo, E., and Greenblatt, D. J., pharmacokinetic and clinical implications of quinidine protein binding, 466
——*see* Greenblatt, D. J., 57
Wood, R. W., and Welles, H. L., determination of phenylmercuric nitrate by potentiometric titration, 1272
Wood, S. G., Al-Ani, M. R., and Lawson, A., GLC determination of purity of Schiff bases bakrine and saddamine, 374
Wright, D. E., *see* Dimmock, J. R., 1033
Wright, G. C., *see* Schwan, T. J., 529
Wu, R. Y., *see* ElGebaly, S. A., 887
——*see* Hall, I. H., 537, 883
Wurster, D. E., Ostrenga, J. A., and Matheson, L. E., Jr., sarin transport across excised human skin I: permeability and adsorption characteristics, 1406
——*see* Matheson, L. E., Jr., 1410

X

Y

Yacobi, A., and Levy, G., effect of serum protein binding on sulfisoxazole distribution, metabolism, and excretion in rats, 742
——*see* Baaske, D. M., 1472
——*see* Lai, C. M., 1243
Yalkowsky, S. H., and Roseman, T. J., stability of E-type prostaglandins in triacetin, 114
——*see* Martin, E., 565
Yamada, S., *see* Tsukatani, H., 1426
Yamada, Y., *see* Uekama, K., 1059
Yamaguchi, H., *see* Yoshida, H., 670
Yamahira, Y., *see* Maeda, T., 1286
Yamana, T., *see* Tsuji, A., 308, 616, 812, 1259
Yang, K. H., Fung, W. P., Lutz, R. J., Dedrick, R. L., and Zaharko, D. S., *in vivo* methotrexate transport in murine Lewis lung tumor, 941
Yang, K. Y., Glemza, R., and Jarowski, C. I., effects of amorphous silicon dioxides on drug dissolution, 560
Yanuka, Y., Superstine, S. Y., and Superstine, E., NMR spectroscopic determination of preferred conformations of quinidine and hydroquinidine, 1400
Yashphe, J., Segal, R., Breuer, A., and Erdreich-Naftali, G., antibacterial activity of *Artemisia herba-alba,* 924
Yates, C. H., *see* Roman, R., 733, 736
Yeh, K. C., and Kwan, K. C., kinetic parameter estimation by numerical algorithms and multiple linear regression: application to pharmacokinetics, 1120
Yeh, S. Y., Krebs, H. A., and Gorodetzky, C. W., isolation and identification of morphine *N*-oxide α- and β-dihydromorphines, β- or γ-isomorphine, and hydroxylated morphine as morphine metabolites in several mammalian species, 133
Yeung, C. C., and Hersey, J. A., powder homogenization using a hammer mill, 721
Yoshida, H., Okumura, K., Hori, R., Anmo, T., and Yamaguchi, H., absorption of insulin delivered to rabbit trachea using aerosol dosage form, 670
Yoshida, K., *see* Kurata, K., 1187
Yoshida, M., Kumakura, M., and Kaetsu, I., controlled drug dissolution by radiation-induced polymerization in the presence of dimethylaminoethyl methacrylate–methyl methacrylate copolymer or methacrylic acid–methyl acrylate copolymer, 860
——Kumakura, M., and Kaetsu, I., drug entrapment for controlled release in radiation-polymerized beads, 628
Yost, Y., and Holtzman, J. L., resolution of (±)-propranolol, 1181

Yu, A. B. C., *see* Shargel, L., 1052
Yu, C. D., Fox, J. L., Ho, N. F. H., and Higuchi, W. I., physical model evaluation of topical prodrug delivery—simultaneous transport and bioconversion of vidarabine-5′-valerate II: parameter determinations, 1347
——Fox, J. L., Ho, N. F. H., and Higuchi, W. I., physical model evaluation of topical prodrug delivery—simultaneous transport and bioconversion of vidarabine-5′-valerate I: physical model development, 1341
Yuen, P.-H., Denman, S. L., Sokoloski, T. D., and Burkman, A. M., loss of nitroglycerin from aqueous solution into plastic intravenous delivery systems, 1163

Z

Zacchei, A. G., *see* Ryan, J. A., 1194
Zaharko, D. S., *see* Yang, K. H., 941
Zahry, S., *see* Amsel, L. P., 384
Zaske, D., *see* Bootman, J. L., 267
Zatz, J. L., Schnitzer, L., and Sarpotdar, P., flocculation of sulfamerazine suspensions by a cationic polymer, 1491
——*see* Liao, W. C., 486, 488
Zbinden, G., *see* Cheng, C. C., 396
Zee-Cheng, R. K. Y., *see* Cheng, C. C., 396
Zeller, H., *see* Merkle, J., 100
Zentner, G. M., Cardinal, J. R., and Gregonis, D. E., progestin permeation through polymer membranes III polymerization solvent effect on progesterone permeation through hydrogel membranes, 794
——Cardinal, J. R., Feijen, J., and Song, S.-Z., progestin permeation through polymer membranes IV: mechanism of steroid permeation and functional group contributions to diffusion through hydrogel films, 970
Zia, H., O'Donnell, J. P., and Ma, J. K. H., identification of griseofulvic acid as a urine metabolite of griseofulvin in humans, 1335
Zimmerer, R. O., Jr., and Lindenbaum, S., enthalpy of bile salt–lecithin mixed micelle formation, 581
Zimmerman, J. J., *see* Rattie, E. S., 1369
Zimmerman, S. B., *see* VandenHeuvel, W. J. A., 1156
Zintel, J., *see* Volpe, F., 1264
Zmijewski, M. J., *see* Ravikumar, P. R., 1302
Zucconi T. D., Janauer, G. E., Donahe, S., and Lewkowicz, C., acid dissociation and metal complex formation constants of penicillamine, cysteine, and antiarthritic gold complexes at simulated biological conditions, 426
Zusi, F. C., *see* Warner, P. L., Jr., 1453
Zuurman, K., *see* Lerk, C. F., 634
Zweidinger, R., *see* Pitt, C. G., 1534
Zweig, J. S., *see* Roman, R., 733

A

Absorption—drugs from *in situ* rat small intestine, effect of metoclopramide administration, 517
GI, incomplete—estimation of first-pass effect and distribution volume, 260
GI—pralidoxime chloride, kinetics in dogs, 141
GI—various monobasic penicillins and cefazolin, effect of ionization, pH, structure–activity relationships, 812
oral—benoxaprofen, effect of particle size, 850
percutaneous—diflorasone diacetate, effect of polyoxypropylene 15 stearyl ether and propylene glycol, 275
percutaneous—nitroglycerin, various topical dosage forms, rats, 608
rectal—thiazinamium methylsulfate in humans, 69
Acetaldehyde—reaction with hydralazine, kinetics, half-life, therapeutic implications, 1256
Acetaminophen—analysis, colorimetry, various pharmaceutical formulations, 750
—*analysis, ion-pair high-performance liquid chromatography,* effervescent tablets, with *p*-aminophenol, stability indicating, 1465
—*antipyretic effects,* suppositories, rats, 1105
—liquid chromatographic analysis in serum, 96
—tablets, *spectrofluorometric analysis of p-aminophenol as impurity,* 1306
—toxicity, prevention by sodium sulfate, effect on *elimination, 803*
Acetazolamide—binding to two carbonic anhydrase isoenzymes, human erythrocytes, *in vitro,* 912
—*nonlinear pharmacokinetic model,* plasma, urine, and red blood cell data, intravenous bolus injection of ^{14}C-acetazolamide, 342
—relationship of pharmacokinetics to pharmacological response, kidney and ocular responses, *347*
Acetophenones, substituted—condensed with substituted isatins to give 3-hydroxy-3-phenacyloxindole analogs, *screened for anticonvulsant activity,* 519
1-(2′-Acetoxybenzoyl)-2-deoxy-α-D-glucopyranose—aspirin prodrug, kinetics and mechanism of hydrolysis, effect of pH, temperature, and dielectric *constant, 299*
Acetylcholine analogs—synthesis, pharmacodynamics, structure–activity relationships, 1325
10-Acetylphenothiazine—stability and degradation *kinetics, pH dependency, 515*
N-Acetylprocainamide—analysis, plasma, high-pressure liquid chromatography, deproteinization *versus extraction methods,* 532
β-Adrenergic blocking activity—biphenyl derivatives, synthesis, structure–activity relationships, 776
α-Adrenergic blocking agents—analysis, NMR spectroscopy, 890
β-Adrenergic blocking agents*—propranolol, nasal* absorption, compared to oral and intravenous dosage forms, rats, bioavailability, 1196
—*synthesis and pharmacology,* substituted aminopropanes, *structure–activity relationships,* 1236
Adrenergics—phenylephrine hydrochloride, high-pressure liquid chromatographic analysis in *pharmaceutical preparations, 118*
vasoconstrictors—pseudoephedrine, analysis, comparison of GLC and high-pressure liquid chromatographic methods, urine, 1472
Adsorption—α-[(dibutylamino)methyl]-6,8-dichloro-2-(3′,4′-dichlorophenyl)-4-quinolinemethanol onto container surfaces, 93
—evaluated from charge profile, streaming current *measurement, 472*
free energies—various local anesthetics at air–water interface, correlated with pharmacological activity, 314
Aerosol propellants—trichloromonofluoromethane, blood levels correlated to cardiovascular and respiratory responses in dogs, 160
Albumin, isotonic solution—osmolality method for analysis of sodium, 239
Alcohols, aliphatic—molecular topology, aqueous solubility, structure–activity relationships, 839
Alkaloids—thebaine, extraction and analysis from various plant tissues of *Papaver bracteatum,* 87
***n*-Alkoxyacetic acids** *and methyl esters—antifungal* activity evaluated *in vitro,* effect of chain length, pH, and adsorbents, 82
***N*-Alkoxymethylbarbituric acids**—syntheses, anticonvulsant activity, structure–activity relationships, 1562
***N*-Alkoxymethylhydantoins**—syntheses, anticonvulsant activity, structure–activity relationships, 1562
Alkylbenzyldimethylammonium chlorides, various—antibacterial activity evaluated in series of *Pseudomonas aeruginosa envelope mutants, 146*
Alkylchlorophenols—structure–selectivity relationships, bioavailability, 1081
Allyl adenine *N*^{1}-oxide—chemical synthesis, 667
Alprenolol—electron-capture GLC determination of serum levels, wall-coated *open tubular column,* 511
Aluminum chlorohydrate—water content analyzed *by Karl Fischer titration, 122*
Aluminum hydroxycarbonate gel—acid neutralization, effect of interaction with magnesium hydroxide *gel, 1498*
Amide–water cosolvent systems—methylparaben solubility, cosolvent excess, 1141
Amino acid derivatives—*N*-benzoyl, potential antineoplastic activity, inhibition of microbial antitumor *screen, structure–activity relationships, 1366*
Amino acids and analogs—*N*-trifluoroacetyl derivatives, effect on microbial antitumor screen, *496*
N-benzoyl derivatives—potential antineoplastic agents, microbial screen, 260
—methionine and histidine, effect of aspirin-induced gastric mucosal damage *in rats, 295*
—*spectrophotometric determination following* derivatization, catalysis by surfactant micelles, 1470
Aminoalcohol esters*—quinuclidinyl benzilate,* hydrolysis in dilute aqueous solution, *kinetics, 856*
***p*-Aminobenzoic acid**—rate of dissolution from solid xylitol dispersions, 791
Aminobenzoic acid derivatives*—quaternary salts* synthesized, antispasmodic activity evaluated, 332
Aminocaproic acid—high-performance liquid chromatographic analysis *in serum,* 249
Aminocephalosporins, *various—solubility and dissolution,* effect of pH, 308
Aminoethylaminoanthraquinones—antineoplastic *activity and cardiotoxicity, compared to doxorubicin* and daunorubicin, 393
Aminolysis—cephalosporins, allergy, kinetic analysis, high-pressure liquid chromatography, 616
***p*-Aminophenol**—*analysis, ion-pair high-performance* liquid chromatography, *effervescent tablets, with* acetaminophen, stability, 1465
—analysis, spectrofluorometry, as impurity in *acetaminophen tablets, 1306*
Aminophylline—spectrophotometric analysis in *pharmaceutical formulations,* 9
Aminopropanes, substituted—synthesis and pharmacology as potential β-adrenergic blockers, *structure–activity relationships, 1236*
Aminopyrine—Fourier transform carbon-13 NMR spectra, 470
2-Aminopyrrole analogs of lidocaine, various—synthesized, evaluated for local anesthetic activity in guinea pigs and antiarrhythmic activity in *mice,* 317
5-Aminosalicylic acid—metabolism, gut wall, effect of dose and administration route, 1323
Amitriptyline hydrochloride—stability, commercial aqueous solutions, high-performance liquid chromatography, 1329
Amoxapine—and metabolites, GLC analysis in serum and urine, 216
Amoxicillin—high-pressure liquid chromatographic determination in urine, 454
Amphetamine analogs—thioureas, dithiocarbamates, negatively substituted amides, synthesis, behavioral effects, antiarthritis effects, cutaneous anapbylaxis, antimicrobial effects, blood pressure, rats, 591
Ampyrone—Fourier transform carbon-13 NMR spectra, 470
Analgesic–muscle relaxant mixtures, various—high-pressure liquid chromatographic analyses of *components, 32*
Analgesics—acetaminophen, analysis, colorimetry, various pharmaceutical formulations, 750
—*acetaminophen, ion-pair high-performance liquid* chromatographic analysis, effervescent tablets, with *p*-aminophenol, stability, 1465
—acetaminophen, liquid chromatographic analysis in serum, 96
—*acetaminophen, toxicity, prevention by sodium* sulfate, 803
—antipyrine, high-pressure liquid chromatographic *assay, plasma, rats, 1052*
—aspirin, acetylation of codeine phosphate in solid dosage forms, pharmacokinetics, 1494
—aspirin, analysis, buffered and unbuffered tablets, modified USP method, liquid chromatography, *spectrophotometry, stability, 780*
—aspirin, effect of colloidal silica on stability in tablets, 197
—*aspirin, isolation of derivatives from tablets,* extraction, high-pressure liquid chromatography, 1167
—cyclazocine, GLC–mass spectrometric analysis, radioimmunoassay, human and dog plasma, *pharmacokinetics, 1447*
—feprazone, analysis in various pharmaceutical formulations, high-pressure liquid chromatog*raphy, 798*
—ketamine, effect on monomolecular films of gangliosides and mitochondrial lipids, 1246
—pentazocine, radioimmunoassay, dog and human *plasma, pharmacokinetics, 626*
—phenylsalicylates, derivatives, synthesis, tested for analgesic activity, 893
topical—methyl salicylate and methanol, GLC analysis, 506
Androgens*—analysis, stability in formulations* containing corn oil, chromatography, separation from degradation products, 733
—*solubilization in various associated colloids,* 542
Anesthetic activity—various halogenated hydrocarbons, related to molecular connectivity indexes, 39
Anesthetics, local—chloroprocaine, GLC *analysis in* plasma and urine, metabolism and elimination in *humans, 75*
local—free energies of adsorption at air–water interface and interaction energies with phospholipid monolayers correlated with pharmacological activity, 314
local—lidocaine, concentration in parotid saliva and *in blood, single dose and continuous infusion,* rats, 1192
local—nortropacocaine, conformation, structure–activity relationships, *788*
Antacids—aluminum hydroxycarbonate, magnesium hydroxide, effect of interaction on acid neutralization, 1498
Anthelmintic agents—mebendazole, high-performance liquid chromatographic analysis in human plasma, 880
—tetramisole, high-pressure liquid chromato-

graphic analysis in veterinary preparations, 796

Anthralin—column chromatographic and TLC analysis and separation from decomposition products, 388

Antiacetylcholine activity—series of substituted indolizines evaluated, 321

Antiarrhythmic agents—bucainide, GLC analysis in plasma, 569
—chloroberberine, synthesis, derivatives, 705
—disopyramide, high-pressure liquid chromatographic analysis, plasma, humans, 1318
—lidocaine analogs, synthesis, structure–activity relationships, 955

Antiarteriosclerotic agents—pyridinol carbamate, pharmacokinetics, bioavailability, comparison of two tablet formulations, humans, 1190

Antiarthritis agents—amphetamine analogs, rats, 591
—benzoylacetonitriles, synthesis, screened in rats, structure–activity relationships, 535

Antiatherosclerotic agents—cetaben sodium, synthesis, 936

Antibacterial activity—evaluated for *Artemisia herba-alba* essential oil, column chromatography, 924
—various 3*H*-1,2,4-thiadiazoles evaluated *in vitro*, 182
—various quaternary ammonium chlorides evaluated in series of *Pseudomonas aeruginosa* envelope mutants, 146

Antibacterials—amoxicillin and penicilloic acid metabolite, high-pressure liquid chromatographic determination in urine, 454
—berberine, analysis in various pharmaceuticals, solvent extraction, spectrophotometry, using thermochromism, 875
—cephacetrile, high-performance liquid chromatographic analysis in various dosage forms, 652
—cephalosporin derivatives, degradation kinetics, aqueous solution, compared to cefazolin, 1369
—cephalothin, deacetylcephalothin, and cefazolin, aminolysis kinetics, cephalosporin allergy, high-pressure liquid chromatography, 616
—chloramphenicol, various dosage forms, bioavailability correlated with dissolution rates, 712
—chloroberberine, synthesis, derivatives, 705
—cinoxacin, effect of urine pH on urinary excretion, bioavailability correlated with physical characteristics of oral dosage forms, dogs, 227
—clindamycin, palmitate ester, aqueous solubility, pH, temperature, micelle formation, 1292
—cryptolepine hydrochloride, action on *Staphylococcus aureus*, microbial kinetics, 1510
—doxycycline, dissolution rates of free base and hydrochloride salts, 1183
—doxycycline monohydrate and hydrochloride dihydrate, solubility in aqueous solution, effect of pH, 188
—erythromycin base and 2′-propanoate, bioavailability in humans, effect of food and fluid volume, 150
—gentamicin, dosage regimens individualized in burn patients, cost–benefit analysis, 267
—lincomycin, palmitate ester, aqueous solubility, pH, temperature, micelle formation, 1292
—penicillin G potassium, high-pressure liquid chromatographic analysis, separation from degradation products, 1316
—*Pseudomonas cepacia*, resistance to benzalkonium chloride, chlorhexidine, phenylethanol, 1436
—structure–selectivity relationships, penicillins, 1081
—sulfasalazine, 5-aminosalicylic acid metabolite, metabolism, gut wall, effect of dose and administration route, 1323
—sulfisoxazole, distribution, metabolism, excretion, effect of serum protein binding, 742
—sulfisoxazole, effect on pharmacokinetics of bilirubin in hyperbilirubinemic rats, 6
—sulfisoxazole, sulfamethoxazole, automated analysis, human plasma and urine, 1387
—tetracycline, controlled-release dosage form, pharmacokinetics, hydroxyethyl methacrylate–methyl methacrylate copolymer implant, rats, *in vivo*, 1151
—tetracycline, controlled-release dosage form, pharmacokinetics, hydroxyethyl methacrylate–methyl methacrylate copolymer, *in vitro*, 1147
—various aminocephalosporins, solubility and dissolution, effect of pH, 308
—various penicillins, ^{13}C-NMR spectra, chemical shifts assigned, 64

Antibilharzial agents—mercaptotriazoles, synthesis, screening, *Schistosoma mansoni*, structure–activity relationships, 1377

Antibiotics—analysis, colorimetry, ampicillin, carbenicillin, methicillin, oxacillin, penicillin G, cephalothin, intravenous solutions, dextrose, 1333
—analysis, FDA diffusion assay, corrections, 797
—carbenicillin, prodrugs, stability in aqueous solutions, pH effects, degradation kinetics, 1259
—cefoxitin sodium, chemical stability, amorphous and crystalline solids, water content, 863
—doxycycline, high-performance liquid chromatographic analysis, human serum and urine, 999
—mecillinam, degradation in aqueous solution, isolation of degradation products, degradation pathways, rate constants, 1207
—minocycline, liquid chromatographic analysis, human serum, 1527
—penicillins and cefazolin, GI absorption, effect of ionization, structure–activity relationships, 812
—streptonigrin, interaction with metals and with DNA, 853
—tetracycline, bioavailability decreased by coadministered bismuth subsalicylate, 586

Anticholesterolemic agents—ciprofibrate, effect on serum lipid levels, hormone-sensitive lipase, compared to clofibrate and lifibrate, rats, 1557

Anticoagulants—anisindione, phenindione, chlorindione, ionization kinetics, 1047
—dicumarol, effect of oral and intravenous phenobarbital on systemic availability, 958
—dicumarol, systemic availability, effect of phenobarbital in bile duct-ligated rats, 1309
—heparin, effect on plasma protein binding of bilirubin and salicylate, rats, 1483
—heparin sodium, molecular weight determination, liquid chromatography, 588
—phenindione, ionization kinetics, pH, 1042
—warfarin, hepatic uptake, concentration dependence, rats, 1569
—warfarin, serum protein binding, effect of ticrynafen, humans, 393

Anticonvulsant activity—alkyl-substituted *N*-benzylcyanoacetamides evaluated in mice, 108
—fluorinated phenytoin analogs evaluated in mice, 115
—screening of 3-hydroxy-3-phenacyloxindole analogs, 519
—various substituted pyrazolidines evaluated, 377

Anticonvulsants—*N*-alkoxymethylbarbituric acids and *N*-alkoxymethylhydantoins, syntheses, structure–activity relationships, 1562
—phenytoin, effect of hydrophilization, *in vitro* and *in vivo* availability, 634
—quantitative structure–activity relationships and dipole moments, 463

Antidepressants—amitriptyline hydrochloride, stability, commercial aqueous solutions, high-performance liquid chromatography, 1329
—amoxapine and metabolites, GLC analysis in serum and urine, 216
—doxepin hydrochloride, isomers, high-performance liquid chromatographic analysis, 1454
—lithium carbonate, bioavailability and dissolution, various commercial products, powder, humans, 952
tricyclic—imipramine, desipramine, high-performance liquid chromatographic analysis in plasma, 703

Antidiabetic agents—chlorpropamide, tolbutamide, high-performance liquid chromatographic analysis of stability and sulfonamide degradation products, 577
—glyburide, high-performance liquid chromatographic analysis, dog serum, 1138
—phenformin, metabolism, plasma or serum levels, and elimination in guinea pigs, rats, and dogs, TLC–autoradiographic analysis, 156
—tolbutamide, spectrophotometric analysis, in combination tablets, 739

Antidiarrheals—bismuth subsalicylate, interference with bioavailability of coadministered tetracycline, 586

Antiemetic agents—metoclopramide, electron-capture GLC analysis, human plasma and urine, 1254

Antifungal activity—*n*-alkoxyacetic acids and methyl esters evaluated *in vitro*, effect of chain length, pH, and adsorbents, 82
—series of isatin and 5-nitroisatin *N*-Mannich bases screened, 459
—synthesis and screening of methyl 1-(3,4-dichlorobenzyl)-hexahydro-2,3-dioxo-4-pyridinecarboxylate, 529
—various 3*H*-1,2,4-thiadiazoles evaluated *in vitro*, 182

Antifungal agents—clotrimazole analogs, frozen conformers, imidazole substitution, antifungal activity, 1453
—griseofulvin, dissolution rate and bioavailability, rabbits compared to humans, 1286
—griseofulvin, high-pressure liquid chromatographic analysis, human plasma, compared to fluorometric assays, 1127
—griseofulvin, human urinary metabolite, identification, griseofulvic acid, 1335

Antiglaucoma agents—isoflurophate, degradation products, diisopropylphosphate isolated from peanut oil formulation, GLC, 1194

Antihistaminic activity—series of substituted indolizines evaluated, 321

Antihistaminics—analysis, ion-pair liquid chromatography, various cough and cold preparations, structure–activity relationships, 1135
—effect on cobaltous chloride-induced hypothermia, 693
—thiazinamium methylsulfate, rectal absorption and metabolism in humans, 69

Anti-5-hydroxytryptamine activity—series of substituted indolizines evaluated, 321

Antihypercholesterolemic activity—β-sitosterol and stigmasterol evaluated in chickens, 245

Antihypertensive agents—*S*-2-(3-*tert*-butylamino-2-hydroxypropoxy)-3-cyanopyridine, analysis, electron-capture GLC, human plasma, 1559
—clonidine, GLC analysis in plasma and urine, 72
—endogenous lipids, phospholipid from dog peritoneal dialysate, TLC, IR, NMR analysis, 1426
—guanabenz, degradation products, stability, UV spectroscopic analysis, 1010
—guanethidine, radioimmunoassay, human plasma, nanogram level, 1419
—hydralazine, reaction with acetaldehyde, kinetics, half-life, therapeutic implications, 1256
—hydralazine, reaction with biogenic aldehydes and ketones, hydrazone formation, high-performance liquid chromatographic analysis, 1524
potential—guanfacine, GLC analysis in plasma and urine, 219
—reserpine, radioimmunoassay, antibody specificity studies, metabolites, synthetic congeners, 1433
—ticrynafen, effect on warfarin protein binding, human serum, 393

Anti-infectives, topical—povidone-iodine, evaluated for mutagenicity in mice and hamsters, 100
—povidone-iodine, structure, hydrogen triiodide adducts, IR spectra, X-ray structure analysis, 1505

Anti-inflammatory activity—taspine isolated from *Croton lechleri* bark, evaluated in rats, 124

Anti-inflammatory agents—benoxaprofen, effect of particle size on dissolution rate and oral absorption in humans, 850
—carprofen, racemic mixtures, stereospecific assay, stereospecific metabolism, rats, 1274

—diflorasone diacetate, percutaneous absorption *rate, effect of polyoxypropylene 15 stearyl ester and propylene glycol*, 275
—fenoprofen calcium, pharmacokinetics, oral administration, 1087
—indoprofen, high-performance liquid chromatographic analysis, human milk, 1113
—ketoprofen, high-performance liquid chromatographic analysis in blood and urine, 484
—*ketoprofen, high-pressure liquid chromatographic* analysis in various body fluids, 366
—naproxen, liquid chromatographic analysis of *enantiomers*, 112
nonsteroidal—effect on tuberculin reaction in *guinea pigs*, 12
—oxyphenbutazone, renal effects, 1178
—pirprofen, disposition, effect of aspirin, rats, 996
potential—bakrine and saddamine, GLC analysis in prepared samples, 374
—*pyridinol carbamate, pharmacokinetics, bio*availability, comparison of two tablet formulations, humans, 1190
—sesquiterpene lactones, structure–activity relationships, edema, arthritis, pleurisy, immunoglobulin synthesis, rats, 537
Antileukemic activity—various quinolinium-2-dithioacetic acid zwitterions evaluated in mice, 336
Antimalarials—analysis, GLC, blood, 718
—α-dibutylaminomethyl-2,6-bis(trifluoromethyl-*phenyl)-4-pyridinemethanol, binding to human* serum albumin, 45
—mefloquine, analysis in blood, plastic ion-selective electrodes, 746
potential—synthesis and screening of phenazines *with two cationic side chains*, 524
Antimicrobial activity—chlormerodrin evaluated *in vitro*, 256
—*quaternary salts of 4-phenyl-1,2,3,6-tetrahy*dropyridine and 3,6-dimethyl-6-phenyltetrahydro-2*H*-1,3-oxazine, 407
—*series of isatin and 5-nitroisatin N-Mannich bases* screened, 459
Antimicrobial agents—benzylfluorene, arylethylamines, quaternary ammonium derivatives, 866
Antineoplastic activity—aminoethylaminoanthraquinones, doxorubicin, daunorubicin, and cardiotoxicity, 393
—cytarabine, carbocyclic analog, 668
—*tenulin, structure–activity relationships, in vivo* study, 715
—various substituted 1,2,4-triazines evaluated in *mice*, 243
Antineoplastic agents—aminoethylaminoanthraquinones, doxorubicin, daunorubicin, and cardiotoxicity, 393
—5-azacytidine, hydrolysis kinetics, aqueous solutions, 807
—azacytidine, prodrugs, sodium bisulfite complex, 822
—*benzyladenosine, metabolism, rats, 1054*
—benzylfluorene, arylethylamines, quaternary ammonium derivatives, 866
—betaine, boron analogs, metabolic effects, protein synthesis, nucleic acid synthesis, methyl transfer, 685
—1,4-bis(2′-chloroethyl)-1,4-diazabicyclo[2.2.1]-heptane cation, synthesis, diperchlorate and dihydrogen dimaleate salts, 1539
—bleomycin A_2, high-performance liquid chromatographic analysis in plasma, 232
—bruceoside A and brusatol, effect on cultured P-388 lymphocytic leukemia cell nucleic acid metabolism, 883
—brusatol, bruceoside A, bruceantin, effect on cellular respiration of P-388 leukemia cells, *in vivo, in vitro*, 887
—chlorambucil, hydrolysis, kinetics and mechanism, reaction order, pH, dielectric constant, ionic strength, 992
—cyclophosphamide, high-performance liquid chromatographic analysis in prepared samples, 172
—cyclophosphamide, high-performance liquid chromatographic analysis, raw material, parenteral dosage forms, 1144
—cytarabine, carbocyclic analog, synthesis, 668
—estimation of clearance through an organ, pharmacokinetics, 1066
—fluorouracil, flame-ionization GLC analysis, human plasma, *in vivo*, 1175
—*methotrexate, absorption, rat small intestine*, competitive inhibition by folic acid, 1552
—methotrexate, transport in murine Lewis lung tumor, *in vivo*, dihydrofolate reductase binding, tumor resistance, 941
—*organometallic, pharmacokinetics, external loop* technique, eigenfunction expansion analysis, 1571
potential—*amino acids, N-benzoyl derivatives*, microbial screen, 260
potential—arylsulfonylhydrazones, derived from *various heterocycles, antimicrobial and cytotoxic* activity, 930
potential—*N-benzoyl amino acid derivatives, in*hibition of microbial antitumor screen, structure–activity relationships, 1366
potential—*chartreusin*, aqueous solubility enhanced by hydroxybenzoates, 728
potential—Mannich bases derived from conjugated *styryl ketones, cytotoxicity, murine leukemia* L-1210 and Walker 256 carcinosarcoma cells, *in vitro* and *in vivo*, 1383
potential—*modified indole alkaloids, cytotoxicity*, structure–activity relationships, 1403
potential—nuclear hydroxy styryl ketones, syntheses, structure–activity relationships, 1216
potential—nuclear-substituted styryl ketones, effects on neoplasms, microorganisms, mitochondrial respiration in normal and tumor cells, structure–activity relationships, 1033
potential—*platinum, palladium, mercaptoalk*ylamine coordination compounds, structure–activity relationships, 1131
potential—*pyridone derivatives, structure–activity* relationships, mice, 816
potential—Yunnan Bai Yao, Chinese herbal, cytotoxic activity of isolated saponins, 900
—streptonigrin, interaction with metals and with DNA, 853
—wikstromol, isolated from plant material, 664
Antioxidants—butylated hydroxyanisole, GLC analysis *in plasma and urine*, 103
Antiparkinsonian agents—GLC analysis of trihexyphenidyl hydrochloride in various pharmaceutical dosage forms, 503
—levodopa, high-performance liquid chromatographic analysis, amino acid impurities, commercial preparations, 1296
—levodopa, high-performance liquid chromatographic analysis, commercial preparations, impurities, degradation products, 1209
Antiprotozoal agents—3*a*,4,5,6,7,7*a*-hexahydro-3-*(1-methyl-5-nitro-1H-imidazol-2-yl)-1,2-* benzisoxazole, urinary metabolites, antibacterial activity, antiprotozoal activity, dog, 1156
—high-performance liquid chromatographic analysis in human plasma, 599
Antipsoriatic agents—anthralin, column chromatographic and TLC analysis and separation from decomposition products, 388
Antipsychotics—loxapine and metabolites, GLC analysis in serum and urine, 216
Antipyretics—acetaminophen, analysis, colorimetry, various pharmaceutical formulations, 750
—acetaminophen, suppositories, rats, 1105
Antipyrine—analysis, high-pressure liquid chromatography, plasma, rats, 1057
Antiradiation agents, potential—dialkyl pyrazolidinethiols, synthesis, structure–activity relationships, 1331
Antispasmodic activity—quaternary salts of various aminobenzoic acid derivatives evaluated, 332
Antispasmodics—analysis, *Teucrium polium* oil, GLC–mass spectrometry, folk medicine, 800
Antitubercular agents, potential—phenylsalicylates, synthesis, analgesic activity, 893
Antitumor activity—pyrocatecholamine analogs, structure–activity relationship, 1519
—18 trifluoroacetyl derivatives of amino acids and amino acid analogs, growth inhibitory activity using *Lactobacillus casei* system, 496
Antitumor agents, CNS—aziridinylbenzoquinones evaluated *in vivo*, various test systems, 185
potential—*synthesis and screening of α-methy*lenebutyrolactams, 350
Antitussive agents—codeine phosphate, acetylation by aspirin in solid dosage forms, pharmacokinetics, 1494
Antiulcerogenic agents—*glycyrrhizin, methylene blue* colorimetric analysis, 1221
Antiviral agents—vidarabine, cutaneous metabolism, *rotating-disk method, guinea pig, in vitro study*, 571
—vidarabine valerate prodrug, topical dosage *forms, physical models, pharmacokinetics, 1341*, 1347
Aponin—effect on *Artemia salina*, unialgal and mixed cultures with *Gomphosphaeria aponina* and *Gymnodinium breve*, potential biological control agent, 963
Apparatus, dissolution test—designed, evaluated with various drugs at various pressures, compared to other methods, 177
Aqueous solubility—lincomycin and clindamycin palmitate esters, 1292
—*organic solids, barely soluble, solubility deter*mination, 1267
Arrhenius equation—use in predicting stability of vitamin A in multivitamin tablets, 49
Artemia salina—effect of aponin, bioassay method, 963
Artemisia herba-alba—antibacterial activity, essential oil, column chromatography, 924
Arylethylamines—*quaternary ammonium derivatives*, synthesis, antimicrobial and antineoplastic activity, structure–activity relationships, 866
Arylsulfonylhydrazones—*derived from various het*erocycles, antimicrobial and cytotoxic activity, 930
Ascorbic acid—methapyrilene nitrosation, prevention of nitrosodimethylamine formation, *in vitro*, 827
Aspirin—acetylation of codeine phosphate in solid dosage forms, GLC analysis of aspirin and salicylic acid, and codeine and acetylcodeine, *pharmacokinetics*, 1494
—analysis, modified USP method, liquid chromatography, spectrophotometry, stability, buffered *and unbuffered tablets*, 780
derivatives—isolated as impurities from tablets, extraction, high-pressure liquid chromatography, 1167
—effect on pirprofen disposition, rats, 996
—impurities in tablets, salicylsalicylic acid, acetylsalicylsalicylic acid, acetylsalicylic anhydride, isolation by extraction and high-pressure *liquid chromatography*, 1167
—induction of gastric mucosal damage in rats, effect of methionine and histidine, 295
prodrug—kinetics and mechanism of hydrolysis, effect of pH, temperature, and dielectric constant, 299
—stability in propylene glycol, effect of L-methionine and histidine, temperature, 645
—stability in tablets, effect of colloidal silica, 197
—tablets, commercial, enteric coated, dissolution *procedures, dissolution times, pretreatment with* simulated gastric juice, 1290
Astringents—aluminum chlorohydrate, water content analyzed by Karl Fischer titration, 122
Athlete's foot—*in vitro* comparison of effectiveness of undecylenic acid and tolnaftate as pure drug and commercial formulations, 384
Atropine—derivatives, urethane diastereomers, chemical synthesis, 1039
Automated analysis—chlorthalidone, plasma and urine, carbonic anhydrase inhibition, humans, 967
—dissolution testing system, automated, programmable, 12 tablet, 1280
—sulfisoxazole and sulfamethoxazole, human plasma and urine, 1387
Autonomic functions—effect of oxybutynin, conscious and phenobarbital-anesthetized dogs, 643
Autoradiography–TLC—analysis, phenformin in biological fluids, 156

Azacytidine—prodrugs, sodium bisulfite, stabilization in aqueous solutions, effect of pH, 822
5-Azacytidine—hydrolysis kinetics, aqueous solutions, high-pressure liquid chromatography, ^{13}C-NMR, 807
Azathioprine—prevention of cytotoxicity by 6,6′-azopurine, 1202
Aziridinylbenzoquinones—evaluated as potential CNS antitumor agents *in vivo*, various test systems, 185
6,6′-Azopurine—inhibition of rabbit liver aldehyde oxidase, *in vitro*, prevention of azathioprine cytotoxicity, 1202
Azosemide—analysis, high-performance liquid chromatography, commercial animal feed, 1413

B

Bakrine and impurities—GLC analysis in prepared samples, 374
Barbital—complex with 1-methylimidazole, crystal structure determined, 361
Barbiturates, various—GLC analysis in serum, 386
Benoxaprofen—effect of particle size on dissolution rate and oral absorption in humans, 850
Benzenes, disubstituted—entropy of fusion, melting point, heat of fusion, structure–activity relationships, 565
Benzisoxazoles— 3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-1,2-benzisoxazole, urinary metabolites, antibacterial activity, antiprotozoal activity, dog, 1156
Benzodiazepines—chemical synthesis, potentially useful haptens, 845
—desmethyldiazepam, radioimmunoassay, 1471
—fluorometric determination of clobazam in human plasma, 494
—lorazepam, pharmacokinetics and bioavailability in humans, various administration routes compared, 57
—plasma binding, equilibrium dialysis, humans, individual variation, age, 1320
Benzoic acid—analysis, high-pressure liquid chromatography, in liquid and solid pharmaceutical dosage forms, stability, 530
—dissolution rate, tablet, eight testing systems compared, 708
Benzoquinolinium halides—binding to butyrylcholinesterase, spectrophotofluorometric analysis, 1025
Benzoylacetonitriles—antiarthritis activity, synthesis, screened in rats, structure–activity relationships, 535
***N*-Benzoyl amino acid derivatives**—antineoplastic activity, potential, inhibition of microbial antitumor screen, structure–activity relationships, 1366
Benzoyl peroxide—high-pressure liquid chromatographic analysis in pharmaceutical preparations, 280
Benzyladenosine—metabolism, rats, 1054
Benzyladenosine phosphate—metabolism, rats, 1054
***N*-Benzylcyanoacetamides**, alkyl substituted—synthesized, evaluated for anticonvulsant activity in mice, 108
Benzylfluorene—quaternary ammonium derivatives, synthesis, antimicrobial and antineoplastic activity, structure–activity relationships, 866
Benzylpenicillin—corneal permeability, effect of cetylpyridinium chloride, 1176
Berberine—analysis, solvent extraction, spectrophotometric method using thermochromism, various pharmaceuticals, 875
Betaine analogs—boron, antineoplastic activity, metabolic effects, protein synthesis, nucleic acid synthesis, methyl transfer, 685
Betamethasone—analysis, skin preparations, reaction rate method, 1479
Betamethesone valerate—analysis, skin preparations, reaction rate method, 1479
Bile duct—ligation, effect on rats, dicumarol systemic availability, phenobarbital, 1309
Bile salts, solutions—dissolution of lecithin, micelle formation, enthalpy, hydrogen bonding, 581
Bilirubin, free and total—pharmacokinetics, effect of salicylic acid in hyperbilirubinemic rats, 1
—pharmacokinetics in hyperbilirubinemic rats, effect of sulfisoxazole, 6
—plasma protein binding, effect of heparin, rats, 1483
Binding—immunoglobulin E to mast cells, *in vitro* method for screening inhibitors, 353
metal—stability constants determined for various aminoalkyl disulfides and thiosulfates, relation to radiation-protective activity, 202
protein—substituted pyridinemethanol to human serum albumin, 45
protein—theophylline, determined by ultrafiltration method, 129
Bioavailability—chloramphenicol, various dosage forms, correlated with dissolution rates, 712
—chlorothiazide in dogs, colorimetric and high-pressure liquid chromatographic analyses compared, 126
—chlorothiazide tablets, humans, 1099
—cinoxacin, correlated with physical characteristics of oral dosage forms, dogs, 227
—commercial methylprednisolone preparations, 1312
—dicumarol in rats, effect of oral and intravenous phenobarbital, 958
—digoxin capsules and tablets compared in cardiac patients, 104
—erythromycin base and 2′-propanoate in humans, effect of food and fluid volumes, 150
—hydrophilized phenytoin, capsule formulation, *in vitro* release rates, 634
—lithium carbonate, various commercial products, powder, humans, 952
—lorazepam in humans, various administration routes compared, 57
—method for assessment under variable renal clearance conditions, 128
—methoxsalen, improved delivery, rats and dogs, 451
—pharmacokinetic models, limited absorption time, fraction of dose absorbed, 1395
—theophylline, various oral dosage forms, 1392
—trisulfapyrimidine suspensions, compared to *in vitro* dissolution behavior, various commercial preparations, screening methods, 699
Bioequivalence—conjugated estrogens, bioinequivalence of generic and proprietary products, postmenopausal women, 986
Biological control—*Gymnodinium breve*, effect of aponin and *Gomphosphaeria aponina* in unialgal and mixed cultures, *Artemia salina* bioassay, 963
Biotin—TLC analysis in lyophilized multivitamin preparation, 364
Biotransformation—camphene in rabbits, four urinary metabolites identified by spectrometry and chemical degradations, 928
Biphenyl derivatives, various—synthesized, evaluated for β-adrenergic blocking activity, structure–activity relationships, 776
1,4-Bis(2′-chloroethyl)-1,4-diazabicyclo[2.2.1]-heptane cation—antineoplastic activity, synthesis, diperchlorate and dihydrogen dimaleate salts, 1539
Bismuth subsalicylate—antidiarrheal mixture, interference with bioavailability of coadministered tetracycline, 586
Bitolterol—microencapsulation for controlled release, effects on bronchodilator and heart rate activities, dogs, 475
Bleomycin A_2—high-performance liquid chromatographic analysis in plasma, 232
Blood pressure—effects of amphetamine analogs, rats, 591
Books
Abrégé De Droit Et Déontologie Pharmaceutiques, Notions Generales, 400
Acetylcholine Synthesis in Neurons, 266
Acta Facultatis Pharmaceuticae. Universitatis Comenianae. XXX, 940
The Action of Drugs on Calcium Metabolism. Progress in Pharmacology, Vol. 2, No. 1, 1474
Advances in Modern Toxicology, Vol. 1. New Concepts in Safety Evaluation, Part 2, 940
Aliphatic Chemistry, Vol. 5, A Specialist Periodical Report, 132
The Alkaloids. Chemistry and Physiology. Vol. XVII, 1473
Analysis of Drugs and Metabolites by Gas Chromatography–Mass Spectrometry, Vol. 5: Analgesics, Local Anesthetics, and Antibiotics, 671
Analysis of Drugs and Metabolites by Gas Chromatography–Mass Spectrometry, Vol. 3: Antipsychotic, Antiemetic, and Antidepressant Drugs, 671
Analysis of Drugs and Metabolites by Gas Chromatography–Mass Spectrometry, Vol. 4: Central Nervous System Stimulants, 671
Analysis of Drugs and Metabolites by Gas Chromatography–Mass Spectrometry, Vol. 2: Hypnotics, Anticonvulsants, and Sedatives, 671
Analysis of Drugs and Metabolites by Gas Chromatography–Mass Spectrometry, Vol. 1: Respiratory Gases, Volatile Anesthetics, Ethyl Alcohol, and Related Toxicological Materials, 671
Analysis of Steroid Hormone Drugs, 672
Analytical Profiles of Drug Substances, Vol. 7, 940
Animal Health Products: Design and Evaluation, 806
Annual Reports in Medicinal Chemistry, Vol. 13, 1339
The Aqueous Cytoplasm, Contemporary Biophysics Series, Vol. 1, 940
Aromatic and Heteroaromatic Chemistry, Vol. 6. A Review of the Literature Abstracted between 7/76 and 6/77, 672
Biosynthetic Products for Cancer Chemotherapy, Vol. 2, 266
Blood Drugs and Other Analytical Challenges (in Methodological Surveys in Biochemistry), Vol. 7, 805
Body Temperature: Regulation, Drug Effects, and Therapeutic Implications, 1473
Botanical Dermatology. Plants and Plant Products Injurous to the Skin, 1474
Cardiovascular Drugs. Vol. 1: Antiarrhythmic, Antihypertensive and Lipid Lowering Drugs. Vol. 2: β-Adrenoceptor Blocking Drugs, 131
Clinical Laboratory Statistics, 2nd Ed., 940
Cocaine: 1977 National Institute on Drug Abuse, 1074
Comparative Endocrinology of Prolactin, 940
Computers in the Clinical Laboratory: An Introduction. Clinical and Biochemical Analysis: A Series of Monographs and Textbooks, Vol. 8, 940
Cutting's Handbook of Pharmacology. The Actions and Uses of Drugs, 6th Ed., 940
Deutsches Arzneibuch. 8. Augsgabe 1978, 400
Discovery, Development and Delivery of New Drugs, 266
Disposition of Toxic Drugs and Chemicals in Man, Vol. 1. Centrally-Acting Drugs, 1074
Diuretic Agents, 1206
Drug Fate and Metabolism: Methods and Techniques, Vol. 2, 266
Drugs and Inheritance of Behavior. A Survey of Comparative Psychopharmacogenetics, 266
Drugs and the Special Child, 940
Drugs. How They Act and Why, 265
Environmental Health Criteria 5: Nitrates, Nitrites, and *N*-Nitroso Compounds, 940
Essentials of Toxicology, 3rd Ed., 805
Etiology, Pathophysiology, and Treatment of Acute Gastroenteritis. Report of the 74th Ross Conference on Pediatric Research, 266
Europaisches Arzneibuch. Band III. Amtliche Ausgabe, 400
Evaluation and Optimization of Laboratory Methods and Analytical Procedures. A Survey of Statistical and Mathematical Techniques, 1474
Formulation and Preparation of Dosage Forms, 131
Functions of the Septo-Hippocampal System. Ciba Foundation Symposium 58 (new series), 400
Genetics of Industrial Microorganisms: Proceedings of the Third International Symposium, 1340
Glycoproteins and Glycolipids in Disease Processes. ACS Symposium Series 80, 1474
Handbook of Experimental Pharmacology, Vol. 51: Uric Acid, 1074

Homöopathisches Arzneibuch. 8. Ausgabe 1978, 400
Hospital-Associated Infections in the Compromised Host. Handbook on Hospital-Associated Infections, Vol. 2, 1474
Hospital-Associated Infections in the General Hospital Population and Specific Measures of Control. Handbook on Hospital-Associated Infections, Vol. 3, 1474
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 18: Polychlorinated Biphenyls and Polybrominated Biphenyls, 1074
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 17: Some *N*-Nitroso Compounds, 1074
Index Nominum 1978, 9th Ed., 1339
The Influenza Virus Hemagglutinin. Topics in Infectious Diseases, Vol. 3: Symposium, Baden near Vienna, 3-21-23, 77, 400
Instrumental Applications in Forensic Drug Chemistry: Proceedings of the International Symposium, May 29–30, 1978, 1473
The International Challenge of Drug Abuse: NIDA Research Monograph 19, 1074
An Introduction to Microscopy by Means of Light, Electrons, X-Rays, or Ultrasound, 266
Lange's Handbook of Chemistry, 12th Ed., 805
Legemiddel-forbruket i Norge. En statistik fremstilling av legmiddel-forbruket i Norge for arena 1975–77 basert pa omsetnig av legemidler fra Norsk Medisinaldepot til apotek og sykehus, 1474
Les essais des nouveaux médicaments chez l'homme. Problems juridiques et éthiques, 400
The Living State and Cancer. Workshop of the National Foundation for Cancer Research, Marine Biological Laboratory, Woods Hole, Mass., 400
Major Mental Handicap: Methods and Costs of Prevention. Ciba Foundation Symposium 59 (new series), 400
Manual of Dermatological Therapeutics with Essentials of Diagnosis, 2nd Ed., 266
Manual of Neurogic Therapeutics with Essentials of Diagnosis, 400
Marihuana Research Findings: 1976. NIDA Research Monograph 14, 132
Methods in Cancer Research, Vol. XVII, Cancer Drug Development, Part B, 1074
Methods in Pharmacology, Vol. 4B, Renal Pharmacology, 1074
Methods of Protein Separation, Vol. 2, 1206
Microbiology—1979, 1340
Molecular Interactions and Activity in Proteins. Ciba Foundation Symposium 60 (new series), 1474
Neurotransmitter Systems and Their Clinical Disorders, 1206
New Trends and Developments in Vaccines, 1206
Nuclear Magnetic Resonance Spectroscopy in Molecular Biology. The Jerusalem Symposia on Quantum Chemistry and Biochemistry, Vol. II, 400
Pharmacological and Biochemical Properties of Drug Substances, Vol. 2, 1474
Pharmacy in Health Care and Institutional Systems, 1339
Pharmacy Management for Students and Practitioners, 2nd Ed., 1474
Pharmacy Technicians' Manual, 2nd Ed., 1206
Pharmazeutische Technologie, 1205
Phosphorus in the Environment: Its Chemistry and Biochemistry. Ciba Foundation Symposium 57 (new series), 400
Practical Antimicrobial Therapy, 400
Prevention and Detection of Cancer, Part II. Detection, Vol. I, High Risk Markers. Detection Methods and Management, 266
Progress in Drug Research, Vol. 22, 806
Psychiatric Aspects of Opiate Dependence, 400
Psychopharmacology: From Theory to Practice, 265
Psychopharmacology of Affective Disorders. A British Association for Psychopharmacology Monograph, 1206
Quality Control of Drugs. Certification Scheme on the Quality of Pharmaceuticals Products Moving in International Commerce. Reprint of the WHO Chronicle, Vol. 31, No. 12, 1206
Quantitative Drug Design: A Critical Introduction, Medicinal Research Series, Vol. 8, 132
Recent Developments in Chromatography and Electrophoresis. Proceedings of the 9th International Symposium on Chromatography, Riva del Gara, May 15–17, 1978, 1474
Recent Development in Mass Spectrometry in Biochemistry and Medicine, Vol. 1, 400
Research Design in Clinical Psychology and Psychiatry, 2nd Ed., 1206
Reviews of Physiology, Biochemistry and Pharmacology 81, 266
Review of Physiology, Biochemistry and Pharmacology, Vol. 82: Catecholamine Receptors, Synthesis and Secretion of Albumin, Gating Currents in Excitable Membranes, 1474
Reviews of Physiology, Biochemistry and Pharmacology, Vol. 83: Transport Processes in Formation of Cerebrospinal Fluid, Optical Measurement of Membrane Potential, Cell–Cell Adhesion, Pharmacogenetics, Biochemistry and Pharmacology, 1474
Schizophrenia. Theory, Diagnosis, and Treatment, 400
Scientific Foundations of Clinical Biochemistry, Vol. 1: Analytical Aspects, 266
Self-Administration of Abused Substances: Methods for Study. NIDA Research Monograph 20, 1206
Serotonin in Health and Disease, Vol. I: Availability, Localization and Disposition, 400
Serotonin in Health and Disease, Vol. III: The Central Nervous System, 1474
Sex Hormones and Behavior. CIBA Foundation Symposium 62 (new series), 1474
Sleeping Pills, Insomnia, and Medical Practice. Report of a Study from the Institute of Medicine, 1474
A Study Guide to Epidemiology and Biostatistics, 400
Taxis and Behavior. Elementary Sensory Systems in Biology. Receptors and Recognition, Series B, Vol. 5, 1206
Terpenoids and Steroids, Vol. 8, 1572
Thrombosis. Animal and Clinical Models. Vol. 102 of Advances in Experimental Medicine and Biology, 266
Topics in Antibiotic Chemistry, Vol. 2: Antibiotics from Marine Organisms, Oligosaccharides, Anthracyclines and their Biological Receptors, 1206
Vitamins: Synthesis, Production and Use, Advances since 1970, 400
Webster's Medical Office Handbook, 1206
Brompheniramine maleate—analysis, ion-pair reversed-phase high-pressure liquid chromatography, cough–cold syrups, 1463
Bromthymol blue—used in spectrophotometric analyses of various quaternary ammonium compounds in prepared and commercial solutions, 110
Brucine—^{13}C-NMR spectrometry, chemical shifts assigned, 89
Bucainide—GLC analysis in plasma, 569
Bupivacaine—aqueous solubility, effect of temperature, 667
Burns, chemical—thioglycolates, percutaneous toxicity, effect of surfactants, percutaneous penetration, rabbits, 1230
***S*-2-(3-*tert*-Butylamino-2-hydroxypropoxy)-3-cyanopyridine**—analysis, electron-capture GLC, diheptafluorobutyryl derivative, human plasma, antihypertensives, 1559
Butylated hydroxyanisole—GLC analysis in plasma and urine, 103
Butylated hydroxytoluene—conversion to tetrabis-(*tert*-butyl)stilbenequinone in polyethylene closures, catalyzed by titanium dioxide, 916
Butylparaben—percutaneous absorption, effect of surfactants, guinea pig, *in vitro,* relation of absorption and preservative activities, 596
Butyrophenones—analysis, TLC, differentiation from phenothiazine derivatives, 1050
Butyrylcholinesterase—binding to benzoquinolinium halides, spectrophotofluorometric analysis, 1025

C

Callicarpone—analogs, structure–activity relationships, toxicity, antimicrobial activity, 1116
Camphene—biotransformation in rabbits, four urinary metabolites identified by spectrometry and chemical degradations, 928
Cannabinoids—GLC analysis, stability in chloroform and ethanol solutions, 262
Carbamates from *N,N'*-disubstituted amines—synthesized and evaluated as mosquito repellents, 390
Carbamazepine—interaction with clonazepam by enzyme induction, pharmacokinetic description, monkeys, 416
Carbenicillin indanyl sodium—prodrug, stability in aqueous solutions, pH, degradation kinetics, 1259
phenyl sodium—prodrug, stability in aqueous solutions, pH, degradation kinetics, 1259
—prodrugs, stability in aqueous solutions, pH effects, degradation kinetics, 1259
Carbobenzoxy amino acid esters—contraceptive activity, antiproteolytic activity, mice, 696
β-Carbolines—monoamine oxidase inhibition, quantum chemistry, 772
Carbon acids—ionization kinetics, stopped-flow spectrophotometric and pH jump analysis, 1047
Carbonic anhydrase inhibitors—acetazolamide, binding to two carbonic anhydrase isoenzymes, human erythrocytes, *in vitro,* 912
—acetazolamide, relationship of pharmacokinetics to pharmacological responses, 347
—dichlorphenamide, GLC analysis in biological fluids, 381
Carcinogens—nitrosamines, analysis, chromophoric or fluorescent products of photochemical degradation, aqueous suspensions, biological fluids, rats, humans, 1159
—nitrosodimethylamine, formation from methapyrilene, prevention by ascorbic acid, *in vitro,* 827
Cardiac depressants—propranolol, high-pressure liquid chromatographic analysis in plasma, 379
—quinidine, pharmacokinetic and clinical implications of protein binding, 466
Cardiac vasodilators—nitroglycerin, analysis, liquid dosage forms and intravenous solutions, 481
Cardiotonic agents—digoxin and digitoxin, stability studies, various commercial powders, 1224
—digoxin, bioavailability and heart function index, capsules and tablets compared in cardiac patients, 104
Cardiotoxicity—evaluated, aminoethylaminoanthraquinones, doxorubicin, daunorubicin, 393
Cardiovascular responses—trichloromonofluoromethane, correlated to blood levels in dogs, 160
Carminative activities—various oxygen-containing compounds, related to solubility, steric considerations, 370
Carprofen—racemic mixtures, stereospecific assay, stereospecific metabolism, rats, 1274
Carriers, drug—magnetic microspheres synthesized, effect of stabilization and heat on drug release *in vitro,* 79
Cascade barrier bed—for testing drug dissolution, 938
Catharanthine—derivatives, cytotoxicity, structure–activity relationships, 1403
Cationic polymer—sulfamerazine suspensions, flocculation, anionic and nonionic surfactants, 1491
Cations—diffusion through silicone polymer tubing, effect of temperature and ion-exchange resin, 1102
Cefazolin—GI absorption, effect of ionization, structure–activity relationships, 812
Cefoxitin sodium—chemical stability, amorphous and crystalline solids, water content, 863
Cellular respiration—P-388 leukemia cells, effect of various quassinoids, 887
Cellulose, microcrystalline—effect on liquid penetration and disintegration of directly compressed tablets, 205
Cephacetrile—high-performance liquid chromato-

graphic analysis in various dosage forms, 652
Cephalosporins—aminolysis kinetics, allergy, high-pressure liquid chromatography, 616
—derivatives, degradation kinetics, aqueous solution, compared to cefazolin, 1369
Cetaben sodium—synthesis, antiatherosclerotic activity, 936
Cetylpyridinium chloride—effect on corneal permeability to penicillin, effect on epithelium, 1176
Charge profile—used to evaluate adsorption of dispersion, streaming current measurement, 472
Chartreusin—aqueous solubility enhanced by hydroxybenzoates, conformation, 728
Chelating agents—various pentetate esters synthesized, evaluated for ability to decorporate polymeric plutonium in mice, 194
Chemical synthesis—luteinizing hormone-releasing hormone derivatives, structure–activity relationships, 1013
Chlorambucil—hydrolysis, kinetics and mechanism, reaction order, pH, dielectric constant, ionic strength, 992
Chloramphenicol degradation products—1-(4′-nitrophenyl)-2-aminopropane-1,3-diol, colorimetric analysis, in commercial chloramphenicol solutions, 1565
—dissolution rates, tablets and powder, eight testing systems compared, 708
—various dosage forms, bioavailability correlated with dissolution rates, 712
Chlordiazepoxide—analysis, high-pressure liquid chromatography, biological fluids, metabolites, 1467
—radioimmunoassay, in blood, plasma, saliva, 261
Chlormerodrin—antimicrobial activity evaluated *in vitro*, 256
Chlorobenzophenone—degradation product of hydroxyzine following UV irradiation, 666
Chloroberberine—synthesis, derivatives, 705
Chloroprocaine—GLC analysis in plasma and urine, metabolism and elimination in humans, 75
Chlorothiazide—bioavailability in dogs, colorimetric and high-pressure liquid chromatographic analyses compared, 126
—bioavailability, tablets, humans, urinary recovery, 1099
Chlorpheniramine metabolites—urinary excretion, humans, high-pressure liquid chromatographic analysis, 1243
—urinary excretion, humans, high-pressure liquid chromatographic analysis, 1243
Chlorpromazine—induction of serum prolactin rise, effect of pyridoxine, rats, 1179
Chlorpropamide—high-performance liquid chromatographic analysis of stability in solid pharmaceutical dosage forms, sulfonamide degradates, 577
Chlorthalidone—analysis, automated, plasma and urine, carbonic anhydrase inhibition, humans, 967
—analysis, differential potentiometry, dissociation constants, 1056
—high-pressure liquid chromatographic analysis in pharmaceutical dosage forms, 106
—analysis, fluorometry, in commercial tablets and biological fluids, in presence of hydroxychlorzoxazone and acetaminophen, 910
and hydroxy metabolite—high-pressure liquid chromatographic analysis in plasma, 253
Cholecystographic agents—iodoxamic acid, iopanoic acid, interactions, biliary excretion, pharmacokinetics, rhesus monkeys, 1430
Choleretic activity—camphene, biotransformation in rabbits, four urinary metabolites identified by spectrometry and chemical degradations, 928
Cholesterol—solubility in organic solvents, *n*-alkanols, ethyl carboxylates, structure–activity relationships, 1090
Cholinergics—acetylcholine analogs, synthesis, pharmacodynamics, structure–activity relationships, 1325
ophthalmic—pilocarpine, precorneal disposition, mechanistic and quantitative evaluation, 673
Cholinesterase inhibitors—sarin, transport across excised human skin, effect of pretreatment on permeability, 1410
—sarin, transport across excised human skin, permeability, adsorption, 1406
Cholinesterase reactivators—pralidoxime chloride, absorption and elimination kinetics in dogs, 141
Chromatographic retention indexes—correlated with molecular connectivity indexes, various organic compounds, 120
Chromatography, column—analysis and separation of anthralin from decomposition products, 388
column—analysis, testosterone and testosterone esters, various pharmaceuticals, acetonitrile–infusorial earth column, 871
microcolumn—analysis, marijuana, field test, compared to other plant substances, 976
paper—followed by γ-counting, analysis of iodide in urine, 258
Cinoxacin—effect of urine pH on urinary excretion, bioavailability correlated with physical characteristics of oral dosage forms, dogs, 227
Ciprofibrate—hypolipidemic effects, effect on hormone-sensitive lipase, compared to clofibrate and lifibrate, rats, 1557
Citric acid—glass formation, glass transition temperature, benzoic acid, phenobarbital, 601
Clindamycin—palmitate ester, aqueous solubility, pH, temperature, micelle formation, 1292
Clobazam—analysis, fluorometry, blood levels, effect on pupillary constriction, and anxiety level, 1002
—fluorometric determination in human plasma, 494
Clofibric acid—effect on binding of racemic warfarin and its enantiomers to human serum albumin, 1515
Clonazepam—interaction with carbamazepine by enzyme induction, pharmacokinetic description, monkeys, 416
Clonidine—GLC analysis in plasma and urine, 72
Clotrimazole—analogs, frozen conformers, imidazole substitution, antifungal activity, 1453
CNS activity—series of substituted indolizines evaluated, 321
antitumor activity—aziridinylbenzoquinones evaluated *in vivo*, various test systems, 185
depressants—quantitative structure–activity relationships and dipole moments, 463
Cobalt irradiation—effect on penicillin G procaine, veterinary mastitis products, sterilization, 1075
Cobaltous chloride—hypothermia, rats, mice, hamsters, effect of phentolamine, diphenhydramine, propranolol, cimetidine, naloxone, species specificity, 693
Cocaine analogs—nortropacocaine, conformation, structure–activity relationships, effect of solvents, PMR spectra, 788
Codeine phosphate—acetylation by aspirin, solid dosage forms, GLC analysis of aspirin and salicylic acid, and codeine and acetylcodeine, pharmacokinetics, 1494
Colchicine—microbial transformations, ^{13}C-NMR spectra, metabolites, 1239
Colloidal silica—in *n*-dodecane and 1-dodecanol gels, rheological analysis, hydrogen bonding, methyl salicylate incorporation and release, 842
Colorimetry—analysis, acetaminophen in various pharmaceutical formulations, 750
—analysis, chloramphenicol degradation products, 1565
—analysis, chlorothiazide in urine, bioavailability estimates compared to high-pressure liquid chromatographic analysis in dogs, 126
—analysis, glycyrrhizin, methylene blue, 1231
—analysis, nitrosamines, aqueous suspensions, biological fluids, 1159
—analysis, penicillins in intravenous solutions, dextrose, nickel(II)-catalyzed hydroxamic acid formation, 1333
Complexation—prostaglandin E_1 with cyclodextrin, dissolution, stability, 1059
Complexes—barbital with 1-methylimidazole, crystal structure determined, 361
charge transfer—nucleic acid bases with isoproterenol, various solvents, UV absorption study, 631
—iodine with inorganic bromide and chloride salts, spectrophotometric determination, 513
Compliance—effect of measurement activities on patient behavior, 272
Conductivity, electrical—effect of aging and humidity, various compressed tablets, 896
Conformations—drug, biological activity, fraction of conformer and partition coefficient, 396
Contact angles—wetting of pharmaceutical solids, 486, 488
Contraceptives, potential—activated *N*-carbobenzoxy amino acid esters, mice, 696
Contrast media—oily iodinated organic carbonates, biological elimination, 1438
Copolymers—anionic and cationic, controlled-release tablets, dissolution rate, various drugs, 860
—controlled-release delivery devices, *n*-hexyl half-ester of a methyl vinyl ether–maleic anhydride, urease, pH-controlled hydrocortisone release, 919
Corn oil—analysis, formulations with estrogens and androgens, stability, 733
Corticosteroids—analysis, skin preparations, reaction rate method, 1479
—hydrocortisone, controlled-release delivery device, 919
***Coryphantha macromeris* cactus**—biosynthetic conversion of epinephrine to normacromerine, 85
Cosmetics—thioglycolates, percutaneous toxicity, effect of surfactants, percutaneous penetration, rabbits, 1230
Cost–benefit—analysis, gentamicin dosage regimens individualized in burn patients, 267
Cough–cold syrup—analysis, ion-pair reversed-phase high-pressure liquid chromatography, pseudoephedrine hydrochloride, brompheniramine maleate, dextromethorphan hydrobromide, 1463
Coumarin anticoagulants—warfarin, hepatic uptake, concentration dependence, rats, 1569
Coyote deterrents—undecenovanillylamide, microencapsulation dissolution, 1561
Creatinine—analysis, high-performance liquid chromatography, ion-exchange membrane assay, 802
—analysis, saliva, high-performance liquid chromatography, 534
—high-pressure liquid chromatographic analysis, membrane method, 802
***Croton lechleri* bark**—taspine isolated, evaluated for anti-inflammatory activity in rats, 124
Cryptolepine hydrochloride—action on *Staphylococcus aureus*, microbial kinetics, 1510
Crystal dissolution—potassium ferricyanide at fluid–fluid interface, 163
Crystals—α- and β-forms of progesterone, various thermodynamic properties determined, 175
Crystal structure—determined for complex of barbital with 1-methylimidazole, 361
Curarimimetic potency—compared in enantiomers of benzyl- and ethyllaudanosinium iodides, 522
Cyclazocine—analysis, GLC–mass spectrometry, radioimmunoassay, human and dog plasma, pharmacokinetics, 1447
Cyclic AMP phosphodiesterase—inhibitors, succinic acid biphenylalkyl monoesters, synthesis, structure–activity relationships, 903
Cyclodextrin—complexation with prostaglandin E_1, dissolution, stability, 1059
Cyclooctylsulfamate—metabolism in rats, 372
Cyclophosphamide—analysis, high-performance liquid chromatography, raw material, parenteral dosage forms, 1144
—high-performance liquid chromatographic analysis in prepared samples, 172
Cysteine—acid dissociation and metal complex formation constants with calcium(II), iron(III), and gold(I), simulated biological conditions, 426
Cytarabine, analogs—synthesis, carbocyclic analog, antileukemic activity, 668
Cytotoxic agents—chartreusin, aqueous solubility enhanced by hydroxybenzoates, 728

D

Dactinomycin—controlled-release dosage forms, polyalkylcyanoacrylate nanoparticles, adsorption and release kinetics, 1521

Decomposition—flupenthixol dihydrochloride in aqueous solution, 169
products, anthralin—column chromatographic and TLC analysis and separation, 388
Decongestants—analysis, ion-pair liquid chromatography, various cough and cold preparations, structure–activity relationships, 1135
Degradation—10-acetylphenothiazine, kinetics, effect of pH, 515
Delivery devices, controlled—hydrogel membranes, progesterone permeation, effect of various nonaqueous polymerization solvents, 794
Delivery, drug—E-type prostaglandins in triacetin system, stability, 114
—magnetic microspheres synthesized as drug carriers, effect of stabilization and heat on drug release *in vitro*, 79
Delivery systems—microencapsulated ion-exchange resin beads, prepared by various methods, evaluated for release rate, 211
potential—silicone rubber membranes, selectivity toward transport of E and F prostaglandins, 263
Demeclocycline—complexation, effect of cations, differential pulse polarography, 1061
Desipramine—analysis in plasma, high-performance liquid chromatography, 703
Desmethyldiazepam—radioimmunoassay, 1471
Dexamethasone—analysis, high-pressure liquid chromatography, various pharmaceutical dosage forms, 926
Dexamethasone sodium phosphate—analysis, high-performance liquid chromatography, identification of impurities in a commercial sample, epimerization, 951
—analysis, high-pressure liquid chromatography, various pharmaceutical dosage forms, 926
Dextromethorphan hydrobromide—analysis, ion-pair reversed-phase high-pressure liquid chromatography, cough–cold syrups, 1463
Dialkyl pyrazolidinethiols—synthesis, potential antiradiation agents, structure–activity relationships, 1331
Dialysis, dynamic—drug–erythrocyte interactions, 546
Diastereomers—atropine and *l*-hyoscyamine urethane derivatives, chemical synthesis, 1039
Diazepam—analysis, high-performance liquid chromatography, stability, tablets, 1185
desmethyl metabolite—radioimmunoassay, 1471
—hydrolysis products, methylaminochlorobenzophenone, pKa, structure–activity relationships, 937
1-(3,4-Dichlorophenyl) -4- dimethylaminomethyl-1-nonen-3-one hydrochloride—cytotoxicity against murine leukemia L-1210 and Walker 256 carcinosarcoma cells, *in vitro* and *in vivo*, 1383
Dichlorphenamide—GLC analysis in biological fluids, 381
Dicumarol—bioavailability, effect of oral and intravenous phenobarbital, 958
—phenobarbital effect on systemic availability in bile duct-ligated rats, 1309
α-Dibutylaminomethyl - 2,6 - bis(trifluoromethylphenyl)-4-pyridinemethanol—binding to human serum albumin, 45
α-[(Dibutylamino)methyl]-6,8-dichloro-2 - (3′,4′-dichlorophenyl)-4-quinolinemethanol — adsorption onto container surfaces, 93
Dielectric constants—solid–liquid and liquid–liquid systems, as a function of composition, polarizations, monoethyl ether, diethylene glycol, propylene glycol, methylparaben, 424
Dienestrol—analysis by high-performance liquid chromatography, in various dosage forms, 508
Dietary supplements—effect of lysine and tryptophan on growth rate, barbiturate toxicity, ethanol toxicity, rats, 1554
Differential pulse polarography—tetracycline analogs, complexation, effect of cations, 1061
Diffusion—effect of lag time on multicompartmental pharmacokinetics for transepidermal infusion, 1469
Diflorasone diacetate—percutaneous absorption rate, effect of polyoxypropylene 15 stearyl ether and propylene glycol, 275
Digitoxin—stability studies, temperature, solubility, aging, various commercial powders, 1224
Digoxin—bioavailability and heart function index, capsules and tablets compared in cardiac patients, 104
—interaction with montmorillonite, mechanism of adsorption and degradation, IR, X-ray diffraction and adsorption studies, 358
—stability studies, temperature, solubility, aging, various commercial powders, 1224
Dihydroquinidine—protein binding, effects on quinidine interactions with plasma constituents, 448
Diisopropylphosphate—analysis, IR, NMR, mass spectra, GLC, isolation as degradation product from peanut oil isoflurophate formulation, 1194
Dimercaptosuccinic acid—analysis, differential pulse polarography, in radiopharmaceuticals, and tin, 657
Dimethylphenobarbital—alkaline hydrolysis, kinetics, reaction products, 639
3,6-Dimethyl -6- phenyltetrahydro-2*H*-1,3-oxazine quaternary salts—synthesis and antimicrobial evaluation, 407
Dinoprost—absorption and penetration, mesenteric circulation, rats, metabolism, 983
—methyl ester, absorption and penetration, mesenteric circulation, rats, metabolism, 983
—prodrugs, C_1-aliphatic esters, synthesis, 836
—prodrugs, C_9- and C_{15}-monoesters, synthesis, bioactivity, 949
Dinoprost and dinoprostone C_1-esters—influence of functional group on melting points, 1069
Dinoprostone—prodrugs, C_1-aliphatic esters, synthesis, 836
Diphenylbutylpiperidines—analysis, TLC, differentiation from phenothiazine derivatives, 1050
Diphenylpyraline hydrochloride—GLC analysis, in syrup, 521
Dipole moments—anticonvulsants and CNS depressants, 463
Directly compressible materials—various inorganic chlorides and sodium citrate, electrical conductances, effects of particle size, lubricant level, moisture content, and compaction pressure, 222
Disintegration—directly compressed tablets, effect of microcrystalline cellulose, 205
Disopyramide—analysis, high-pressure liquid chromatography, plasma, metabolites, humans, 1318
—metabolites, analysis, high-pressure liquid chromatography, humans, 1318
Dispersions, solid—effect of amorphous silicon dioxides on prednisone, digoxin, griseofulvin, simulated GI fluids, solvent deposition compared to ball milling, 560
Dissolution—coyote deterrent, undecenovanillylamide, microencapsulation, 1561
devices—spin filter, effects of tablet position and basket type, comparison to USP basket method, 1542
devices—spin filter, hydrodynamic analysis, models, 1084
in vitro—trisulfapyrimidine suspensions, compared to bioavailability, various commercial preparations, screening methods, 699
—potassium ferricyanide crystals at fluid–fluid interface, 163
rate—*p*-aminobenzoic acid esters from solid xylitol dispersions, 791
rate—benoxaprofen, effect of particle size, 850
rate—effects of amorphous silicon dioxides on prednisone, digoxin, griseofulvin, simulated GI fluids, solvent deposition compared to ball milling, 560
rate—lithium carbonate, various commercial products, powder, humans, 952
rates—chloramphenicol tablets and powder, benzoic acid tablet, 708
rates—chloramphenicol, various dosage forms, correlated with bioavailability, 712
rates—doxycycline free base and hydrochloride salts, 1183
rates—various drugs, tablets containing radiation-induced polymers of glass-forming monomers in the presence of cationic and anionic copolymers, 860
studies—aspirin tablets, commercial, enteric coated, dissolution times, pretreatment with simulated gastric juice, 1290
—7,7′-succinylditheophylline, effect of pH, 288
—suspending agent effects on steroid suspensions, 1475
—test apparatus, cascade barrier bed, 938
test apparatus—designed, evaluated with various drugs at various air pressures compared to other methods, 177
testing—hydrochlorothiazide, urinary excretion correlated with *in vitro* dissolution, 1486
testing systems—automated programmable 12-tablet system, 1280
testing systems—spin filter compared to USP basket method, effects of tablet position and basket type, 1542
testing systems—eight systems compared, chloramphenicol tablets and powder, benzoic acid tablet, 708
tests—effects of instrumental vibration, tablets, 1336
—various aminocephalosporins, effect of pH, 308
Distribution—enterohepatic circulation, effect of biliary excretion and reabsorption rates, pharmacokinetics, two-compartment model, 792
ocular—pilocarpine, mechanistic and quantitative evaluation, 673
volume—estimation and first-pass effect, drugs with incomplete oral absorption and partial renal excretion, 260
Disulfides, aminoalkyl—metal-binding stability constants determined, relation to radiation-protective activity, 202
Dithioacetic acids, quinolinium—zwitterions synthesized, antileukemic activity evaluated in mice, 336
Diuretics—azosemide, high-performance liquid chromatographic analysis, commercial animal feed, 1413
—chlormerodrin, antimicrobial activity evaluated *in vitro*, 256
—chlorothiazide, bioavailability in dogs, colorimetric and high-pressure liquid chromatographic analyses compared, 126
—chlorothiazide, tablets, bioavailability, humans, 1099
—chlorthalidone, automated analysis, plasma and urine, carbonic anhydrase inhibition, humans, 967
—chlorthalidone, high-pressure liquid chromatographic analysis in pharmaceutical dosage forms, 106
—hydrochlorothiazide, urinary excretion correlated with *in vitro* dissolution, various methods, bioavailability, 1486
—indapamide, photolytic and thermal decomposition, products identified, 1063
Diuretic–vasodilators—minophylline, spectrophotometric analysis in pharmaceutical formulations, 9
DNA—interaction with streptonigrin and with metals, 853
***n*-Dodecane**—gels, colloidal silica, rheological analysis, methyl salicylate incorporation and release, 842
1-Dodecanol—gels, colloidal silica, rheological analysis, methyl salicylate incorporation and release, 842
Dopamine—oxidation in phenothiazine cation radicals, kinetics, structure–activity relationships, 612
Dosage forms, aerosol—insulin, tracheal administration, absorption, rabbits, 670
—controlled-release bitolterol formulations prepared by microencapsulation, effects on bronchodilator and heart rate activities, dogs, 475
—controlled-release delivery devices, radiation-induced polymerization of glass-forming monomers, low temperature, in the presence of dimethylaminoethyl methacrylate–methyl methacrylate or methacrylic acid–methyl acrylate copolymers, for various drugs, dissolution rate from tablets, 860
—controlled-release delivery devices, radiation-

polymerized beads, potassium chloride, 628
—controlled-release devices, *n*-hexyl half-ester of a methyl vinyl ether–maleic anhydride copolymer, urease, pH-controlled hydrocortisone release, 919
controlled release—morphine sulfate, release from silicone polymer, effect of water-soluble carriers, 662
controlled release—polyalkylcyanoacrylate nanoparticles, adsorption and release of dactinomycin and methotrexate, 1521
—controlled release, progesterone from silicone matrix, effect of hydroxylation, kinetics, thermodynamics, 689
controlled release—tetracycline, hydroxyethyl methacrylate–methyl methacrylate copolymer implant, rats, *in vivo*, 1151
controlled release—tetracycline, hydroxyethyl methacrylate–methyl methacrylate copolymer, *in vitro*, 1147
—hydrocortisone, various rectal dosage forms, degradation in human feces, 623
—intrauterine devices, estriol releasing, prepared, release rate and stability evaluated, 20
liquid—prednisolone and prednisone, separation by high-pressure liquid chromatography, 908
—methoxsalen solution compared to suspension, bioavailability characteristics evaluated, rats and dogs, 451
nasal—propranolol, absorption, compared to oral and intravenous dosage forms, rats, bioavailability, 1196
ocular—pilocarpine, shear-facilitated release, ointments, 724
parenteral—lyophilization, physicochemical model, 1170
potential—ethylcellulose–polyethylene glycol films, containing model dispersed drugs, drug release kinetics, 325
potential—microencapsulated ion-exchange resin beads, prepared by various methods, evaluated for release rate, 211
solid—dispersions, *p*-aminobenzoic acid esters in xylitol, dissolution rate, 791
solid—suppositories, acetaminophen, antipyretic effects, rats, 1105
solid—tablets, aspirin, enteric coated, commercial, dissolution procedures, dissolution times, pretreatment with simulated gastric juice, 1290
sustained release—silicone polymer tubing, effect of temperature and ion-exchange resin on cation diffusion, 1102
—tablets, dissolution testing, spin filter compared to USP basket method, effects of tablet position and basket type, 1542
—tablets, effect of colloidal silica on aspirin stability, 197
topical—lanolin alcohol films, kinetics of triamcinolone acetonide release, 782
topical—nitroglycerin, percutaneous absorption, rats, 608
topical—pilocarpine, precorneal disposition, mechanistic and quantitative evaluation, 673
various—analysis, sulfonamides, high-performance liquid chromatography, stability indicating, 922
Dosage regimens—design, calculation of drug distribution volume, arithmetic mean method, harmonic mean method, 1067
—effect of compliance measurement activities on patient behavior, 272
—gentamicin, individualized in burn patients, cost–benefit analysis, 267
—theophylline, predictive scheme, effect of various patient variables on metabolism, 1358
Doses—predictability of warfarin requirements, theoretical considerations, 432
Doxepin hydrochloride—isomers, high-performance liquid chromatographic analysis, 1454
Doxycycline—analysis, human serum and urine, high-performance liquid chromatography, 999
—dissolution rates, free base and hydrochloride salts, 1183
—monohydrate and hydrochloride dihydrate salts, solubility in aqueous solution, effect of pH, 188
Drug absorption—estimation of times required to attain various fractions of steady-state level, pharmacokinetics, 1546
absorption—pharmacokinetic models, limited absorption time, 1395
binding—plasma, volume of distribution, effect of altered plasma protein binding, 1203
clearance—estimation of clearance through an organ, pharmacokinetics, 1066
delivery systems, intravenous—loss of nitroglycerin from aqueous solution into plastics, 1163
delivery systems—kinetics, biodegradation, diffusion, films, capsules, 1534
delivery systems—morphine sulfate, release from silicone polymer, effect of water-soluble carriers, 662
design—structure–selectivity relationships, penicillins, alkylchlorophenols, 1081
distribution volume—calculations, arithmetic mean method, harmonic mean method, 1067
impurities—trihexyphenidyl, tablets and elixir, TLC analysis, 1124
interactions—phenobarbital effect on dicumarol systemic availability in bile duct-ligated rats, 1309
Drug–antibiotic interactions—bismuth subsalicylate interference with tetracycline bioavailability, 586
Drug–drug interactions—pharmacokinetics, iodoxamic acid, iopanoic acid, biliary excretion, rhesus monkeys, 1430
Dyes, FD&C—effect on stability of norethindrone and ethinyl estradiol in tablets, 368
various—TLC determination in tablet-coating formulations, 97
Dyphylline—urinary excretion, pharmacokinetics, humans, 1327

E

Echites hirsuta—whole plant ethanolic extract, various flavonoids and sterol glycoside isolated and identified, 247
Editorials
Antibiotic Certification—Obsolete and Archaic (February)
APhA Perspective on "Lannett" (April)
Bureaucratic Overkill (May)
Caution Urged in Rationing Research (September)
Consistency in Stability Testing (January)
Instilling Science in the Regulatory Process (November)
On Staying Competent (October)
Pharmaceutical Excipients Come of Age (August)
A Plea for FDA Stability (July)
Postmarketing Drug Surveillance (December)
Risking Public Credibility (March)
Too Many Regulations? (June)
Electrical conductances—various directly compressible inorganic chlorides and sodium citrate, effect of particle size, lubricant levels, moisture content, and compaction pressure, 222
Electrodes, plastic ion selective—analysis, mefloquine and derivatives in blood, dogs, hydrophobic amines, 746
Electron-capture GLC—comparison of various fluoroacyl derivatives of ephedrine, 557
Elimination—chloroprocaine in humans, 75
—phenformin in guinea pigs, rats, and dogs, TLC–autoradiographic analysis, 156
—pralidoxime chloride, kinetics in dogs, 141
Enantiomers—benzyl- and ethyllaudanosinium iodides synthesized, curarimimetic potencies compared, 522
—carprofen, stereospecific assay, stereospecific metabolism, rats, 1274
—of naproxen, liquid chromatographic analysis, 112
—propranolol, resolving agents, 1181
Enterohepatic circulation—effect of biliary excretion and reabsorption rates on drug pharmacokinetics, two-compartment model, 792
Enthalpy—dissolution of lecithin in aqueous bile salt solutions, micelle formation, hydrogen bonding, 581
Entropy of fusion—disubstituted benzenes independent of hydrogen bonding, shape, size, dipole moment of rigid molecules, structure–activity relationships, 565
Enzyme activity—effect of activated *N*-carbobenzoxy amino acid esters on sperm proteolysis, mice, 696
inactivation—kinetics, application of Weibull distribution to solid-state studies, 1381
induction—drug induced, time-dependent kinetics, pharmacokinetic theory, 398
induction—effect of proadifen on intestinal methylglucose transport, rats, fasting, 945
induction—pharmacokinetic description of carbamazepine–clonazepam interaction, monkeys, 416
inhibition—by sodium fluoride and tetraethyl pyrophosphate, dog plasma and blood, effect on heroin hydrolysis, 26
inhibition—effect of proadifen on intestinal methylglucose transport, rats, fasting, 945
inhibitors—6,6′-azopurine, inhibition of rabbit liver aldehyde oxidase, *in vitro*, prevention of azathioprine cytotoxicity, 1202
kinetics—application of Weibull distribution to inactivation studies, 1381
Enzymes, hepatic—conversion of fluorenone oxime to phenanthridinone, *in vitro*, kinetics, 820
Ephedrine—electron-capture GLC analysis in human plasma and urine, 557
Epimerization—dexamethasone sodium phosphate in a commercial solution, 551
Epinephrine—biosynthetic conversion to normacromerine in *Coryphantha macromeris* cactus, 85
Erythrocytes—acetazolamide binding to two carbonic anhydrase isoenzymes, *in vitro*, 912
—drug interactions, dynamic dialysis analysis, 546
Erythromycin base and 2′-propanoate—bioavailability in humans, effect of food and fluid volume, 150
Essential amino acids—effect of dietary lysine and tryptophan supplementation on growth rate, barbiturate toxicity, ethanol toxicity, 1554
Estriol—delivered by intrauterine devices, release rate and stability evaluated, 20
Estrogens—analysis, stability in formulations containing corn oil, chromatography, separation from degradation products, 733
conjugated—bioinequivalence of generic and proprietary products, postmenopausal women, 986
esterified—high-performance liquid chromatographic analysis in prepared solutions, 311
—estriol, delivered by intrauterine devices, release rate and stability evaluated, 20
—solubilization in various association colloids, 542
synthetic—high-performance liquid chromatographic analysis in various dosage forms, 508
Ethanol toxicity—effect of dietary lysine and tryptophan supplementation, 1554
Ethinyl estradiol—stability in tablets, effect of FD&C dyes, 368
Ethiodized oil—various emulsions for intravenous administration prepared, effect of oil globule size on liver opacification in rabbits and monkeys, 52
Ethylcellulose–polyethylene glycol films—containing model dispersed drugs, drug release kinetics, 325
Ethylene chlorohydrin—analysis, GLC, ophthalmic solutions, 1547
Ethylene glycol—analysis, GLC, ophthalmic solutions, 1547
Ethylene oxide—analysis, GLC, ophthalmic solutions, 1547
Excipients, tablet—microcrystalline cellulose, effect on liquid penetration and disintegration of directly compressed tablets, 205
Excretion, renal, partial—estimation of first-pass effect and distribution volume, 260
urinary—cinoxacin, effect of urine pH, dogs, 227
Expectorants—potassium guaiacolsulfonate, high-pressure liquid chromatographic analysis in pharmaceutical preparations, 118
External loop technique—blood collection, pharmacokinetics, eigenfunction expansion analysis,

1571
Eye—pilocarpine distribution following topical administration, rabbits, models, 435

F

FDA—assay, antibiotics, correction, 797
Fenoprofen—pharmacokinetics, oral administration, calcium salt, 1087
Feprazone—analysis, high-pressure liquid chromatography, various pharmaceutical formulations, 798
Films—ethylcellulose-polyethylene glycol containing model dispersed drugs, drug release kinetics, 325
First-pass effect—estimation and distribution volume, drugs with incomplete oral absorption and partial renal excretion, 260
Flavonoids, various—isolated and identified in whole plant ethanolic extract of *Echites hirsuta,* 247
Flocculation—sulfamerazine suspensions, cationic polymer, anionic and nonionic surfactants, 1491
Fludrocortisone acetate—and solid dosage forms, high-performance liquid chromatographic analysis, 421
Fluocinolone acetonide—analysis, skin preparations, reaction rate method, 1479
Fluorenone oxime—metabolic conversion to phenanthridinone by hepatic enzymes, *in vitro,* kinetics, 820
Fluorinated phenytoin analogs—synthesized, evaluated for anticonvulsant activity in mice, 115
Fluorocarbon aerosol propellants—trichloromonofluoromethane, blood levels correlated to cardiovascular and respiratory responses in dogs, 160
Fluorometry—analyses, various hydroxynaphthoquinones, three different procedures, 16
—analysis, chlorzoxazone in commercial tablets and biological fluids, in presence of hydroxychlorzoxazone and acetaminophen, 910
—analysis, clobazam in human plasma, 494
—analysis, griseofulvin in human plasma, compared to high-pressure liquid chromatography, 1127
—analysis, methadone in lung, liver, brain, serum, rats, 1097
—analysis, nitrosamines, aqueous suspensions, biological fluids, 1159
—analysis, pancuronium bromide in maternal arterial and umbilical venous serum, 914
—analysis, salicylamide in plasma, compared to radiochemical assay, rats, 648
Fluorouracil—analysis, flame-ionization GLC, human plasma, *in vivo,* 1175
Flupenthixol dihydrochloride—decomposition in aqueous solution, 169
Folic acid—absorption, rat small intestine, competitive inhibition by methotrexate, 1552
—high-pressure liquid chromatographic analysis in prepared samples, collaborative study, 241
Folk medicine—antispasmodics, *Teucrium polium* oil, GLC–mass spectrometry, 800
—*Artemisia herba-alba,* antibacterial activity of essential oil, 924
—*Yunnan Bai Yao,* Chinese herbal, cytotoxic activity of isolated saponins, 900
Formulations—improved delivery of methoxsalen using solution form, 451
Fungistatic agents—trichothecans, epoxide analogs, structure-activity relationships, toxicity, 1501

G

Gallstones—cholesterol, solubility in organic solvents, treatment of stones retained in common bile duct, 1090
Gangliosides—monomolecular films, effect of ketamine, 1246
Gastric mucosal damage—induced by aspirin in rats, effect of methionine and histidine, 295
Gels—colloidal silica in *n*-dodecane and 1-dodecanol, rheological analysis, hydrogen bonding, methyl salicylate incorporation and release, 842
Gentamicin—dosage regimens individualized in burn patients, cost–benefit analysis, 267
GI motility—somatostatin effect, species specificity, dogs, cats, rabbits, rats, 1107
GI tract—drug absorption, griseofulvin, rabbits compared to humans, 1286
—magnesium deficiency, motility, metabolism, rats, 978
Glass formation—citric acid, benzoic acid, phenobarbital, 601
transition temperature—citric acid glass, benzoic acid, mechanical stress, phenobarbital, 601
GLC—analyses, theophylline, hydroxyethyltheophylline, diphenylpyraline hydrochloride, 521
—analysis, butylated hydroxyanisole in plasma and urine, 103
—analysis, chloroprocaine in plasma and urine, 75
—analysis, clonidine in plasma and urine, 72
—analysis, dichlorphenamide in biological fluids, 381
—analysis, diisopropylphosphate, isolation as degradation product from peanut oil isoflurophate formulation, 1194
—analysis, ethylene oxide, ethylene chlorohydrin, ethylene glycol, ophthalmic solutions, 1547
—analysis, guanfacine in plasma and urine, 219
—analysis, loxapine, amoxapine, and their metabolites in serum and urine, 216
—analysis, marijuana, stability of cannabinoids in chloroform and ethanol solutions, 262
—analysis, methyl salicylate and methanol, topical analgesic formulation, 506
—analysis, oxycodone in plasma, 43
—analysis, pemoline in biological fluids, 445
—analysis, pentobarbital and various barbiturates in serum, 386
—analysis, pseudoephedrine, comparison with high-pressure liquid chromatographic method, urine, 1472
—analysis, trihexyphenidyl hydrochloride, in various pharmaceutical dosage forms, analogs, 503
—analysis, verapamil in plasma, 574
—analysis, vitamin E, collaborative study of 11 samples by 11 laboratories, 98
—bucainide, analysis in plasma, 569
—determination of alprenolol and oxprenolol in serum using wall-coated open tubular column and electron-capture detection, 511
electron-capture—analysis, ephedrine in plasma and urine, 557
electron-capture—analysis, isosorbide dinitrate and mononitrates, human plasma, 659
electron-capture—analysis, mefloquine, pyridine-methanol derivatives, blood, 718
electron-capture—analysis, metoclopramide, human plasma and urine, 1254
electron-capture—analysis, oxycodone and noroxycodone in plasma and urine, 527
electron-capture—analysis, pseudoephedrine, human serum, bioavailability, 1567
electron-capture—analysis, theophylline in serum, 443
electron-capture — *S*-2-(3-*tert*-butylamino-2-hydroxypropoxy)-3-cyanopyridine, human plasma, 1559
electron-capture—specific assay for naltrexone, 411
flame-ionization—analysis, fluorouracil, human plasma, in vivo, 1174
flash-methylation—analysis, phenobarbital in biological fluids, degradates, 1187
GLC–mass spectrometry—analysis, cyclazocine, human and dog plasma, 1447
—analysis, hydroxyzine, human plasma, 1456
—analysis, *Teucrium polium* oil, antispasmodics, folk medicine, 800
Glucocorticoids—hydrocortisone, high-pressure liquid chromatographic and fluorometric analysis, plasma, humans, 1374
—methylprednisolone, bioavailability, tablet variability, commercial preparations, Latin square study, 1312
—triamcinolone acetonide, release from lanolin alcohol films, kinetics, 782
Glutethimide—metabolites, identified in human urine, synthesized, 283
Glyburide—analysis, high-performance liquid chromatography, dog serum, 1138
Glycerol—analysis, spectrophotometry, comparison with enzymatic method, 1064
Glycyrrhizin—analysis, methylene blue colorimetry, 1221
Gold complexes—stability constants of antiarthritic gold(I) complexes and penicillamine and cysteine, simulated biological conditions, 426
Goldfish—effect of lidocaine and derivatives on times of death and overturn, effect of pH on time of death and overturn, 401
Griseofulvic acid—metabolite of griseofulvin, human urine, identification, 1335
Griseofulvin—analysis, high-pressure liquid chromatography, human plasma, compared to fluorometric assays, 1127
—dissolution rate and bioavailability, rabbits compared to humans, 1286
—human urinary metabolite, identification, griseofulvic acid, 1335
Growth hormone inhibitors—somatostatin, effect on GI motor activities, species specificity, dogs, cats, rabbits, rats, 1107
Guaifenesin—analysis, high-pressure liquid chromatography, in liquid and solid pharmaceutical dosage forms, stability, 530
Guanabenz—degradation products, stability, UV spectroscopic analysis, 1010
Guanethidine—radioimmunoassay, human plasma, nanogram level, 1419
Guanfacine—GLC analysis in plasma and urine, 219
Gymnodinium breve—effect of aponin, *Gomphosphaeria aponina,* unialgal and mixed cultures, potential biological control, 963

H

Hallucinogenic agents—mescaline, analogs, hallucinogenic activity, structure-activity relationships, molecular connectivity analysis, 906
Halogenated hydrocarbons, various—molecular connectivity indexes related to anesthetic activity, 39
Hammer mill—powder homogenization, sucrose-salicylic acid, 721
Haptens—benzodiazepines, chemical synthesis, 845
Hardness—effect of aging and humidity, various compressed tablets, 896
Heart function index—digoxin capsules and tablets compared in cardiac patients, 104
Hemostatic agents—aminocaproic acid, high-performance liquid chromatographic analysis in serum, 249
—Yunnan Bai Yao, cytotoxic activity of isolated saponins, Chinese herbal, 900
Heparin—effect on plasma protein binding of bilirubin and salicylate, rats, 1483
Heparin sodium—molecular weight determination of commercial products and sterile solutions using liquid chromatography, 588
Hepatocytes—myoinositol uptake, pharmacokinetics, *in vitro,* rats, 1022
Hepatography, intravenous—various emulsions of ethiodized oil prepared, effect of oil globule size on liver opacification in rabbits and monkeys, 52
Heroin—hydrolysis in dog plasma and blood, effect of sodium fluoride and tetraethyl pyrophosphate, protein binding and partition coefficient evaluated, 26
Heterocyclic anticancer agents—1,4-bis(2′-chloroethyl)-1,4-diazabicyclo[2.2.1]heptane cation, synthesis, diperchlorate and dihydrogen dimaleate salts, 1539
Hexahydrocannabinol derivatives, various—synthesized, pharmacological activity evaluated in mice, 330
***3a,4,5,6,7,7a* - Hexahydro-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-1,2-benzisoxazole** — urinary metabolites, antibacterial activity, antiprotozoal activity, dog, 1156
Hexobarbital toxicity—effect of dietary lysine and tryptophan supplementation, 1554
Hexylresorcinol—high-pressure liquid chromato-

graphic analysis in commercial preparations, 240
High-performance liquid chromatography—analysis, acetaminophen, *p*-aminophenol, effervescent tablets, 1465
—analysis, aminocaproic acid in serum, 249
—analysis, amitriptyline hydrochloride in commercial aqueous solutions, stability, 1329
—analysis, azosemide, commercial animal feed, 1413
—analysis, bleomycin A_2 in plasma, 232
—analysis, cephacetrile in various dosage forms, 652
—analysis, chlorpropamide, tolbutamide, *p*-chlorobenzenesulfonamide, *p*-toluenesulfonamide, stability in solid pharmaceutical dosage forms, 577
—analysis, creatinine, 802
—analysis, cyclophosphamide in prepared samples, 172
—analysis, cyclophosphamide, raw material, parenteral dosage forms, 1144
—analysis, dexamethasone sodium phosphate and impurities in a commercial sample, 551
—analysis, diazepam tablets, stability indicating, 1185
—analysis, dienestrol in various dosage forms, 508
—analysis, doxepin hydrochloride isomers, 1454
—analysis, doxycycline in human serum and urine, 999
—analysis, esterified estrogens in prepared solutions, 311
—analysis, fludrocortisone acetate and solid dosage forms, 421
—analysis, glyburide in dog serum, 1138
—analysis, hydralazine reaction with biogenic aldehydes and ketones, hydrazone formation, 1524
—analysis, hydroquinidine contamination of quinidine raw materials and dosage forms, 917
—analysis, imipramine, desipramine, 2-hydroxylated metabolites in plasma, 703
—analysis, indoprofen, human milk, 1113
—analysis, isoxsuprine hydrochloride, nylidrin hydrochloride, tablets, stability indicating, 1264
—analysis, ketoprofen in blood and urine, 484
—analysis, levodopa, amino acid impurities, commercial preparations, 1296
—analysis, levodopa, commercial preparations, impurities, degradation products, 1209
—analysis, mebendazole in human plasma, 880
—analysis, nitroglycerin in various dosage forms, 237
—analysis, propylthiouracil in plasma, alcoholic liver disease, 1459
—analysis, saliva creatinine, 534
—analysis, sulfonamides in various pharmaceutical formulations, stability indicating, 922
—analysis, tinidazole in human plasma, 599
—penicillin V analysis in penicillin V benzathine bulk drug and oral suspensions, 555
High-pressure liquid chromatographic assay—hydralazine, human plasma, 1423
High-pressure liquid chromatography—analyses, components of various muscle relaxant–analgesic mixtures, 32
—analyses, potassium guaiacolsulfonate and phenylephrine hydrochloride, high-pressure liquid chromatographic analysis in pharmaceutical preparations, 118
—analysis, amoxicillin and penicilloic acid metabolite in urine, 454
—analysis, antipyrine, plasma, rats, 1052
—analysis, aspirin derivatives in tablets, 1167
—analysis, benzoyl peroxide in pharmaceutical preparations, 280
—analysis, cephalosporins, aminolysis kinetics, aminolysis products, 616
—analysis, chlordiazepoxide and metabolites, biological fluids, 1467
—analysis, chlorothiazide in urine, bioavailability estimates compared to colorimetric analysis in dogs, 126
—analysis, chlorpheniramine and pseudoephedrine in human urine, 1243
—analysis, chlorthalidone in pharmaceutical dosage forms, 106
—analysis, chlorzoxazone and hydroxy metabolite in plasma, 253
—analysis, creatinine, membrane method, 802
—analysis, dexamethasone and dexamethasone sodium phosphate, various pharmaceutical dosage forms, 926
—analysis, feprazone in various pharmaceutical formulations, 798
—analysis, folic acid in prepared samples, collaborative study, 241
—analysis, hexylresorcinol in commercial preparations, 240
—analysis, hydrocortisone, human plasma, fluorometry, 1374
—analysis, ketoprofen in various body fluids, 366
—analysis, nitroglycerin liquid dosage forms and intravenous solutions, 481
—analysis, papaverine in human plasma, bioavailability, 1550
—analysis, penicillin G potassium, separation from degradation products, 1316
—analysis, pentobarbital–pyrilamine suppositories, compared to GLC, 605
—analysis, prednisolone and prednisone in liquid dosage forms, 908
—analysis, procainamide and *N*-acetylprocainamide in plasma, deproteinization *versus* extraction methods, 532
—analysis, propranolol in plasma, 379
—analysis, propylthiouracil, human plasma, 1461
—analysis, saccharin in various artificial sweeteners and pharmaceuticals, stability indicating, 878
—analysis, tetramisole in veterinary preparations, 796
—analysis, theophylline, elimination of ampicillin and 1,7-dimethylxanthine interference, 1200
—analysis of theophylline, guaifenesin, benzoic acid in liquid and solid pharmaceutical dosage forms, 530
—ticrynafen, reduced metabolite, 1451
Histidine—effect on aspirin-induced gastric mucosal damage in rats, 295
Hormones—esterified estrogens, high-performance liquid chromatographic analysis in prepared solutions, 311
—luteinizing hormone-releasing hormone, derivatives, synthesis, structure–activity relationships, 1013
Hydralazine—extraction, high-pressure liquid chromatographic assay, human plasma, 1423
—reaction with acetaldehyde, kinetics, half-life, therapeutic implications, 1256
—reaction with biogenic aldehydes and ketones, hydrazone formation, high-performance liquid chromatographic analysis, 1524
Hydrazine derivatives—kinetics and mechanism of reaction with acetic acid, 301
—derivatives, various heterocycles, antimicrobial and cytotoxic activity, 930
Hydrochlorothiazide—urinary excretion correlated with *in vitro* dissolution, various methods, bioavailability, 1486
Hydrocortisone—analysis, high-pressure liquid chromatography, fluorometry, plasma, humans, 1374
—controlled-release delivery, pH controlled, *n*-hexyl half-ester of a methyl vinyl ether–maleic anhydride copolymer, urease, 919
—degradation, human feces, various rectal dosage forms, 623
Hydrodynamics—dissolution devices, spin filter, salicylic acid disks, 1084
Hydrogel films—progesterone permeation, structure–activity relationships, steroids, models, 970
Hydrogels, poly(hydroxyethyl methacrylate)—progesterone permeation, effect of various nonaqueous polymerization solvents, 794
Hydrolysis, alkaline—dimethylphenobarbital, kinetics, reaction products, 639
—aspirin prodrugs, kinetics and mechanism, effect of pH, temperature, and dielectric constant, 299
—chlorambucil, kinetics and mechanism, 992
—heroin in dog plasma and blood, effect of sodium fluoride and tetraethyl pyrophosphate, 26
kinetics—5-azacytidine, aqueous solutions, 807
kinetics—quinuclidinyl benzilate in dilute aqueous solution, pH, temperature, 856
kinetics—2-tetrahydropyranyl benzoate, effect of pH, 235
—mecillinam in aqueous solution, degradation products, 1207
—7,7′-succinylditheophylline, effect of pH, 288
Hydrophobic amines—mefloquine, analysis in blood, plastic ion-selective electrodes, 746
Hydroquinidine—analysis, high-performance liquid chromatography, as contaminant in quinidine raw materials and dosage forms, 917
—conformation, NMR spectroscopic analysis, concentration dependence, 1400
Hydroxybenzoates—electrostatic and hydrophobic interactions, stability constants, 728
Hydroxyethyl methacrylate—hydrogel films, progesterone permeation, effect of various nonaqueous polymerization solvents, 794
Hydroxyethyltheophylline—GLC analysis, in syrup, 521
Hydroxylation—progesterone, effect on release from silicone matrix, 689
Hydroxynaphthoquinones, various—fluorometric analyses, three different procedures, 16
3-Hydroxy-3-phenacyloxindole analogs—synthesized as potential anticonvulsants, 519
Hydroxyzine—analysis, GLC–mass spectrometry, human plasma, following therapeutic doses, 1456
—decomposition by UV irradiation, tritiation, degradation products, 666
Hyoscyamine—derivatives, urethane diastereomers, chemical synthesis, 1039
Hyperuricemia—animal models, rats, 651
Hypolipidemic agents—allyl adenine N^1-oxide, chemical synthesis, 667
Hypotensive agents—ticrynafen, reduced metabolite, extraction, high-pressure liquid chromatography, urine and serum, 1451
Hypothermia—cobaltous chloride induced, effect of phentolamine, diphenhydramine, propranolol, cimetidine, naloxone, rats, mice, hamsters, species specificity, central *versus* peripheral effects, 693

I

Ibuprofen—analysis, differential potentiometry, dissociation constant, 1056
Imidazolinium salts—analysis, product from reaction of benzathine with iodine, 1322
Imipramine—analysis in plasma, high-performance liquid chromatography, metabolites, 703
Immune systems, cell mediated—tuberculin reaction, effect of nonsteroidal anti-inflammatory and various other pharmacological agents in guinea pigs, 12
Immunoglobulin E—binding to mast cells, *in vitro* method for screening inhibitors, 353
Indapamide—photolytic decomposition, thermal decomposition, decomposition products identified, 1063
Indole alkaloids—semisynthetic, cytotoxicity, structure–activity relationships, 1403
Indolizines, substituted—series synthesized, evaluated for pharmacological activity, 321
Indoprofen—analysis, high-performance liquid chromatography, human milk, 1113
Inhibitors—immunoglobulin E to rat peritoneal mast cells, *in vitro* screening method, 353
Inorganic salts—spectrophotometric determination of aqueous solutions, 513
Insecticides—callicarpone, analogs, structure–activity relationships, toxicity, antimicrobial activity, 1116
Insulin—aerosol dosage forms, tracheal administration, absorption, rabbits, 670
Interaction energies—various local anesthetics with phospholipid monolayers, correlated with pharmacological activity, 314
Interactions—carbamazepine and clonazepam in monkeys by enzyme induction, pharmacokinetic

description, 416
—digoxin and montmorillonite, mechanism of adsorption and degradation, IR, X-ray diffraction, and adsorption studies, 358
—quinidine and dihydroquinidine in human plasma, 448
Intestinal absorption—folic acid, methotrexate, competitive inhibition, rats, 1552
Intestinal epithelium—metabolism, 5-aminosalicylic acid, effect of dose and administration route, 1323
Intrauterine devices—estriol releasing, prepared, release rate and stability evaluated, 20
Iodide—analyzed in urine by paper chromatography–γ-counting, methyl iodide exchange, and reverse isotopic dilution, 258
Iodination—*l*-tyrosine, lactoperoxidase catalysis, kinetics, *in vitro*, iodide-specific electrode, 1530
Iodine—analysis, potentiometric, various, pharmaceuticals, ion-selective electrodes, 1416
—differential pulse polarographic analysis in thyroid hormone and tablets, 338
Iodometric assays—penicillin V benzathine, interference by imidazolinium salt, 1322
Ion-exchange microencapsulated resin beads—prepared by various methods, evaluated for release rate, 211
resins—effect on cation diffusion through silicone polymer tubing, 1102
Ionization kinetics—carbon acids, anisindione, phenindione, clorindione, 1047
Iopanoic acid—solid forms, physical characterization, polymorphism, thermal behavior, 1005
Iron(III) and calcium(II) complexes—with penicillamine, cysteine, thiomalic acid, and thioglucose, simulated biological conditions, 426
Isatin *N*-Mannich bases—screened for antimicrobial and antifungal activities, 459
Isatins, substituted—condensed with substituted acetophenones to give 3-hydroxy-3-phenacyloxindole analogs, screened for anticonvulsant activity, 519
Isoflurophate—degradation products, diisopropylphosphate, analysis, peanut oil formulation, 1194
Isomerization—testosterone hydrazones, effect of crystallization solvent, 736
Isoniazid—absorption from rat small intestinal lumen, effect of metoclopramide administration, 517
Isoproterenol—*in vivo* effects on small intestinal motor activities, dogs, 127
Isosorbide dinitrate—and mononitrates, simultaneous electron-capture GLC analysis, human plasma, 659
mononitrates—and dinitrate, simultaneous electron-capture GLC analysis, human plasma, 659
Isoxsuprine hydrochloride—analysis, high-performance liquid chromatography, tablets, stability indicating, 1264

J

Journals
Infertility: An Interdisciplinary Journal for the Rapid Communication of Clinical Aspects of Human Infertility, 400
Journal of Veterinary Pharmacology and Therapeutics, 266

K

Karl Fischer titration—water content of aluminum chlorohydrate analyzed, 122
Keratolytics—benzoyl peroxide, high-pressure liquid chromatographic analysis in pharmaceutical preparations, 280
Ketamine—effect on monomolecular films of gangliosides and mitochondrial lipids, 1246
Ketoprofen—high-performance liquid chromatographic determination in blood and urine, 484
—high-pressure liquid chromatographic analysis in various body fluids, 366
15-Ketoprostaglandin E_2—biosynthesis, ram seminal vesicles, dependence on arachidonic acid, cofactors, 1302
Kidney—effect of oxyphenbutazone, 1178
—radionuclide imaging, technetium mercaptan complexes, structure–activity relationships, 621
Kinetics—absorption and elimination of pralidoxime chloride in dogs, 141
—cephalosporin aminolysis, high-pressure liquid chromatography, 616
—dimethylphenobarbital alkaline hydrolysis, 639
—hydralazine reaction with acetaldehyde, 1256
hydrolysis—2-tetrahydropyranyl benzoate, effect of pH, 235
ionization—phenindione, 1042
—reactions of hydrazines with acetic acid, 301
time dependent—enzyme induction, pharmacokinetic theory, 398

L

β-Lactam antibiotics—various aminocephalosporins, solubility and dissolution, effect of pH, 308
Lactones, sesquiterpene—anti-inflammatory activity, structure–activity relationships, edema, arthritis, pleurisy, immunoglobulin synthesis, rats, 537
Lactoperoxidase—*l*-tyrosine iodination, catalysis, kinetics, *in vitro*, 1530
Lanolin alcohol—films, kinetics of triamcinolone acetonide release, topical dosage forms, 782
Laplace transforms—inverse, in mathematical treatment of linear mammillary models, 932, 933
Lecithin—dissolution in aqueous bile salt solution, micelle formation, enthalpy, hydrogen bonding, 581
Leukemia, lymphocytic—*in vitro* P-388 cells, effect of quassinoids on nucleic acid metabolism, 883
P-388—effect of quassinoids on cellular respiration, *in vivo, in vitro*, 887
Levodopa—analysis, high-performance liquid chromatography, amino acid impurities, commercial preparations, 1296
—analysis, high-performance liquid chromatography, commercial preparations, impurities, degradation products, 1299
Lidocaine analogs—2-aminopyrroles synthesized, 317
analogs—synthesis of 2-diethylaminoacetamido-3-carbamyl-4-methylpyrroles, local anesthetic activity, antiarrhythmic activity, structure–activity relationships, 955
—aqueous solubility, effect of temperature, 667
—concentration in parotid saliva and in blood, single dose and continuous infusion, rats, 1192
—effect on time of death in goldfish, effect on time of overturn in goldfish, derivatives, ionization, absorption, 401
Lincomycin—palmitate ester, aqueous solubility, pH, temperature, micelle formation, 1292
Liothyronine—differential pulse polarographic analysis in thyroid hormones and tablets. 338
Liquid chromatography—analysis, acetaminophen in serum, 96
—analysis, aspirin in buffered and unbuffered tablets, modified USP method, stability, 780
—analysis, enantiomers of naproxen, 112
—analysis, minocycline in human serum, 1527
ion-pair—analysis, decongestants and antihistaminics in various cough and cold preparations, structure–activity relationships, 1135
—molecular weight determination of commercial heparin sodium USP and its sterile solutions, 588
Liquid–liquid extraction—analysis, methadone, morphine, naloxone, brain, blood, plasma, urine, 660
Liquid–liquid systems—dielectric constants determined as a function of composition, 424
Lithium carbonate—bioavailability and dissolution, various commercial products, powder, humans, 952
Liver—myoinositol uptake, *in vitro*, pharmacokinetics, rats, 1022
Local anesthetics—aqueous solubility, effect of temperature, 667
—lidocaine analogs, synthesis, structure–activity relationships, 955
—procaine, pharmacokinetics, intravenous infusion, humans, drug interactions, 1016
Lorazepam—pharmacokinetics and bioavailability in humans, various administration routes compared, 57
Loxapine—and metabolites, GLC analysis in serum and urine, 216
Lung neoplasms—Lewis, methotrexate transport, dihydrofolate reductase binding, *in vivo*, 941
Luteinizing hormone-releasing hormone—derivatives, synthesis, structure–activity relationships, 1013
Lyophilization—physicochemical model, parenteral formulations, 1170

M

Macromerine—biosynthetic conversion from epinephrine in *Coryphantha macromeris* cactus, 85
Magnesium deficiency—GI motility, metabolism, rats, 979
hydroxide gel—acid neutralization, effect of interaction with aluminum hydroxycarbonate gel, 1498
Maintenance dose requirements—predicting warfarin levels, theoretical considerations, 432
Mammillary models, linear—mathematics, inverse Laplace transforms, 932, 933
Mannich bases—derivatives, effects on neoplasms, microorganisms, mitochondrial respiration in normal and tumor cells, structure–activity relationships, 1033
—derived from conjugated styryl ketones, cytotoxicity, murine leukemia L-1210 and Walker 256 carcinosarcoma cells, *in vitro* and *in vivo*, 1383
Marijuana—analysis, microcolumn, field test, compared to other plant substances, 976
—GLC analysis, stability of cannabinoids in chloroform and ethanol solutions, 262
Mass spectrometry—analysis, phenobarbital in biological fluids, degradates, 1187
Mathematics—inverse Laplace transforms in linear mammillary models, 932, 933
Mebendazole—analysis, high-performance liquid chromatography, in human plasma, 880
Mecillinam—degradation in aqueous solution, isolation of degradation products, degradation pathways, rate constants, 1207
Mefloquine—analysis, blood, plastic ion-selective electrodes, derivatives, 746
—analysis, GLC, blood, 718
Melting point—analysis, disubstituted benzenes, structure–activity relationships, 565
Membranes—surface properties, ketamine interaction with ganglioside and mitochondrial lipid monomolecular films, 1246
Menthol—GLC analysis, topical analgesic formulation, 506
Mepivacaine—aqueous solubility, effect of temperature, 667
Mercaptotriazoles—antibilharzial activity, synthesis, screening, *Schistosoma mansoni*, structure–activity relationships, 1377
Mescaline analogs—hallucinogenic activity, structure–activity relationships, molecular connectivity analysis, 906
Metabolism—chloroprocaine in humans, 75
—cyclooctylsulfamate and 4-methylcyclohexylsulfamate in rats, 372
—phenformin in guinea pigs, rats, and dogs, TLC–autoradiographic analysis, 156
—thiazinamium methylsulfate in humans, 69
Metabolite—of griseofulvin, human urine, identification, griseofulvic acid, 1335
Metabolites—of glutethimide, identified in human urine, synthesized, 283
—of morphine, isolated and identified in various mammalian species, 133
Metal binding—stability constants determined for various aminoalkyl disulfides and thiosulfates, relation to radiation-protective activity, 202
Metals—complexation with streptonigrin and with DNA, 853

Methadone—analysis, fluorescence assay, lung, liver, brain, serum, rats, 1097
—analysis, liquid–liquid extraction, brain, blood, plasma, urine, 660
Methapyrilene—nitrosation, *in vitro*, with sodium nitrite, nitrosodimethylamine formation, effect of pH, prevented by ascorbic acid, 827
Methionine—effect on aspirin-induced gastric mucosal damage in rats, 295
Methotrexate—absorption, rat small intestine, competitive inhibition by methotrexate, 1552
—controlled-release dosage forms, polyalkylcyanoacrylate nanoparticles, adsorption and release kinetics, 1521
—transport in murine Lewis lung tumor, *in vivo*, dihydrofolate reductase binding, tumor resistance, 941
Methoxsalen—solution formulated for improved delivery, bioavailability characteristics, rats and dogs, 451
Methylaminochlorobenzophenone—pKa, diazepam hydrolysis product, structure–activity relationships, 937
Methylation—effect of boron betaine analogs, 685
4-Methylcyclohexylsulfamate—metabolism in rats, 372
Methyl 1-(3,4-dichlorobenzyl)-hexahydro-2,3-dioxo-4-pyridinecarboxylate—synthesized and screened for antifungal activity, 529
Methylene blue—analysis, glycyrrhizin, 1221
α-Methylenebutyrolactams—synthesized as potential antitumor agents and screened, 350
Methylglucose—effect of proadifen on intestinal transport, rats, fasting, 945
1-Methylimidazole—complex with barbital, crystal structure determined, 361
Methyl iodide exchange—analysis of iodide in urine, 258
Methyl methacrylate—polymers, distribution and elimination, intravenous and intramuscular administration, rats, mice, 1443
Methylparaben—solubility in amide–water cosolvent systems, cosolvent excess, 1141
Methylprednisolone—bioavailability, tablet variability, commercial preparations, Latin square study, 1312
Methyl salicylate—gels, colloidal silica, *n*-dodecane, 1-dodecanol, rheological analysis, 842
—GLC analysis, topical analgesic formulation, 505
Metoclopramide—analysis, electron-capture GLC, human plasma and urine, 1254
—effect on absorption of other drugs, *in situ* rat small intestine preparation, 517
Microencapsulated ion-exchange resin beads—prepared by various methods, evaluated for release rate, 211
Microencapsulation—bitolterol, controlled-release characteristics assessed, effects on bronchodilator and heart rate activities, dogs, 475
—coyote deterrent, undecenovanillylamide, dissolution, 1561
Microsomes—seminal vesicles, prostaglandin synthesis, arachidonic acid metabolism, 1302
Microspheres, magnetic—synthesized as drug carriers, effect of stabilization and heat on drug release *in vitro*, 79
Milk, human—analysis, indoprofen, high-performance liquid chromatography, 1113
Minocycline—analysis, liquid chromatography, human serum, 1527
—complexation, effect of cations, differential pulse polarography, 1061
Minophylline—spectrophotometric analysis in pharmaceutical formulations, 9
Mitochondria—effect of nuclear-substituted styryl ketones on respiration, normal and tumor cells, 1033
Mitochondrial lipids—monomolecular films, effect of ketamine, 1246
Models, animals—rabbits, use in GI drug absorption studies, griseofulvin tablet dissolution rate and bioavailability, compared to humans, 1286
—drug interactions by enzyme induction, carbamazepine–clonazepam, monkeys, 416
hydrodynamic—dissolution devices, spin filter, salicylic acid disks, 1084
molecular—povidone-iodine, 1505
—nonlinear pharmacokinetic model proposed for acetazolamide, 342
pharmacokinetic—apparent volume of distribution, effect of altered plasma protein binding, 1203
pharmacokinetic—bioavailability, limited absorption time, fraction of dose absorbed, 1395
pharmacokinetic—equations for drug levels during induction and during constant clearance, 934
pharmacokinetic—pilocarpine distribution following topical administration, eye, 435
pharmacokinetic—procaine, intravenous infusion, humans, drug interactions, 1016
pharmacokinetic—tetracycline, controlled-release dosage form, *in vitro*, 1147
pharmacokinetic—tetracycline, controlled-release dosage form, rats, *in vivo*, 1151
pharmacokinetic—times required to attain various fractions of steady-state plasma drug level, 1546
pharmacokinetic—transepidermal infusion, effect of diffusional lag time, 1469
physical—vidarabine valerate prodrug, topical dosage forms, mouse skin, 1341, 1347
physicochemical—lyophilization, parenteral formulations, 1170
—steroid permeation through hydrogel films, 970
Molecular connectivity indexes—correlated with structural features influencing chromatographic retention indexes, various organic compounds, 120
—related to anesthetic activity of various halogenated hydrocarbons, 39
Molecular weight determination—commercial heparin sodium USP and its sterile solutions, liquid chromatography, 588
Monoamine oxidase—inhibition by β-carbolines, quantum chemistry, 772
inhibitors—β-carbolines, quantum chemistry, 772
Mono-*N*-dealkyldisopyramide—analysis, high-pressure liquid chromatography, plasma, humans, 1318
Montmorillonite—interaction with digoxin, mechanism of adsorption and degradation, IR, X-ray diffraction, and adsorption studies, 358
Morphine—analysis, liquid–liquid extraction, brain, blood, plasma, urine, 660
—metabolites isolated and identified in various mammalian species, 133
monoglucuronide—pharmacokinetics, dose related, dogs, 753
—pharmacokinetics, dose related, dogs, 753
sulfate—release from silicone polymer, effect of water-soluble carriers, 662
Morphine-type agonists and antagonists—substituents, long-range effects, structure–activity relationships, 1250
Motor activity—effects of amphetamine analogs, rats, 591
in vitro—effect of isoproterenol on muscularis mucosa and muscularis externa motility, 127
Multiple linear regression—estimation of kinetic parameters, 1120
Muscle relaxant–analgesic mixtures, various—high-pressure liquid chromatographic analyses of components, 32
Muscle relaxants—chlorzoxazone, fluorometric analysis in commercial tablets and biological fluids, in presence of hydroxychlorzoxazone and acetaminophen, 910
—pancuronium bromide, analysis, fluorometry, maternal arterial and umbilical venous serum, 914
smooth—dyphylline, urinary excretion, pharmacokinetics, humans, 1327
smooth muscle—theophylline, oral dosage forms, pharmacokinetics, bioavailability, capsule compared to liquid, 1392
Mutagenicity—povidone-iodine evaluated in mice and hamsters, 100
Myelographic agents—oily iodinated organic carbonates, biological elimination, 1438
Myoinositol—uptake by hepatocytes, *in vitro*, rats, pharmacokinetics, 1022

N

Naloxone—analysis, liquid–liquid extraction, brain, blood, plasma, urine, 660
Naltrexone—plasma kinetics after intravenous bolus administration, dogs and monkeys, electron-capture GLC assay, 411
Nanoparticles—poly(methyl methacrylate), elimination and distribution, intravenous and intramuscular administration, rats, mice, 1443
Naproxen—liquid chromatographic analysis of enantiomers, 112
Narcotic analgesics—methadone, fluorescence assay, lung, liver, brain, serum, rats, 1097
—methadone, morphine, naloxone, liquid–liquid extraction, brain, blood, plasma, urine, 660
—morphine, metabolites isolated and identified in various mammalian species, 133
—oxycodone, GLC analysis in plasma, 43
Narcotic antagonists—effect on cobaltous chloride-induced hypothermia, 693
—naltrexone, pharmacokinetics after intravenous bolus administration, dogs and monkeys, electron-capture GLC assay, 411
Narcotics—heroin, hydrolysis in dog plasma and blood, effect of enzyme inhibitors, protein binding and partition coefficient evaluated, 26
—thebaine, extraction and analysis from various plant tissues of *Papaver bracteatum*, 87
Nasal decongestants—chlorpheniramine and pseudoephedrine, urinary excretion, humans, 1243
Neuromuscular blocking effect—tubocurarine chloride, comparison of synthesized and naturally derived materials, 655
Neuromuscular junction blocking agents—enantiomers of benzyl- and ethyllaudanosinium iodides synthesized, curarimimetic potencies compared, 522
***m*-Nitrobenzhydrazide**—and mechanism of reaction with acetic acid, 301
Nitroglycerin—analysis, stability, various procedures compared, 1198
—assay of liquid dosage forms and intravenous solutions, stability, degradation products, 481
—high-performance liquid chromatographic analysis in various dosage forms, 237
—intravenous delivery systems, loss from aqueous solution into plastics, 1163
—percutaneous absorption, various topical dosage forms, rats, 608
Nitroisatin *N*-Mannich bases—screened for antimicrobial and antifungal activities, 459
1-(4′-Nitrophenyl)-2-aminopropane-1,3-diol—colorimetric analysis, in commercial chloramphenicol solutions, 1565
Nitrosamines—analysis, chromophoric or fluorescent products of photochemical degradation, aqueous suspensions, biological fluids, rats, humans, 1159
Nitrosodimethylamine—formation from methapyrilene, prevention by ascorbic acid, *in vitro*, 827
NMR spectroscopy—ampyrone and aminopyrine, 470
—analysis, tolazoline, dibenamine, azapetine, phenoxybenzamine, phentolamine, 890
—analysis, tubocurarine chloride, 655
—quinidine and hydroquinidine, conformations, concentration dependence, 1400
^{13}C-NMR spectrometry—brucine and strychnine, chemical shifts assigned, 89
^{13}C-NMR spectroscopy—various penicillins, chemical shifts assigned, 64
Noracronine thio analog—7-thionoracronine synthesized from acronine and tetraphosphorus decasulfide, 36
Norethindrone—stability in tablets, effect of FD&C dyes, 368
Normacromerine—biosynthetic conversion from epinephrine in *Coryphantha macromeris* cactus, 85
Noroxycodone—analysis in plasma and urine, electron-capture GLC method, 527
Nortropacocaine—conformation, effect of solvents, PMR spectra, structure–activity relationships, 788
Nuclear hydroxy styryl ketones—syntheses, anti-

neoplastic activity, antimicrobial activity, analgesic activity, anti-inflammatory activity, antianaphylactic activity, structure–activity relationships, 1216
Nucleic acid bases—charge transfer complex formation with isoproterenol, various solvents, UV absorption study, 631
synthesis—effect of boron betaine analogs, 685
synthesis, tumor—effect of quassinoids on P-388 lymphocytic leukemia cells, 883
Numerical algorithms—estimation of kinetic parameters, 1120
Nutritional disorders—magnesium deficiency, GI motility, metabolism, rats, 978
Nylidrin hydrochloride—analysis, high-performance liquid chromatography, tablets, stability indicating, 1264

O

Ointments—pilocarpine, shear-facilitated release, ocular, 724
Ophthalmic dosage forms—phenylmercuric nitrate, potentiometric titration analysis, dilute aqueous solutions, excipients, 1272
Opiate receptors—effect of opiate substituents, structure–activity relationships, 1250
Opiates—substituents, long-range effects, structure–activity relationships, 1250
Organic solids—solubility determinations, barely aqueous soluble, group contribution, partition coefficient, 1267
Organic solvents—cholesterol dissolution, treatment of gallstones retained in common bile duct, structure–activity relationships, 1090
Osmolality method—analysis of sodium in isotonic solutions of human albumin and plasma protein fractions, 239
Osmolality—parenteral solutions, compared to osmolarity, calculations, 1028
Osmolarity—parenteral solutions, compared to osmolality, calculations, 1028
Oxprenolol—electron-capture GLC determination of serum levels, wall-coated open tubular column, 511
Oxybutynin—effect on autonomic functions in conscious and phenobarbital-anesthetized dogs, 643
Oxycodone—analysis in plasma and urine, metabolites, electron-capture GLC method, 527
—GLC analysis in plasma, 43
Oxyphenbutazone—effect on renal sodium and water excretion, renal blood flow, glomerular filtration rate, blood pressure, prostaglandin synthesis, 1178

P

Palladium—mercaptoalkylamine coordination compounds, antineoplastic activity, structure–activity relationships, 1131
Pancuronium bromide—analysis, fluorometry, maternal arterial and umbilical venous serum, transplacental transfer, 914
Papaver bracteatum—various plant tissues, extraction and analysis of thebaine, 87
Papaverine—analysis, high-pressure liquid chromatography, human plasma, bioavailability, 1550
Parenterals—analysis of vidarabine stability, 499
Parenteral solutions—osmolality and osmolarity compared, calculations, 1028
Partition coefficients—drug conformers, structure–activity relationships, biological activity, 396
—heroin between red blood cells and enzyme-inhibited dog plasma, 26
Pemoline—GLC assay using nitrogen-specific detection, biological fluids, 445
Penetration, liquid—isooctane and water into directly compressed tablets, effect of microcrystalline cellulose, 205
Penicillamine—acid dissociation and metal complex formation constants with calcium(II), iron(III), and gold(I), simulated biological conditions, 426
Penicillin G potassium—analysis, high-pressure liquid chromatography, separation from degradation products, 1316
Penicillin G procaine—effect of cobalt irradiation, veterinary mastitis products, sterilization, 1075
Penicillin V—analysis in penicillin V benzathine bulk drug and oral suspensions, high-performance liquid chromatography, 555
Penicillin V benzathine—analysis, iodometric assay, interference by imidazolinium salt reaction product, 1322
—high-performance liquid chromatographic analysis of penicillin V content in bulk drug and oral suspensions, 555
Penicillins—analysis, colorimetry, intravenous solutions, dextrose, nickel(II)-catalyzed hydroxamic acid formation, 1333
—structure–selectivity relationships, bioavailability, 1081
various—GI absorption, effect of ionization, structure–activity relationships, 812
various—^{13}C-NMR spectra, chemical shifts assigned, 64
Pentazocine—radioimmunoassay, dog and human plasma, pharmacokinetics, 626
Pentetate esters, various—synthesized, evaluated for ability to decorporate polymeric plutonium in mice, 194
Pentobarbital—GLC analysis in serum, 386
toxicity—effect of dietary lysine and tryptophan supplementation, 1554
Pentobarbital–pyrilamine suppositories—analysis, paired-ion reversed-phase high-pressure liquid chromatography, compared to GLC, 605
Peptides—spectrophotometric determination following derivatization, catalysis by surfactant micelles, 1470
Percutaneous absorption—butylparaben, guinea pig, *in vitro,* effect of surfactants, relation to preservative activities, 596
Pharmaceutical formulations—powders, homogenization using a hammer mill, sucrose–salicylic acid, 721
Pharmacokinetics—acetazolamide, relationship to two pharmacological responses, 347
—anticoagulants, warfarin, hepatic uptake, rats, 1569
—bilirubin in hyperbilirubinemic rats, effect of sulfisoxazole, 6
—bioavailability under variable renal clearance conditions, 128
—cephalosporin derivatives, degradation, aqueous solutions, compared to cefazolin, 1369
—description of carbamazepine–clonazepam interaction by enzyme induction, monkeys, 416
—dinoprost and dinoprost methyl ester, mesenteric circulation, rats, 983
—drug clearance through an organ, estimation, 1066
—drug dissolution tests, apparatus, cascade barrier bed, 938
—drug–drug interactions, iodoxamic acid, iopanoic acid, biliary excretion, rhesus monkeys, 1430
—dyphylline urinary excretion, humans, 1327
—enterohepatic circulation, effect of biliary excretion and absorption rates, two-compartment model, 792
—estimation by numerical algorithms and multiple linear regression, 1120
—fenoprofen calcium, oral administration, 1087
—free and total bilirubin, effect of salicylic acid in hyperbilirubinemic rats, 1
—lorazepam in humans, various administration routes compared, 57
—morphine, morphine monoglucuronide, dose related, dogs, 753
—myelographic agents, oily iodinated organic carbonates, biological elimination, 1438
—naltrexone after intravenous bolus administration, dogs and monkeys, electron-capture GLC assay, 411
—nonlinear model proposed for acetazolamide, 342
—organometallic antineoplastic agents, external loop blood sampling techniques, eigenfunction expansion analysis, Fourier transform analysis, 1571
—pentazocine, dog and human plasma, radioimmunoassay, 626
—procaine in humans, intravenous infusion, drug interactions, 1016
—pyridinol carbamate, humans, 1190
—quinidine, clinical implications of protein binding, equilibrium dialysis, 466
—steady-state volume of distribution, noncompartmental determination, calculations, 1071
—time dependent, equations for drug levels during induction and during constant clearance, 934
—vidarabine valerate prodrug, topical dosage forms, physical models, 1341, 1347
Phenanthridinone—produced from fluorenone oxime by hepatic enzymes, *in vitro,* kinetics, 820
Phenazines—with two cationic side chains, synthesized and screened as potential antimalarials, 524
Phenformin—metabolism, plasma or serum levels, and elimination in guinea pigs, rats, and dogs, TLC—autoradiographic analysis, 156
Phenindione—ionization kinetics, stopped-flow spectrophotometric and pH analysis, model, 1042
Phenobarbital—analysis, flash-methylation GLC, degradates, 1187
—effect on dicumarol systemic availability in bile duct-ligated rats, 1309
—effect on oxybutynin response, autonomic functions, dogs, 643
—effect on systemic availability of oral dicumarol, comparison of oral and intravenous doses, 958
—glass formation with citric acid, 601
Phenothiazine derivatives—oxidation of dopamine, kinetics, structure–activity relationships, 612
—thiazinamium methylsulfate, rectal absorption and metabolism in humans, 69
Phenothiazines—10-acetylphenothiazine, stability and degradation kinetics, pH dependency, 515
Phenylbutazone—effect on binding of racemic warfarin and its enantiomers to human serum albumin, 1515
Phenylephrine hydrochloride—high-pressure liquid chromatographic analysis in pharmaceutical preparations, 118
Phenylmercuric nitrate—analysis, potentiometric titration, dilute aqueous solutions, excipients, 1272
Phenylsalicylates—synthesis of phenyl-3- and phenyl-5-acetamidosalicylates, analgesic activity, 893
4-Phenyl-1,2,3,6-tetrahydropyridine quaternary salts—*synthesis and antimicrobial evaluation,* 407
Phenytoin analogs, fluorinated—synthesized, evaluated for anticonvulsant activity in mice, 115
hydrophilized—*in vitro* and *in vivo* availability from capsules, 634
Phosphodiesterase inhibitors—succinic acid biphenylalkyl monoesters, synthesis, structure–activity relationships, 903
Phospholipid monolayers—interaction energies with various local anesthetics correlated with pharmacological activity, 314
Phospholipids—antihypertensive activity, endogenous phospholipid from dog peritoneal dialysate, TLC, IR, NMR analysis, 1426
Photolysis—indapamide, products identified, 1063
Pilocarpine—distribution following topical administration, precorneal area, cornea, aqueous humor, lens, vitreous humor, rabbits, models, 435
—precorneal disposition, mechanistic and quantitative evaluation, 673
—release, shear facilitated, ocular ointments, 724
Pirprofen—disposition, effect of aspirin, rats, 996
Plastics—loss of nitroglycerin from aqueous solution into intravenous delivery system components, 1163
Platinum—mercaptoalkylamine coordination compounds, antineoplastic activity, structure–activity relationships, 1131
Plutonium, polymeric—decorporation in mice, various pentetate esters evaluated, 194
Polarography, differential pulse—analysis, dimercaptosuccinic acid and tin in radiopharmaceuticals, 657
differential pulse—analysis, iodine, thyroxine, and liothyronine in thyroid hormone and tablets,

338
Polyalkylcyanoacrylate nanoparticles—adsorption and release of dactinomycin and methotrexate, liberation kinetics, controlled release, 1521
Poly (ε-caprolactone)—homopolymers, copolymers, release rates, films, capsules, 1534
Polyesters, biodegradable—poly(ε-caprolactone), poly(DL-lactic acid), copolymers, steroid release, films, capsules, 1534
Polyethylene—drug packaging, discoloration, butylated hydroxytoluene conversion to tetrabis(*tert*-butyl)stilbenequinone catalyzed by titanium dioxide, 916
Polyethylene glycol—ethylcellulose films—containing model dispersed drugs, drug release kinetics, 325
Plasma binding—benzodiazepines, humans, individual variation, age, 1320
drug levels—rapid estimation of times required to attain various fractions of steady-state level, pharmacokinetics, 1546
or serum levels—phenformin in guinea pigs, rats, and dogs, TLC–autoradiographic analysis, 156
protein binding—effect of alterations on apparent drug volume of distribution, 1203
protein fractions—osmolality method for analysis of sodium, 239
Polymers—controlled-release delivery devices, beads, potassium chloride, 628
Poly(methyl methacrylate) nanoparticles—distribution and elimination, intravenous and intramuscular administration, radioactive tracer study, rats, mice, 1443
Polymorphism—iopanoic acid, physical characterization, thermal behavior, 1005
Potassium chloride—controlled-release delivery devices, radiation-polymerized beads, 628
Potassium ferricyanide—dissolution of crystals at fluid–fluid interface, 163
Potassium guaiacolsulfonate—high-pressure liquid chromatographic analysis in pharmaceutical preparations, 118
Potassium oxonate—used to produce hyperuricemia in rats, 651
Potentiometric titration—analysis, phenylmercuric nitrate, dilute aqueous solutions, 1272
Potentiometry—analysis, iodine in various pharmaceuticals, 1416
differential—analysis, chlorthalidone dissociation constants, ibuprofen dissociation constant, 1056
Povidone-iodine—evaluated for mutagenicity in mice and hamsters, 100
—structure, hydrogen triiodide adducts, IR spectra, X-ray structure analysis, 1505
Powders—application of charge profile for characterizing unusual adsorption behavior, 472
—homogenization using a hammer mill, sucrose–salicylic acid, 721
Pralidoxime chloride—absorption and elimination kinetics in dogs, 141
Precorneal area—pilocarpine disposition, mechanistic and quantitative evaluation, 673
Prednisolone—analysis, high-pressure liquid chromatography, liquid dosage forms, separation from prednisone, 908
Prednisone—analysis, high-pressure liquid chromatography, liquid dosage forms separation from prednisolone, 908
Preservatives—butylparaben, percutaneous absorption, effect of surfactants, relation of absorption and preservative activities, guinea pig, *in vitro,* 596
—various quaternary ammonium compounds, spectrophotometric analyses in prepared and commercial solutions, 110
Proadifen—effect on intestinal methylglucose transport, rats, fasting, 945
Procainamide—analysis, plasma, high-pressure liquid chromatography deproteinization *versus* extraction methods, 532
Procaine—pharmacokinetics, intravenous infusion, humans, drug interactions, 1016
Product substitution—estrogens, conjugated, bioinequivalence of generic and proprietary products, postmenopausal women, 986
Prodrugs, aspirin—kinetics and mechanism of hydrolysis, effect of pH, temperature, and dielectric constant, 299
—azacytidine, stabilization by sodium bisulfite, 822
—dinoprost and dinoprostone, C_1-aliphatic esters, synthesis, biological activity, 836
—dinoprost, C_9- and C_{15}-monoesters, synthesis, bioactivity, 949
—dinoprostone, stabilization in solid state of *crystalline* C_1-*phenyl esters,* biological activity, 833
potential—7-thionoracronine *synthesized from* acronine and tetraphosphorus decasulfide, 36
—prostaglandins, influence of functional group on melting points, dinoprostone and dinoprost C_1-esters, 1069
theophylline—7,7′-succinylditheophylline, hydrolysis and dissolution, effect of pH, 288
—vidarabine valerate, topical dosage forms, physical models, pharmacokinetics, 1341, 1347
Progesterone—controlled-release dosage forms, effect of hydroxylation on release from silicone matrix, 689
—α- and β-forms of crystals, various thermodynamic properties determined, 175
—permeation through hydrogel films, models, structure–activity relationships, steroids, 970
—permeation through hydrogel membranes, effect of various nonaqueous polymerization solvents, 794
Prolactin—chlorpromazine-induced rise, effect of pyridoxine, rats, 1179
Propranolol—high-pressure liquid chromatographic analysis in plasma, 379
—nasal absorption, rats, compared to oral and intravenous dosage forms, bioavailability, 1196
—racemic mixtures, resolution of enantiomers, (+)- and (−)-di-(*p*-toluoyl)tartaric acids used as resolving agents, 1181
Propylene glycol—stability of aspirin solutions, effect of L-methionine and histidine, temperature, 645
Propylthiouracil—analysis, high-performance liquid chromatography in plasma, alcoholic liver disease, 1459
—analysis, high-pressure liquid chromatography, human plasma, 1461
Prostaglandin D_2—biosynthesis, ram seminal vesicle microsomes, dependence on arachidonic acid, cofactors, 1302
Prostaglandin E_1 derivatives—cyclodextrin complexation, dissolution, stability, 1059
Prostaglandins—dinoprost, dinoprost methyl ester, absorption and penetration, mesenteric circulation, rats, metabolism, 983
—dinoprostone, prodrugs, stabilization in solid state of crystalline C_1-phenyl esters, biological activity, 833
—dinoprost, prodrugs, C_9- and C_{15}-monoesters, synthesis, bioactivity, 949
E and F—transport selectivity of silicone rubber membranes, 263
E type—stability in triacetin drug delivery system, 114
—influence of functional group on melting points, dinoprostone and dinoprost C_1-esters, 1069
—prodrugs, dinoprost, dinoprostone, C_1-aliphatic esters, synthesis, biological activity, 836
Protein binding—heroin in enzyme-inhibited dog plasma, 26
binding—quinidine and dihydroquinidine interactions in plasma, 448
binding—quinidine, clinical implications, 466
binding, serum—sulfisoxazole, distribution, metabolism, excretion, rats, 742
binding—theophylline, determined by ultrafiltration method, 129
binding—theophylline in humans, 252
binding—warfarin to serum protein, effect of ticrynafen, humans, 393
Proteins—aerosol dosage forms, insulin, tracheal administration, absorption, rabbits, 670
synthesis—effect of boron betaine analogs, 685
Protoberberine salts—chloroberberine, synthesis, derivatives, 705
Pseudoephedrine—analysis, comparison of GLC and high-pressure liquid chromatographic methods, urine, 1472
—analysis, electron-capture GLC, human serum, bioavailability, 1567
—urinary excretion, humans, high-pressure liquid chromatographic analysis, 1243
Pseudoephedrine hydrochloride—analysis, ion-pair reversed-phase high-pressure liquid chromatography, cough–cold syrups, 1463
Pseudomonas cepacia—resistance to antibacterial agents, benzalkonium chloride, chlorhexidine, phenylethanol, 1436
Pupillary constriction—clobazam effect, blood level, and anxiety level, 1002
Pyrazolidines, substituted—synthesized, anticonvulsant activity *evaluated,* 377
Pyridinemethanol derivatives—analysis, GLC, blood, 718
substituted—binding to human serum albumin, 45
Pyridinol carbamate—pharmacokinetics, bioavailability, comparison of two tablet formulations, humans, 1190
Pyridone derivatives—antineoplastic activity, structure–activity relationships, mice, 816
Pyridoxine—analysis, combination tablets with thiamine and tolbutamide, spectrophotometry, first derivative curve, 739
—effect on chlorpromazine-induced serum prolactin rise, rats, 1179
Pyrocatecholamine—analogs, antitumor activity, structure–activity relationship, 1519
Pyrrolidinones, substituted—synthesized as potential antitumor agents, screened, 350

Q

Quassinoids—antineoplastic activity, effect on cellular respiration of P-388 leukemia cells, *in vivo, in vitro,* 887
—antineoplastic activity, effect on cultured P-388 lymphocytic leukemia cell nucleic acid metabolism, 883
Quaternary ammonium chlorides, various—antibacterial activity evaluated in series of *Pseudomonas aeruginosa* envelope mutants, 146
Quaternary ammonium compounds, various—spectrophotometric analyses in prepared and commercial solutions, 110
Quaternary ammonium probes—enantiomers of benzyl- and ethyllaudanosinium iodides synthesized, curarimimetic potencies compared, 522
Quaternary salts—of aminobenzoic acid derivatives synthesized, antispasmodic activity evaluated, 332
Quinidine—absorption from rat small intestinal lumen, effect of metoclopramide administration, 517
—analysis, high-performance liquid chromatography, hydroquinidine contamination in raw materials and dosage forms, 917
—conformation, NMR spectroscopic analysis, concentration dependence, 1400
—interactions with plasma constituents, effects of dihydroquinidine on binding, 448
—pharmacokinetic and clinical implications of protein binding, equilibrium dialysis, 466
Quinuclidinyl benzilate—hydrolysis in dilute aqueous solution, kinetics, pH, temperature, 856

R

Radiation-protective activity—various aminoalkyl disulfides and thiosulfates, relation to metal-binding stability constants, 202
Radiochemistry—analysis, salicylamide in plasma, compared to fluorescence assay, rats, 648
Radioimmunoassay—analysis, cyclazocine, human and dog plasma, 1447
—analysis, reserpine, metabolites, synthetic congeners, 1433
—chlordiazepoxide in blood, plasma, saliva, 261
—desmethyldiazepam, 1471

—guanethidine, human plasma, nanogram level, 1419
—pentazocine, dog and human plasma, 626
Radionuclide imaging, renal—technetium mercaptan complexes, low molecular weight, localization in kidney tissue, synthesis, structure–activity relationships, 621
Radiopaque media—ethiodized oil, various emulsions for intravenous administration prepared, effect of oil globule size on liver opacification in rabbits and monkeys, 52
—*iopanoic acid, solid forms, physical characterization,* polymorphism, thermal behavior, 1005
Relaxants, skeletal muscle—chlorzoxazone and hydroxy metabolite, high-pressure liquid chromatographic analysis in plasma, 253
smooth muscle—aminophylline, spectrophotometric analysis in pharmaceutical formulations, 9
smooth muscle—electron-capture GLC analysis of theophylline in serum, 443
smooth muscle—papaverine, high-pressure liquid chromatographic analysis, human plasma, bioavailability, 1550
smooth muscle—theophylline, protein binding determined by ultrafiltration method, 129
smooth muscle—theophylline, protein binding in humans, 252
Renal clearance conditions, variable—effect on bioavailability, 128
Repellents, mosquito—various carbamates derived from *N,N'*-disubstituted diamines synthesized and evaluated, 390
mosquito—various *N*-substituted ureas and cyclic ureas synthesized and evaluated, 391
Reserpine—antibody specificity studies, metabolites, synthetic congeners, radioimmunoassay, 1433
Resorcinol—inhibitory activity, kinetics, iodide-specific electrode, 1530
Respiratory responses—trichloromonofluoromethane, correlated to blood levels in dogs, 160
Reverse isotopic dilution—analysis of iodide in urine, 258
Rotating disk—analysis, cutaneous metabolism of vidarabine, guinea pig, *in vitro* study, 571

S

Saccharin—analysis, high-pressure liquid chromatographic, in various artificial sweeteners and pharmaceuticals, stability indicating, 878
Saddamine and impurities—GLC analysis in prepared samples, 374
Salicylamide—radiochemical analysis, from plasma, compared to fluorescence assay, rats, 648
Salicylate—plasma protein binding, effect of heparin, rats, 1483
Salicylic acid—effect on pharmacokinetics of free and total bilirubin in hyperbilirubinemic rats, 1
Saliva—analysis, creatinine, high-performance liquid chromatography, 534
—lidocaine concentration after single dose and continuous infusion, compared to serum, 1192
Salts—spectrophotometric determination of inorganic bromide and chloride salts in aqueous solutions, 513
Sarin—transport across excised human skin, effect of pretreating callus membranes with dimethyl sulfoxide, dimethylacetamide, dimethylformamide, formamide, dioxane, methyl orthoformate, 1410
—transport across excised human skin, hydrous, anhydrous, temperature influence, activation energy, adsorption and desorption, powdered keratin, permeability, 1406
Schistosoma mansoni—treatment with mercaptotriazoles, synthesis, screening in mice, structure–activity relationships, 1377
Scintigraphy, kidney—analysis of dimercaptosuccinic acid and tin(II) in commercial preparations, differential pulse polarography, 657
Screening methods—trisulfapyrimidine suspensions, bioavailability compared to *in vitro* dissolution behavior, various commercial preparations, 699
Sedatives—benzodiazepines, plasma binding, equilibrium dialysis, humans, individual variation, age, 1320
—chlordiazepoxide, high-pressure liquid chromatographic analysis, biological fluids, metabolites, 1467
—diazepam, high-performance liquid chromatographic analysis, tablets, stability indicating, 1185
—glutethimide, metabolites identified in human urine, synthesized, 283
—pentobarbital and various barbiturates, GLC analysis in serum, 386
Seminal vesicles—microsomes, prostaglandin synthesis, arachidonic acid metabolism, 1302
Serum—lidocaine concentration after single dose and continuous infusion, compared to saliva, 1192
Serum proteins—binding, sulfisoxazole, distribution, metabolism, excretion, rats, 742
Shear—facilitation of pilocarpine release from ocular ointments, 724
Silica, colloidal—surface chemistry, evaluated for stabilizing effect on aspirin in tablets, 197
Silicon dioxide, amorphous—effect on dissolution rates of prednisone, digoxin, griseofulvin in simulated GI fluids, solvent deposition compared to ball milling, 560
Silicone polymers—release of morphine sulfate, effect of water-soluble carriers, 662
Silicone rubber membranes—selectivity toward transport of E and F prostaglandins, 263
β-Sitosterol—antihypercholesterolemic activity evaluated in chickens, 245
solubility in organic solvents, *n*-alkanols, structure–activity relationships, 1090
Sitosteryl glucoside—isolated from whole plant ethanolic extract of *Echites hirsuta,* 247
Skin—metabolism of vidarabine, rotating-disk method, guinea pig, *in vitro* study, 571
Skin preparations—analysis, corticosteroids, reaction rate method, 1479
Smooth muscle relaxants—theophylline, metabolism, effect of age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, ethanol, pulmonary patients, 1358
—theophylline, reversed-phase high-pressure liquid chromatographic analysis, elimination of ampicillin and 1,7-dimethylxanthine interference, 1200
Sodium—osmolality method for analysis in isotonic solutions of human albumin and plasma protein fractions, 239
Sodium bisulfite—stabilization of azacytidine in aqueous solutions, effect of pH, prodrugs, 822
Sodium 4-(hexadecylamino)benzoate—synthesis, antiatherosclerotic activity, 936
Sodium sulfate—effect on acetaminophen elimination, protection against acetaminophen toxicity, rats, 803
Solid–liquid systems—dielectric constants determined as a function of composition, 424
Solids—surface tensions, 488
Solubility, aqueous—aliphatic alcohols, molecular topology, structure–activity relationships, 839
determinations—organic solids, barely aqueous soluble, group contribution, partition coefficient, 1267
—doxycycline monohydrate and hydrochloride dihydrate in aqueous solution, effect of pH, 188
—methylparaben in amide–water cosolvent systems, cosolvent excess, 1141
—various oxygen-containing compounds, related to carminative activities, steric considerations, 370
Solubilization—androgens and estrogens in various association colloids, 542
Solvents, various—charge transfer complex formation, nucleic acid bases with isoproterenol, UV absorption study, 631
Somatostatin—effect on GI motor activities, species specificity, dogs, cats, rabbits, rats, 1107
Spectrofluorometry—analysis, *p*-aminophenol as impurity in acetaminophen tablets, 1306
Spectrophotofluorometry—analysis, benzoquinolinium halides, binding to butyrylcholinesterase, 1025
Spectrophotometry—analyses, minophylline and aminophylline in pharmaceutical formulations, 9
—analyses, various quaternary ammonium compounds in prepared and commercial solutions, 110
—analysis, glycerol, comparison with enzymatic method, 1084
—analysis, tolbutamide in combination tablets, 739
solvent extraction—analysis, berberine in various pharmaceuticals, using thermochromic...
Spectroscopy, UV—analysis, guanethidine...products, 1010
Sperm—enzymes, effect of fatty acid esters, mice, 236
Stability—aspirin in tablets, effect of methionine and histidine, ...
—aspirin in tablets, ...
—...amorphous content, 863
—...digitoxin, various conditions, 1224
—estrogens and androgens in oils containing corn oil, chromatographic analysis of degradation products, ...
—E-type prostaglandins in ... system, 114
—guanabenz, degradation products in ...
—hydrocortisone in ... dosage forms, 623
—nitroglycerin, analysis, various ... compared, 1198
—nitroglycerin in intravenous solutions, 481
—norethindrone and ethinyl estradiol in tablets, effect of FD&C dyes, 368
—saccharin, various artificial sweeteners and pharmaceuticals, high-pressure liquid chromatography, 878
—vidarabine in aqueous parenteral formulations, 499
—vitamin A in multivitamin tablets, predicted using Arrhenius equation, 49
Staphylococcus aureus—effect of cryptolepine hydrochloride, microbial kinetics, 1510
Statistics—numerical algorithms, multiple linear regression, estimation of kinetic parameters, 1120
Sterilization—penicillin G procaine, veterinary mastitis products, cobalt irradiation, 1075
Steroids—controlled-release dosage forms, progesterone, effect of hydroxylation on release from silicone matrix, 689
—fludrocortisone acetate and solid dosage forms, high-performance liquid chromatographic analysis, 421
—prednisolone acetate suspensions, effects of suspending agents on dissolution, 1475
—progesterone, α- and β-forms of crystals, various thermodynamic properties determined, 175
Stigmasterol—antihypercholesterolemic activity evaluated in chickens, 245
Stimulants, central—nortropacocaine, conformation, structure–activity relationships, 788
—pemoline, GLC assay in biological fluids, 445
Streptomyces griseus—colchicine metabolism, 1239
Streptomyces spectabilis—colchicine metabolism, 1239
Streptonigrin—interaction with metals and with DNA, complexation, spectrophotometry, gel permeation chromatography, 853
Structure–activity relationships—acetylcholine analogs, 1325
—aliphatic alcohols, molecular topology, aqueous solubility, 839
—*n*-alkoxyacetic acids and methyl esters, antifungal activity evaluated *in vitro*, 82
—amphetamine analogs, thioureas, dithiocarbamates, negatively substituted amides, synthesis, behavioral and biological effects, rats, 591
—anticonvulsants and CNS depressants, 463
—aziridinylbenzoquinones evaluated as potential CNS antitumor agents *in vivo*, various test systems, 185
—*N*-benzoyl amino acid derivatives, inhibition of

microbial antitumor screen, 1366
—*N*-benzylcyanoacetamides evaluated for anticonvulsant activity in mice, 108
—biphenyl derivatives, β-adrenergic blocking activity, 776
—callicarpone *analogs, antimicrobial activity*, 1116
—carminative activities of various oxygen-containing compounds related to solubility, steric considerations, 370
—decongestants and antihistaminics, various cough and cold preparations, 1135
—dialkyl pyrazolidinethiols, as potential antiradiation agents, 1331
—diazepam hydrolysis products, pKa, 937
—drug conformers, biological activity, fraction of *conformer and partition coefficient*, 396
—enantiomers of benzyl- and ethyllaudanosinium iodides, curarimimetic potencies compared, 522
—fluorinated phenytoin analogs evaluated for anticonvulsant activity in mice, 115
—lidocaine analogs, local anesthetic activity, antiarrhythmic activity, 955
—luteinizing hormone-releasing hormone derivatives, 1013
—mercaptotriazoles, antibilharzial activity, synthesis, screening, *Schistosoma mansoni*, 1377
—mescaline analogs, molecular connectivity analysis, 906
—modified indole alkaloids, antineoplastic activity, 1403
—molecular connectivity indexes related to anesthetic activity of various halogenated hydrocarbons, 39
—nuclear hydroxy styryl ketones, antineoplastic activity, antimicrobial activity, analgesic activity, anti-inflammatory activity, antianaphylactic activity, 1216
—phenothiazine cation radicals oxidation of dopamine, kinetics, 612
—pyridone derivatives, antineoplastic activity, mice, 816
—pyrocatecholamine analogs, antitumor activity, 1519
—quaternary salts of aminobenzoic acid derivatives evaluated for antispasmodic activity, 332
—quinolinium-2-dithioacetic acid zwitterions evaluated for antileukemic activity in mice, 336
—series of substituted indolizines evaluated, 321
—sesquiterpene lactones, anti-inflammatory activity, 537
—β-sitosterol and stigmasterol evaluated for antihypercholesterolemic activity in chickens, 245
—steroid permeation through hydrogel films, 970
—substituted aminopropanes as potential β-adrenergic blockers, synthesis and pharmacology, 1236
—substituted morphine-type agonists and antagonists, 1250
—substituted pyrazolidines evaluated for anticonvulsant activity, 377
—substituted 1,2,4-triazines evaluated for antineoplastic activity in mice, 243
—surface tension, various surfactants, 486
—technetium mercaptan complexes, localization in kidney tissue, 621
—various alkylbenzyldimethylammonium chlorides, antibacterial activity evaluated in series of *Pseudomonas aeruginosa* envelope mutants, 146
—various 2-aminopyrrole analogs of lidocaine evaluated for local anesthetic activity in guinea pigs and antiarrhythmic activity in mice, 317
—various carbamates derived from *N,N'*-disubstituted diamines evaluated as mosquito repellents, 390
—various pentetate esters evaluated for ability to decorporate polymeric plutonium in mice, 194
—various *N*-substituted ureas and cyclic ureas evaluated as mosquito repellents, 391
—various tetrahydrocannabinol and hexahydrocannabinol derivatives, pharmacological activity evaluated in mice, 330
—various 3*H*-1,2,4,-thiadiazoles evaluated for *antibacterial and antifungal activities in vitro*, 182
Structure–selectivity relationships—penicillins, alkylchlorophenols, drug design, bioavailability, structure–activity relationships, 1081
Strychnine—^{13}C-NMR *spectrometry, chemical shifts* assigned, 89
Succinic acid biphenylalkyl monoesters—*phosphodiesterase inhibition, synthesis*, structure–activity relationships, 903
7,7'-Succinylditheophylline—hydrolysis and dissolution, *effect of* pH, 288
Sulfamerazine—suspensions, flocculation, cationic polymer, anionic and nonionic *surfactants*, 1491
Sulfamethoxazole—automated analysis, human plasma and urine, with sulfisoxazole, 1387
Sulfasalazine metabolites—5-aminosalicylic acid, metabolism, gut wall, effect of dose and administration route, 1323
Sulfisoxazole—automated analysis, human plasma and urine, with sulfamethoxazole, 1387
—distribution, metabolism, excretion, effect of serum protein binding, rats, 742
—effect on pharmacokinetics of bilirubin in hyperbilirubinemic rats, 6
Sulfonamides—degradation products of chlorpropamide and tolbutamide, high-performance liquid chromatographic analysis, 577
various—analysis, high-performance liquid chromatography, *various* pharmaceutical formulations, *stability indicating*, 922
Suppositories, pentobarbital–pyrilamine—analysis, paired-ion reversed-phase high-pressure liquid chromatography, compared to GLC, 605
Suppressant, gout—colchicine, microbial transformations, NMR spectra, metabolites 1239
Surface activities—various local anesthetics, correlated with pharmacological activity, 314
Surface tensions—analysis, various drugs, solid–liquid mixtures, surfactants, 486
critical—various pharmaceutical solids analysis, by sessile drop method, 488
Surfactants—cetrimonium bromide, micelle formation, catalysis of amino acid and peptide derivatization, spectrophotometry of derivatives, 1470
—cetylpyridinium chloride, effect on corneal permeability to penicillin, effect on epithelium, 1176
—effect on percutaneous absorption of butylparaben, guinea pig, *in vitro*, 596
nonionic—used to determine surface tensions of various pharmaceutical solids, 488
polyoxyethylene octylphenols—test liquids for measurement of critical surface tension, 486
Suspensions—steroids, effects of suspending agents on dissolution, 1475
Sustained-release films—ethylcellulose–polyethylene glycol, containing model dispersed drugs, drug release kinetics, 325
Sustained-release systems—biodegradable polyesters, poly(ε-caprolactone), films, capsules, 1534
Styryl ketones, nuclear substituted—effects on neoplasms, microorganisms, mitochondrial respiration in normal and tumor cells, structure–activity relationships, 1033
Sweeteners, nonnutritive—cyclooctylsulfamate and 4-methylcyclohexylsulfamate, metabolism in rats, 372
Sympathoplegics—effect on cobaltous chloride-induced hypothermia, 693

T

Tablet-coating formulations—TLC determination of various dyes, 97
Tablets—aspirin, effect of colloidal silica on stability, 197
compressed—effect of aging and humidity on electrical conductivity and hardness, 896
directly compressed—liquid penetration and disintegration, effect of microcrystalline cellulose, 205
—drug dissolution rate, radiation-induced polymerization of glass-forming *monomers in the* presence of dimethylaminoethyl methacrylate–methyl methacrylate or methacrylic acid–methyl *acrylate copolymers, various drugs, 860*
—norethindrone and ethinyl estradiol, effect of FD&C dyes on stability, 368
—*various directly compressible inorganic chlorides* and sodium citrate, electrical conductances, effects of particle size, lubricant level, moisture content, and compaction pressure, 222
Taspine—isolated from *Croton lechleri* bark, evaluated for *anti-inflammatory activity in rats*, 124
Technetium mercaptan complexes—localization in kidney tissue, synthesis, low molecular weight, *structure–activity relationships*, 621
Temperature—effect on cation diffusion through silicone polymer tubing, 1102
Tenulin—antineoplastic activity, structure–activity relationships, *in vivo* study, 715
Testosterone—analysis, acetonitrile–infusorial earth column chromatography, separation from testosterone esters, various pharmaceuticals, 871
esters—analysis, acetonitrile–infusorial earth column chromatography, separation from testosterone esters, various pharmaceuticals, 871
hydrazones—isomerization, UV spectrophotometry, high-pressure liquid chromatography, NMR, effect of crystallization solvent, 736
Tetrabis(*tert*-butyl)stilbenequinone—analysis, isolation from polyethylene closures, synthesis from butylated hydroxytoluene catalyzed by titanium dioxide, 916
Tetracycline analogs—complexation, effect of cations, *differential pulse polarography*, 1061
—bioavailability, decreased by coadministered bismuth subsalicylate antidiarrheal, 586
—complexation, effect of cations, differential pulse polarography, 1061
—controlled-release dosage form, pharmacokinetics, hydroxyethyl methacrylate–methyl methacrylate copolymer, *in vitro*, 1147
—controlled-release form, pharmacokinetics, hydroxyethyl methacrylate–methyl methacrylate copolymer implant, rats, *in vivo*, 1151
Tetrahydrocannabinol derivatives, various—synthesized, pharmacological activity evaluated in mice, 330
2-Tetrahydropyranyl benzoate—hydrolysis kinetics, effect of pH, 235
Tetramisole—high-pressure liquid chromatographic analysis, veterinary preparations, 796
Teucrium polium—oil, GLC–mass spectrometry, 800
Thebaine—extraction and analysis from various plant tissues of *Papaver bracteatum*, 87
Theophylline—analysis, high-pressure liquid chromatography, in liquid and solid pharmaceutical dosage forms, stability, 530
—analysis, reversed-phase high-pressure liquid chromatography, elimination of ampicillin and 1,7-dimethylxanthine interference, 1200
—electron-capture GLC determination of serum levels, 443
—GLC analysis in syrup, 521
—metabolism, effect of age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, ethanol, pulmonary patients, 1358
—oral dosage forms, pharmacokinetics, bioavailability, capsule compared to liquid, 1392
prodrugs—7,7'-succinyldiheophylline, hydrolysis and dissolution, effect of pH, 288
—protein binding determined by ultrafiltration method, 129
—protein binding in humans, 252
Thermochromism—analysis, berberine in various pharmaceuticals, solvent extraction, spectrophotometry, 875
Thermodynamic properties, various—determined for α- and β-forms of crystalline progesterone, 175
Thermolysis—indapamide, products identified, 1063
3*H*-1,2,4-Thiadiazoles, various—synthesized, eval-

uated for antibacterial and antifungal activities *in vitro*, 182
Thiamine—analysis, combination tablets with tolbutamide and pyridoxine, spectrophotometry, first *derivative curve*, 739
Thiazinamium methylsulfate—rectal absorption and metabolism in humans, 69
Thioglucose—acid dissociation and metal complex formation constants with calcium(II), iron(III), and gold(I), *simulated biological conditions*, 426
Thioglycolates—percutaneous toxicity, effect of surfactants, percutaneous penetration, rabbits, 1230
Thiomalic acid—acid dissociation and metal complex formation constants with calcium(II), iron(III), and gold(I), simulated biological conditions, 426
7-Thionoracronine—synthesized from acronine and tetraphosphorus decasulfide, 36
Thiosulfates, aminoalkyl—metal-binding stability constants determined, relation to radiation-protective activity, 202
Thyroid—differential pulse polarographic analysis of iodine, thyroxine, and liothyronine in hormone and tablets, 338
inhibitors—propylthiouracil, high-performance liquid chromatographic analysis in plasma, alcoholic liver disease, 1459
inhibitors—propylthiouracil, high-pressure liquid chromatographic analysis, human plasma, 1461
Thyroxine—differential pulse polarographic analysis in thyroid hormone and tablets, 338
Ticrynafen—analysis, extraction, high-pressure liquid chromatography, reduced metabolite, urine and serum, 1451
—effect on warfarin protein binding, human serum, 393
Tin—analysis, differential pulse polarography, in radiopharmaceuticals, and dimercaptosuccinic acid, 657
Tinidazole—high-performance liquid chromatographic assay, human plasma, 599
Titanium dioxide—in polyethylene closures, catalysis of butylated hydroxytoluene discoloration reaction, 916
TLC—analysis and separation of anthralin from decomposition products, 388
—analysis, biotin in lyophilized multivitamin preparation, 364
—analysis, butyrophenones, diphenylbutylpiperidines, phenothiazine derivatives, 1050
—determination, various dyes in tablet-coating formulations, 97
TLC–autoradiography—analysis, phenformin in biological fluids, 156
Tolbutamide—analysis, combination tablets with thiamine and pyroxidine, spectrophotometry, first derivative curve, 739
—effect on binding of racemic warfarin and its enantiomers to human serum albumin, 1515
—high-performance liquid chromatographic analysis of stability in solid pharmaceutical dosage forms, sulfonamide degradates, 577
Tolnaftate—*in vitro* comparison to undecylenic acid against athlete's foot fungi, drugs and formulations, 384
Topological indexes—aliphatic alcohols, molecular surface area, molecular connectivity, aqueous solubility, structure–activity relationships, 839
—molecular connectivity indexes correlated with structural features influencing chromatographic retention indexes, 120
—molecular connectivity, related to anesthetic activity of various halogenated hydrocarbons, 39
Toxicity—lidocaine and derivatives, use of goldfish as biological models, 401
Tranquilizers—benzodiazepines, various, chemical synthesis, potentially useful haptens, 845
—chlordiazepoxide, radioimmunoassay in blood, plasma, saliva, 261
—chloroberberine, synthesis, derivatives, 705
—clobazam, fluorometric determination in human plasma, 494
—flupenthixol dihydrochloride, decomposition in *aqueous solution*, 169
minor—clobazam, fluorometric analysis, blood levels, effect on pupillary constriction, and anxiety level, 1002
(minor)—hydroxyzine, GLC–mass spectrometric analysis, human plasma, following therapeutic doses, 1456
minor—hydroxyzine, UV photodecomposition, tritiation, degradation products, 666
Transepidermal infusion—effect of diffusional lag time on multicompartmental pharmacokinetics, 1469
Transepidermal transport—sarin, excised human skin, effect of pretreatment, 1410
—sarin, excised human skin, permeability, adsorption, 1406
Transplacental transfer—pancuronium bromide, 914
Triamcinolone acetonide—analysis, skin preparations, reaction rate method, 1479
—release from lanolin alcohol films, kinetics, topical dosage forms, 782
1,2,4-Triazines, substituted—synthesized, antineoplastic activity evaluated in mice, 243
Trichloromonofluoromethane—blood levels correlated to cardiovascular and respiratory responses in dogs, 160
Camptothecans—epoxide analogs, structure–activity relationships, toxicity, 1501
Trihexyphenidyl—analysis, TLC, impurities in tablets and elixir, 1124
derivatives—1-phenyl-2-propenone, 3-piperidinopropiophenone, 3-aminopropiophenone, TLC analysis, impurities in tablets and elixir, TLC analysis, 1124
hydrochloride—GLC analysis in various pharmaceutical dosage forms, analogs, 503
Trisulfapyrimidine suspensions—bioavailability, compared to *in vitro* dissolution behavior, various commercial preparations, screening methods, 699
Tuberculin reaction—effect of nonsteroidal anti-inflammatory and various other pharmacological agents in guinea pigs, 12
Tubocurarine chloride—chemical synthesis, comparison to naturally derived material, NMR analysis, 655
***l*-Tyrosine**—iodination, lactoperoxidase catalysis, kinetics, *in vitro*, iodide-specific electrode, 1530

U

Ultrafiltration method—determination of theophylline protein binding, 129
Undecenovanillylamide—coyote deterrent, microencapsulation, dissolution, 1559
Undecylenic acid—*in vitro* comparison to tolnaftate against athelete's foot fungi, drugs and formulations, 384
Ureas and cyclic ureas, *N*-substituted—synthesized and evaluated as mosquito repellents, 391
Urease—controlled-release delivery devices, pH-controlled hydrocortisone release, 919
Uric acid—steady-state serum levels, rats, dietary training, potassium oxonate, 651

V

Vasoconstrictors, adrenergic—pseudoephedrine, electron-capture GLC analysis, human serum, bioavailability, 1567
Vasodilators, coronary—nitroglycerin, high-performance liquid chromatographic analysis in various dosage forms, 237
coronary—nitroglycerin, stability analysis, various procedures compared, 1198
—*hydralazine, extraction, high-pressure liquid* chromatographic assay, 1423
peripheral—nylidrin hydrochloride and isoxsuprine hydrochloride, high-performance liquid chromatographic analysis, 1264
—verapamil, GLC analysis in plasma, 574
Vehicles—polyoxypropylene 15 stearyl ether and propylene glycol, effect on percutaneous absorption rate of diflorasone diacetate, 275
Verapamil—GLC analysis, plasma fluorometric analysis, metabolite interference, 574
Vibration—effect on dissolution tests, tablets, 1336
Vidarabine—cutaneous metabolism, analysis by rotating-disk method, guinea pig, *in vitro* study, 571
—stability-indicating assay, analysis in aqueous parenteral formulations, behavior in aqueous solutions, analysis in the presence of decomposition products, 499
Vidarabine valerate prodrug—topical dosage forms, physical models, pharmacokinetics, 1341
—topical dosage forms, prodrugs, physical models, pharmacokinetics, 1347
Vitamin A—stability in multivitamin tablets, predicted using Arrhenius equation, 49
Vitamin E—GLC analysis, collaborative study of 11 samples by 11 laboratories, 98
Vitamins—biotin, TLC analysis in lyophilized multivitamin preparation, 364
—folic acid, high-pressure liquid chromatographic analysis in prepared samples, collaborative study, 241
Voacangine—derivatives, cytotoxity, structure–activity relationships, 1403
Volume of distribution—effect of altered plasma protein binding, pharmacokinetics, 1203
—steady state, noncompartmental determination, calculations, 1071

W

Warfarin—effect of phenylbutazone, tolbutamide, and clofibric acid on binding of racemate and enantiomers to human serum albumin, 1515
—hepatic uptake, concentration dependence, rats, 1569
—predictability of dose requirements, theoretical considerations, correlations between hypothetical patient responses and projected maintenance dose requirements, 432
—serum protein binding, effect of ticrynafen, humans, 393
Water content—aluminum chlorohydrate, Karl Fischer titration, 122
Weibull distribution function—application to solid-state enzyme inactivation studies, 1381
Wikstromol—isolation from plant material, antineoplastic activity, 664

X

Xylitol—carrier, solid dispersions of *p*-aminobenzoic acid esters, 791

Y

Yunnan Bai Yao—analysis, cytotoxic saponins, Chinese herbal, 900

Z

Zwitterions—quinolinium-2-dithioacetic acids synthesized, antileukemic activity evaluated in mice, 336